Development, Characterization And Evaluation Of NTPDase-Modified Polymer For Inhibiting Platelet Deposition by Muthuvijayan, Vignesh
DEVELOPMENT, CHARACTERIZATION AND 
EVALUATION OF NTPDase-MODIFIED  
POLYMER FOR INHIBITING  
PLATELET DEPOSITION 
 
By 
VIGNESH MUTHUVIJAYAN 
Bachelor of Technology 
A. C. Tech, Anna University 
Chennai, Tamil Nadu, India 
2002 
 
Master of Science 
University of Maryland, Baltimore County 
Baltimore, MD 
2004 
 
 
Submitted to the Faculty of the 
Graduate College of the 
Oklahoma State University 
in partial fulfillment of 
the requirements for 
the Degree of 
DOCTOR OF PHILOSOPHY 
May 2009
 ii
DEVELOPMENT, CHARACTERIZATION AND 
EVALUATION OF NTPDase-MODIFIED  
POLYMER FOR INHIBITING  
PLATELET DEPOSITION 
 
 
 
 
   Dissertation Approved: 
 
Dr. Randy S. Lewis 
   Dissertation Adviser 
 
Dr. Sundararajan V. Madihally 
 
Dr. Gary L. Foutch 
 
Dr. Karen A. High 
 
Dr. Warren T. Ford 
 
  Dr. A. Gordon Emslie 
   Dean of the Graduate College
 iii 
ACKNOWLEDGMENTS 
 
First of all, I would like to dedicate this dissertation to my parents, Muthuvijayan 
and Niruba Rani. I thank them for all the love and guidance they provided throughout my 
life that has given me the strength and good judgment to be the person I am today. I am 
eternally grateful to my parents for teaching the values of life and being there for me 
through thick and thin. I also want to express my sincerest gratitude to my advisor Dr. 
Randy Lewis. Through his guidance, support and encouragement, Dr. Lewis helped me to 
work towards accomplishing my goal. I admire and hope to emulate the sincerity and 
dedication Dr. Lewis has shown towards my success. I would also like to thank Dr. Jun 
Gu, my labmate, who helped me in all possible ways during my stay at Oklahoma State 
University. I would like to thank Dr. Gu for training me during the beginning stages of 
my research and providing me with valuable inputs during every stage of my work. 
I would like to thank Dr. Sundararajan Madihally, Dr. Karen High, Dr. Gary 
Foutch and Dr. Warren Ford for serving in my committee and their valuable inputs 
during my research. I greatly appreciate Dr. Susheng Tan for training me to use the 
atomic force microscope. I would like to thank Dr. Heather Gappa-Fahlenkamp for her 
guidance during my in vitro studies. I would also like to thank Dr. Wei Yin for providing 
me with platelet rich plasma for my experiments. I would also like to express my sincere 
appreciation to Dr. Jim Smay and Dr. Ben Lawrence for helping me with the scanning 
electron microscope analysis.  
 iv
I am grateful to the School of Chemical Engineering for supporting me financially 
and also making my stay at Oklahoma State University a memorable and pleasant one. I 
very much appreciate the staffs in the School of Chemical Engineering for making my 
stay at Oklahoma State University a great experience. 
I would also like to thank my sister, Sona, and my brother-in-law, Dr. Karthik 
Kadirvel for their moral support and professional guidance. I would like to thank my 
cousin, Vani and her husband, Muthukani, without whom it would have been impossible 
to stay committed. I would like to thank every person in my family, whose prayers and 
well-wishes have helped me through all the obstacles. I would also like to thank my dear 
friends, Ganesh Balakrishnan, Prasath Periyasamy, Srikanth Gopi, Latha Madhavan, 
Anupama Ravindar, Anitha Sathiamoorthy, Vanitha Sathiamoorthy and all others who 
helped me stay positive and focused on my goal. 
Most importantly, I would like to thank God Almighty for blessing me with the 
health, great family and friends and all the benefits one can ask for.
 v
TABLE OF CONTENTS 
 
 
Chapter              Page 
1. INTRODUCTION ....................................................................................................... 1 
1.1 Objective #1: Analysis of functionalized PET.............................................. 10 
1.2 Objective #2: Kinetic analysis of immobilized NTPDase ............................ 10 
1.3 Objective #3: In vitro studies of NTPDase-modified PET ........................... 11 
1.4 Objective #4: Immobilization of both NTPDase and cysteine ..................... 11 
2. LITERATURE REVIEW .......................................................................................... 13 
2.1 Constituents of Blood ................................................................................... 13 
2.1.1 Plasma ....................................................................................................... 14 
2.1.2 Red Blood Cells ........................................................................................ 16 
2.1.3 White Blood Cells ..................................................................................... 18 
2.1.4 Platelets ..................................................................................................... 19 
 
2.2 Blood Coagulation ........................................................................................ 20 
2.2.1 Platelet Adhesion and Activation.............................................................. 22 
2.2.2 Platelet Aggregation.................................................................................. 24 
2.2.3 Granular Secretion .................................................................................... 24 
2.2.4 Platelet Coagulant Activity ....................................................................... 25 
2.2.5 Coagulation Cascade ................................................................................. 25 
 
2.3 Anti-thrombotic control mechanisms ........................................................... 28 
2.3.1 Naturally occurring inhibitors ................................................................... 30 
2.3.2 Protein C Pathway..................................................................................... 31 
2.3.3 Fibrinolysis ............................................................................................... 32 
2.3.4 Prostacyclin ............................................................................................... 32 
2.3.5 Nitric Oxide (NO) ..................................................................................... 35 
2.3.6 Endothelial ecto-adenosine phosphatase (ADPase/CD39/NTPDase) ...... 38 
 
2.4 Current technologies used to improve haemocompatibility ......................... 41 
 
2.5 Polyethylene terephthalate – a model polymer ............................................. 46 
 vi
3. ANALYSIS OF FUNCTIONALIZED POLYETHYLENE TEREPHTHALATE 
WITH IMMOBILIZED NTPDase ............................................................................. 49 
3.1 Introduction ................................................................................................... 50 
 
3.2 Materials and methods .................................................................................. 55 
3.2.1 Aminolysis ................................................................................................ 55 
3.2.2 Hydrolysis ................................................................................................. 56 
3.2.3 Carboxylation ............................................................................................ 56 
3.2.4 Analysis of surface properties ................................................................... 58 
3.2.5 Analysis of mechanical properties ............................................................ 60 
3.2.6 NTPDase immobilization.......................................................................... 60 
3.2.7 Analysis of NTPDase attachment ............................................................. 62 
 
3.3 Results and Discussion ................................................................................. 66 
3.3.1 Surface characterization of modified PET ................................................ 66 
3.3.2 Bulk characterization of modified PET .................................................... 71 
3.3.3 NTPDase immobilization on aminolyzed PET ......................................... 71 
3.3.4 NTPDase immobilization on carboxylated PET ....................................... 74 
3.3.5 Effect of EDC to NTPDase ratio on NTPDase immobilization ............... 82 
3.3.6 Comparison of NTPDase immobilizations ............................................... 82 
 
3.4 Conclusions ................................................................................................... 85 
4. KINETIC STUDIES OF FREE AND IMMOBILIZED NTPDase ........................... 87 
4.1 Introduction ................................................................................................... 87 
 
4.2 Materials and methods .................................................................................. 88 
4.2.1 Free NTPDase batch kinetics .................................................................... 89 
4.2.2 Immobilized NTPDase batch kinetics ...................................................... 90 
 
4.3 Results and Discussion ................................................................................. 91 
4.3.1 Free NTPDase kinetics ............................................................................. 91 
4.3.2 Immobilized NTPDase kinetics (PET-NH2-NTPDase) ............................ 96 
4.3.3 Immobilized NTPDase kinetics (PET-COOH-NTPDase) ...................... 104 
 
4.4 Conclusions ................................................................................................. 114 
5. IN VITRO STUDIES OF NTPDase-MODIFIED POLYETHYLENE 
TEREPHTHALATE TO VERIFY IMPROVED HAEMOCOMPATIBILITY ...... 116 
5.1 Introduction ................................................................................................. 117 
5.1.1 In vitro systems ....................................................................................... 118 
5.1.2 Ex vivo systems ....................................................................................... 120 
5.1.3 In vivo systems ........................................................................................ 121 
5.1.4 Clinical trials ........................................................................................... 121 
 vii
 
5.2 Materials and methods ................................................................................ 122 
5.2.1 Protein adsorption studies ....................................................................... 123 
5.2.2 Platelet rich plasma (PRP) studies .......................................................... 124 
5.2.3 Whole blood studies ................................................................................ 125 
 
5.3 Results and Discussion ............................................................................... 126 
5.3.1 Protein adsorption studies ....................................................................... 126 
5.3.2 Platelet rich plasma studies ..................................................................... 129 
5.3.3 Whole blood studies ................................................................................ 133 
 
5.4 Conclusions ................................................................................................. 138 
6. DUAL FUNCTIONAL POLYMER TO EXPLOIT THE ADDITIVE EFFECT OF 
NTPDase AND NITRIC OXIDE (NO) ................................................................... 140 
6.1 Introduction ................................................................................................. 141 
 
6.2 Materials and methods ................................................................................ 145 
6.2.1 Dual functional polymer ......................................................................... 146 
6.2.2 Cysteine immobilization ......................................................................... 146 
6.2.3 Analysis of NTPDase attachment ........................................................... 148 
6.2.4 Analysis of cysteine attachment .............................................................. 148 
 
6.3 Results and Discussion ............................................................................... 149 
6.3.1 NTPDase activity on the dual functional polymer .................................. 149 
6.3.2 Surface concentration of cysteine on the dual functional polymer ......... 151 
6.3.3 Stability of cysteine immobilization ....................................................... 151 
 
6.4 Conclusions ................................................................................................. 155 
7. CONCLUSIONS AND FUTURE WORK .............................................................. 156 
7.1 Successfully accomplished objectives ........................................................ 157 
7.2 Future direction ........................................................................................... 161 
8. REFERENCES ........................................................................................................ 163 
IRB Approval Form ................................................................................................. 188 
 viii 
LIST OF TABLES 
 
 
Table                   Page 
 
1.1 Number of medical devices involving blood-contacting polymers  
in US per year (Global numbers are typically 2 – 3 times the US number) 
(Ratner et al. 2004b)………………………………………………………………6 
 
3.1 Roughness analysis of modified polymers………………………………………69 
 
3.2 Tensile testing of modified polymers……………………………………………72 
 
4.1 vmax and KM calculated using Michaelis-Menten model for different 
initial ADP concentrations……………………………………………………...110 
 ix
LIST OF FIGURES 
 
 
Figure                   Page 
 
2.1 Cellular components of blood. (a) erythrocytes or red Blood Cells; (b) 
neutrophils; (c) eosinophils; (d) basophils; (e) monocytes; (f)  
lymphocytes; (g) platelets. Images were obtained from The Merck Manuals: 
Online Medical Library (Frenkel 2006)………………………….........................17 
 
2.2 Structure of human platelet (Hanson 2004)……………………………………...21 
 
2.3 Platelet reactions to a stimulus (injured blood vessel or contact to foreign  
surface). Figure modified from (Adams 1985)…………………………………..23 
 
2.4 Blood coagulation cascade.         represents conversion or activation of  
factors, –| represents inhibition,           represents reactions catalyzed and        
represents the other functions of thrombin. Image adapted from Wikipedia. 
HMWK – high molecular weight kininogen, PK – prekallikrein, F – factor,  
TFPI – tissue factor pathway inhibitor. Figure from (Jfdwolff 2004)…………...27 
 
2.5 A simplified schematic of fibrinolysis. –| represents inhibition and  
 represents reactions. sc-u-PA – single chain urokinase plasminogen  
activator, sc-t-PA – single chain tissue plasminogen activator, tc-u-PA –  
two chain urokinase plasminogen activator, tc-t-PA – two chain tissue 
plasminogen activator, PAI – plasminogen activator inhibitor, α2-MG – α2-
macroglobulin. Figure adapted from (Cesarman-Maus and Hajjar 2005)……….34 
 
2.6 Effects of nitric oxide on platelet inhibition. NO – nitric oxide, TXA2  
receptors – thromboxane A2 receptors, sGC – soluble guanylate cyclase, 
GTP – guanosine triphosphate, cGMP – cyclic guanosine monophosphate.  
 represents activation or formation, –| represents inhibition or suppression  
and        represents diffusion. Figure adapted from (Jin et al. 2005)…………….37 
 
2.7 Mechanism of platelet inhibition by CD39/NTPDase by regulating  
ADP-induced platelet aggregation.  represents formation or release and  
–| represents inhibition…………………………………………………………...40 
 x
Figure                   Page 
 
3.1 Schematic diagram showing surface modification of PET (a) primary  
amines introduced by ethylenediamine treatment, (b) carboxyl groups  
exposed due to aminolysis, (c) carboxyl groups introduced by hydrolysis, 
(d) hydroxylated intermediates formed during carboxylation and (e)  
carboxyl groups introduced by carboxylation. The active functional groups 
introduced to the PET surface are highlighted…………………………………...57 
 
3.2 Schematic diagram showing NTPDase immobilization: (a) NTPDase  
immobilized on aminolyzed PET via imine bonds [PET-NH2-NTPDase], 
(b) NTPDase immobilized on carboxylated PET via amide bonds  
[PET-COOH-NTPDase]…………………………………………………………61 
 
3.3 Experimental designs for analyzing NTPDase attachment. (a) 50 ml of 
0.25 mM ADP in the presence of 0.1 M Tris buffer (pH = 7.4) and  
5 mM CaCl2 with 10 cm2 of NTPDase-modified PET (b) 1.5 ml of 0.25 mM 
ADP in the presence of 0.1 M Tris buffer (pH = 7.4) and 5 mM CaCl2  
with 2 cm2 of NTPDase-modified PET. Inorganic phosphate (Pi)  
concentration is measured using a malachite green assay (MG).………………..63 
 
3.4 Malachite green assay sensitivity over time. The plot shows absorbance at 
630 nm (Abs630) vs. Pi concentrations for malachite green solution that was 
freshly prepared (♦), stored for 3 h (□), 6 h (▲), 9 h (∆) and 11 h (■)…………..65 
 
3.5 Scanning electron microscope images of (a) unmodified PET, (b)  
aminolyzed PET, (c) hydrolyzed PET and (d) carboxylated PET. Cracks on 
aminolyzed PET are clearly visible and pits on hydrolyzed PET are 
highlighted…………...…………………………………………………………..67 
 
3.6 Atomic force microscope images of (a) unmodified PET, (b) 20%  
aminolyzed PET, (b) 40% aminolyzed PET, (d) hydrolyzed PET and (e) 
carboxylated PET. Cracks on aminolyzed PET are clearly visible and pits on 
hydrolyzed PET are highlighted…………………………………………………70 
 
3.7 Rate of inorganic phosphate (Pi) release due to ADP hydrolysis catalyzed  
by NTPDase immobilized on aminolyzed PET (PET-NH2-NTPDase). 
Pi released from 50 ml of 0.25 mM ADP (initially 12.5 µmoles) by 10 cm2  
freshly prepared (◊), stored in air for 100 min (□) stored in air for  
200 min (∆), stored in solution for 100 min (■), and stored in solution  
for 200 min (♦) are shown. The solution in which PET-NH2-NTPDase  
was stored contains equal volumes of 0.1 M Tris buffer (pH = 7.4) and  
5 mM CaCl2. All storage and kinetic analysis were done at 37˚C……………….73 
 
 xi
Figure                   Page 
 
3.8 Inorganic phosphate (Pi) release due to ADP hydrolysis catalyzed by  
NTPDase immobilized on carboxylated PET (PET-COOH-NTPDase) for 
prolonged reaction. Pi released from 50 ml of 0.25 mM ADP (initially 12.5 
µmoles) by 10 cm2 of PET-COOH-NTPDase (a) during the first 450 minutes  
and (b) after 18 hours are shown…………………………………………………75 
 
3.9 Inorganic phosphate (Pi) release due to ADP hydrolysis catalyzed by  
NTPDase immobilized on carboxylated PET (PET-COOH-NTPDase). Pi  
released from 50 ml of 0.25 mM ADP (initially 12.5 µmoles) by 10 cm2  
freshly prepared (♦), stored in air for 200 min (▲), stored in solution for  
200 min (■) are shown. All PET-COOH-NTPDase were prepared in  
phosphate buffer.  The solution contains equal volumes of 0.1 M Tris  
buffer (pH = 7.4) and 5 mM CaCl2. The figure also shows Pi released  
from 1.5 ml of 0.25 mM ADP (initially 0.375 µmoles) by 2 cm2  
PET-COOH-NTPDase freshly prepared in phosphate buffer (□) and  
freshly prepared in MES buffer (∆). All storage and kinetic analysis was 
performed at 37˚C…………………………………………………………….….77 
 
3.10 Rate of inorganic phosphate (Pi) release due to ADP hydrolysis catalyzed  
by NTPDase immobilized on carboxylated PET (PET-COOH-NTPDase)  
using different concentrations of EDC. Pi released from 50 ml of 0.25 mM  
ADP (initially 12.5 µmoles) by 10 cm2 of PET-COOH-NTPDase prepared  
using 0.05 M EDC (◊), 0.1 M EDC (□), 0.2 M EDC (∆) and 0.3 M EDC  
(■) are shown…………………………………………………………………….83 
 
4.1 Pi formation from free NTPDase with (a) initial [ADP] = 0.05 mM,  
(b) initial [ADP] = 0.1 mM, (c) initial [ADP] = 0.15 mM, (d) initial [ADP]  
= 0.2 mM, (e) initial [ADP] = 0.25 mM and (f) initial [ADP] = 0.3 mM….........92 
 
4.2 Effect of storing free NTPDase in 0.1 M Tris buffer at 37ºC for 0 minutes (♦), 
60 minutes (□), 120 minutes (▲) and 240 minutes (◊)………………………….93 
 
4.3 Lineweaver-Burke plot using initial rates from free NTPDase kinetics with 
different initial [ADP]. Using the slope and intercept the Michaelis-Menten 
constants were calculated as vmax = 0.0118 mM/min and KM = 0.0643 mM…....95 
 
4.4 (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.1  
mM. Pi (□) and ADP (♦) concentrations are shown. The ADP concentration  
was fitted to a polynomial for estimating the derivative, (b) Rate of ADP  
conversion using PET-NH2-NTPDase for initial [ADP] = 0.1 mM. Solid  
line is the Michaelis-Menten model with vmax = 0.01131 mM/min and KM = 
0.1247 mM……………………………………………………………………….97 
 
 xii
Figure                   Page 
 
4.5 (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.15  
mM. Pi (□) and ADP (♦) concentrations are shown. The ADP concentration  
was fitted to a polynomial for estimating the derivative, (b) Rate of ADP  
conversion using PET-NH2-NTPDase for initial [ADP] = 0.15 mM. Solid  
line is the Michaelis-Menten model with vmax = 0.006949 mM/min and KM =  
0.05151 mM….………………………………………………………………….98 
 
4.6 (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.2  
mM. Pi (□) and ADP (♦) concentrations are shown. The ADP concentration  
was fitted to a polynomial for estimating the derivative, (b) Rate of ADP  
conversion using PET-NH2-NTPDase for initial [ADP] = 0.2 mM. Solid  
line is the Michaelis-Menten model with vmax = 0.06934 mM/min and KM =  
0.01509 mM.………………………..……………………………………………99 
 
4.7 (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.25  
mM. Pi (□) and ADP (♦) concentrations are shown. The ADP concentration  
was fitted to a polynomial for estimating the derivative, (b) Rate of ADP  
conversion using PET-NH2-NTPDase for initial [ADP] = 0.25 mM. Solid  
line is the Michaelis-Menten model with vmax = 0.01242 mM/min and KM = 
0.02425 mM……………..………………………………..…………………….100 
 
4.8 (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.3  
mM. Pi (□) and ADP (♦) concentrations are shown. The ADP concentration  
was fitted to a polynomial for estimating the derivative, (b) Rate of ADP  
conversion using PET-NH2-NTPDase for initial [ADP] = 0.3 mM. Solid  
line is the Michaelis-Menten model with vmax = 0.009873 mM/min and KM = 
0.09461 mM……………..………………………………..…………………….101 
 
4.9 Effect of storing PET-NH2-NTPDase at -20ºC for 4 weeks. Pi formation for 
freshly prepared PET-NH2-NTPDase (♦) and PET-NH2-NTPDase stored at  
-20ºC for 4 weeks (□), with 0.2 mM ADP, are shown…………………………103 
 
4.10 (a) NTPDase reaction kinetics for PET-COOH-NTPDase using [ADP] = 0.1  
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was  
fitted to a polynomial for estimating the derivative, (b) Rate of ADP  
conversion using PET-COOH-NTPDase for initial [ADP] = 0.1 mM. Solid  
line is the Michaelis-Menten model with vmax = 0.000702 mM/min and KM = 
0.003225 mM…………………………………………………………………...105 
 
 xiii 
Figure                   Page 
 
4.11 (a) NTPDase reaction kinetics for PET-COOH-NTPDase using [ADP] = 0.15  
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was  
fitted to a polynomial for estimating the derivative, (b) Rate of ADP  
conversion using PET-COOH-NTPDase for initial [ADP] = 0.15 mM. Solid  
line is the Michaelis-Menten model with vmax = 0.000863 mM/min and KM = 
0.01494 mM………………………………………………………………….....106 
 
4.12 (a) NTPDase reaction kinetics for PET-COOH-NTPDase using [ADP] = 0.2  
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was  
fitted to a polynomial for estimating the derivative, (b) Rate of ADP  
conversion using PET-COOH-NTPDase for initial [ADP] = 0.2 mM. Solid  
line is the Michaelis-Menten model with vmax = 0.00181 mM/min and KM = 
0.02246 mM………………………………………………………………..…...107 
 
4.13 (a) NTPDase reaction kinetics for PET-COOH-NTPDase using [ADP] = 0.25  
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was  
fitted to a polynomial for estimating the derivative, (b) Rate of ADP  
conversion using PET-COOH-NTPDase for initial [ADP] = 0.25 mM. Solid  
line is the Michaelis-Menten model with vmax = 0.00278 mM/min and KM = 
0.03848 mM………………………………………………………………….....108 
 
4.14 (a) vmax vs. initial [ADP], (b) KM vs. initial [ADP]…………………………….111 
 
5.1 Protein adsorption studies on unmodified and modified PET surfaces………...128 
 
5.2 SEM images of unmodified PET exposed to platelet rich plasma to  
understand platelet adhesion. All images are at 3000x magnification.  
Platelet aggregates are highlighted……………………………………………..130 
 
5.3 SEM images of PET-COOH exposed to platelet rich plasma to understand  
platelet adhesion. All images are at 3000x magnification. Platelet aggregates  
are highlighted………………………………………………………………….131 
 
5.4 SEM images of PET-COOH-NTPDase exposed to platelet rich plasma to 
understand platelet adhesion. All images are at 3000x magnification………….132 
 
5.5 SEM images of unmodified PET exposed to whole blood to understand  
thrombus formation. (a) 1400x, (b) 2000x, (c) 3000x and (d) 10000x 
magnifications…………………………………………………………………..135 
 
5.6 SEM images of PET-COOH exposed to whole blood to understand  
thrombus formation. (a) 2000x and (b) 8000x magnifications…………………136 
 
 xiv
Figure                   Page 
 
5.7 SEM images of PET-COOH-NTPDase exposed to whole blood to  
understand thrombus formation (a) 1400x, (b) 2000x, (c) 2977x and  
(d) 10000x magnifications……………………………………………………...137 
 
6.1 Schematic diagram showing the mechanism of exploiting endogenous  
NO and ADP scavenging using an NTPDase/cysteine-modified dual  
functional polymer to improve haemocompatibility. (a) L-cysteine utilizing 
endogenous NO (1) Transnitrosation – NO transfer from S-nitrosoalbumin to  
L-cysteine immobilized on the surface, (2) Decomposition – Spontaneous  
release of NO from unstable S-nitrosocysteine. (b) NTPDase scavenging  
ADP and forming adenosine……………………………………………………144 
 
6.2 Schematic diagram of NTPDase and cysteine immobilization on  
carboxylated PET to form a dual functional polymer. The amide bonds  
formed during immobilization are highlighted…………………………………147 
 
6.3 Analysis of NTPDase and cysteine attachment on dual functional polymers  
(a) NTPDase activity on high NTPDase/low cysteine PET (▲), low 
NTPDase/high cysteine PET (∆) and PET-COOH-NTPDase (■)  
(b) Cysteine surface concentrations on PET-COOH-Cys and the dual  
functional polymers, HNLC – high NTPDase/low cysteine PET, LNHC –  
low NTPDase/high cysteine PET………………………………………………150 
 
6.4 Stability of cysteine immobilization on PET-COOH-Cys. Cysteine  
concentrations were measured with time, when stored in DI water.  
Loss of cysteine from the polymer is probably due to thioester formation  
during carbodiimide coupling. Data from work done by Jun Gu………………152 
 
6.5 Thioester formation in a dual functional polymer. The thioester bond,  
which might be the reason behind the instability of cysteine immobilization  
to carboxylated PET, is highlighted…………………………………………….154 
 xv
NOMENCLATURE 
 
5-HT Serotonin 
ADA American Dental Association 
ADP Adenosine diphosphate 
ADPase/CD39 Endothelial ecto-adenosine phosphatase 
AFM Atomic force microscope 
AlbSH Albumin 
AlbSNO S-nitroso albumin 
AMP Adenosine monophosphate 
ASTM American Society of Testing and Materials International 
ATIII Antithrombin III 
ATP Adenosine triphosphate 
ATR-FTIR Attenuated Total Reflection Fourier Transform Infrared 
BCA Bicinchoninic acid 
BSA Bovine serum albumin 
cGMP 3, 5-cyclic guanosine monophosphate 
CySH Cysteine 
CySNO Nitrosated cysteine 
EDC 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride 
 xvi
EDRF Endothelium derived relaxing factor 
eNOS/NOS III Endothelial nitric oxide synthase 
FDA Food and Drug Administration 
GP Glycoprotein 
GTP Guanosine triphosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HMWK High molecular weight kininogen 
iNOS/NOS II Inducible nitric oxide synthase 
ISO International Standards Organization 
MES 2-(N-morpholino) ethanesulfonic acid  
MG Malachite green assay reagent 
NIH National Institutes of Health 
nNOS/NOS I Neuronal nitric oxide synthase 
NO Nitric oxide 
NOS Nitric oxide synthase 
NTPDase Nucleoside triphosphate diphosphohydrolase 
PAI Plasminogen activator inhibitor 
PBS Phosphate buffered saline 
PEO Polyethylene oxide  
PET Polyethylene terephthalate 
PET-COOH Carboxylated PET 
PET-COOH-Cys Cysteine-modified carboxylated PET 
PET-COOH-NTPDase NTPDase-modified carboxylated PET 
 xvii
PET-NH2 Aminolyzed PET 
PET-NH2-NTPDase NTPDase-modified aminolyzed PET 
PF4 Platelet factor 4 
PGI2 Prostacyclin 
Pi Inorganic phosphate 
PK Prekallikrein 
PMEA Poly-2-methoxy ethylacrylate 
PMMA Polymethyl methacrylate 
PRP Platelet rich plasma 
PVA Polyvinyl alcohol 
RBC Red blood cells 
RSH Sulfhydryl amino acids 
RSNO S-nitrosothiols 
SDS n-Sodium dodecyl sulfate 
SEM Scanning electron microscope 
sGC Soluble guanylate cyclase 
SMA Surface modifying additives 
TFPI Tissue factor pathway inhibitor 
TM Thrombomodulin 
t-PA Tissue plasminogen activator 
TXA2 Thromboxane A2 
u-PA Urokinase plasminogen activator 
vWF von Willebrand factor 
 xviii 
WBC White blood cells 
α2-MG α2-macroglobulin 
 1
CHAPTER 1 
 
 
INTRODUCTION 
 
 According to the definition provided by Clemson University Advisory Board for 
Biomaterials at the 6th Annual International Biomaterial Symposium (1974), “a 
biomaterial is a systemically and pharmacologically inert substance designed for 
implantation within or incorporation with living systems”. Biomaterials include any 
material, such as metals, ceramics, carbons, composites and polymers, which 
intermittently or continuously comes in contact with biological systems. Biomaterials 
have a vast array of applications ranging from catheters, probes, sutures and bone plates 
to vascular grafts, heart valve prostheses, cardiac pacemakers, joint and limb 
replacements, renal dialyzers and blood oxygenators. With such a wide range of 
applications, design and development of compatible biomaterials is critical for 
construction of both extracorporeal devices and implants. The first reported use of 
“biomaterials” was in 1759, when Hallowell repaired an injured artery with a wooden peg 
and twisted thread (Wesolowski and Dennis 1963). However, use of biomaterials in 
surgery was not successful until the development of aseptic surgical techniques by Dr. J. 
Lister in the 1860s, due to infections (Park 1984). As infections were drastically reduced 
with widespread implementation of aseptic surgical procedures, the effect of the 
properties of biomaterials used in the success of implantation was recognized (Friedman 
et al. 1994). 
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With this understanding, the interest in developing effective biomaterials for 
successful implantation grew. Early implants were largely applied to healing broken 
bones and joints. In the 1900s, biomaterials were primarily chosen based on their 
mechanical strength and they usually corroded rapidly (Woo et al. 2004). In the 1930s, 
stainless steel and cobalt-chromium based alloys were introduced in fracture repair and 
joint replacement surgeries (Park 1984). In 1946, the Judet brothers from France 
developed the first biomechanically designed hip prosthesis using polymethyl 
methacrylate (PMMA) (Park 1984). At around the same time, PMMA was also used for 
corneal replacement (Park 1984). After these developments, use of plastics and polymers 
as biomaterials grew exponentially. 
With the knowledge gained through the past experiences, the first biomaterials 
were developed. These were mostly commonly available materials. For example, 
cellulose acetate, a commodity plastic, was used for dialysis tubing; Dacron, a textile 
polymer, was used for vascular grafts and commercial grade polyurethanes were used for 
artificial heart parts (Woo et al. 2004). Although these materials were partly effective, 
they also introduced serious complications due to inflammatory reactions. For instance, 
dialysis tubing activated platelets and the complement system; vascular grafts made from 
Dacron could be used only when the diameter was larger than 6 mm, otherwise the graft 
was clogged due to blood coagulation and blood clots formed because of blood-
biomaterial interaction in artificial hearts posed serious possibility of stroke or other 
complications. The limitations experienced were due to lack of biocompatibility of the 
materials used. 
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Biocompatibility is defined as “the ability of a material to perform with an 
appropriate host response in a specific application” (Williams 1987). This would include 
the physical properties of the biomaterial and the biological reaction occurring due to the 
interaction between the biomaterial and the host. Biocompatibility of materials coming in 
direct contact with blood is called haemocompatibility. Lack of haemocompatibility 
causes serious complications like platelet adhesion and aggregation, thrombus formation 
and shedding of emboli (Ratner 1996; Mowery et al. 2000; Schoenfisch et al. 2000). 
Such complications not only compromise the device function, but also cause serious side 
effects like severe bleeding, stroke, ischemia, vasospasm, hypertension and inflammation, 
all of which can be life threatening in patients (Vallance 1989; Traub and Berk 1998).  
Most of the blood-contacting materials used today are not completely 
haemocompatible. To overcome the limitations in haemocompatibility of biomaterials, 
thrombin and platelet antagonists like heparin and prostacyclin are added to blood-based 
perfusates to reduce thrombogenicity. However, the drawback is that loss of heparin 
activity over time results in loss of haemocompatibility (Larsson et al. 1987). Also, 
antithrombogenicity induced by heparin and prostacyclin is not site-specific due to the 
deactivation of coagulation factors in the plasma (Larsson et al. 1987). Hence, improving 
the haemocompatibility of biomaterials is a major concern. Two possible ways to 
improve haemocompatibility of blood-contacting surfaces are to develop new 
biomaterials with surfaces which are completely haemocompatible or modify the surface 
of currently available biomaterials. It is usually complicated to develop a new biomaterial 
with desired physical and biological properties. Hence, modifying surfaces of currently 
available biomaterials is a more viable solution. 
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Many surface modification techniques are currently used to improve 
haemocompatibility of biomaterials. One approach is to disguise the biomaterial surface 
in such a way that it is not recognized as a foreign body. One technique to achieve this is 
albumin passivation (Kottke-Marchant et al. 1989). It has been shown that platelet 
activation was reduced by pre-coating albumin to the surface of tubing in an 
extracorporeal system (Amiji et al. 1992). However, during prolonged exposure to blood, 
the albumin was replaced by other proteins (Vroman and Adams 1969; Vroman et al. 
1980) and hence the material lost its haemocompatibility. Also, this technique doesn’t 
prevent platelet activation in extracorporeal devices (Borgdorff et al. 1999).  
Other techniques used for surface disguising are endothelial seeding (Herring et 
al. 1984) and biomembrane mimicry by coating with  phospholipids such as 
phosphorylcholine (Durrani et al. 1986; Chapman and Lee 1987). However, these 
techniques change the surface properties and are effective only for medium periods of 
time (Lowe et al. 2005). Also, the time, money and energy required for preparing and 
storing these biomaterials is a serious limitation (Tanzi 2005). Another surface 
modification technique currently used is attaching hydrophilic chains, such as poly-2-
methoxyethyl acrylate (PMEA) (Saito et al. 2000; Ninomiya et al. 2003) and 
polyethylene oxide (PEO) (Golander and Kiss 1988; Brinkman et al. 1989; Nojiri et al. 
1990; Litauszki et al. 1997) to the surface. This minimizes adsorption and denaturation of 
proteins and blood cells, thereby improving haemocompatibility. However, the long 
chain polymers present on surface of the biomaterial can cause steric hindrance that 
would alter the biological property to the material. 
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Mixing synthetic materials with surface modifying additives (SMA) during 
production phase has been done to improve haemocompatibility (Tsai et al. 1994; Gu et 
al. 1998). However, clinical studies showed that only minor improvements were observed 
using SMA treated devices (van Oeveren 2005). Another commonly used technique to 
improve haemocompatibility is attaching biologically active compounds (Han et al. 1989; 
Seifert et al. 1997). This is achieved by grafting these molecules to the biomaterial and 
releasing it over a period of time. Some of the compounds currently used are heparin 
(Han et al. 1989), hirudin (Seifert et al. 1997) and NO-releasing compounds (Smith et al. 
1996). However, the biomaterial loses haemocompatibility once the active molecule is 
completely released and hence prolonged haemocompatibility is not achieved. The other 
major problem associated with this technique is the difficulty to control the release rate. 
This could potentially lead to dangerously high levels of the compound in the blood 
stream. 
As seen in Table 1.1, millions of medical devices use blood-contacting 
biomaterials. Improving haemocompatibility of the blood-contacting biomaterials will 
vastly improve the clinical application and save and improve the lives of millions of 
patients. As the market for biomaterials exceeds $100 billion (Peppas and Langer 1994; 
Ratner et al. 2004a), the economic impact will also be very significant. According to the 
American Heart Association, from 1979 to 2005, the total number of inpatient 
cardiovascular operations and procedures has increased 484 percent to 6,989,000 
annually (Rosamond et al. 2008). The number of cardiac catheterizations has increased 
342 percent (Rosamond et al. 2008). An estimated 1,322,000 cardiac catheterizations 
were performed in 2005 (Rosamond et al. 2008).  
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Table 1.1. Number of medical devices involving blood-contacting polymers in US per 
year (Global numbers are typically 2 – 3 times the US number) (Ratner et al. 2004b) 
Medical Devices Number/year 
Vascular Graft 
Catheter 
Blood Bags 
Heart Valve 
Coronary Stents 
Pacemaker 
Heart-Lung Oxygenators 
Renal Dialysis (number of patients, 2001) 
Left Ventricular Assist Devices 
300,000 
200,000,000 
40,000,000 
100,000 
1,500,000 
400,000 
300,000 
320,000 
100,000 
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Also, it is estimated that 469,000 coronary artery bypass procedures on 261,000 
patients (Pleis and Lethbridge-Cejku 2006) and 699,000 open-heart surgery procedures 
(Rosamond et al. 2008), both using extracorporeal blood oxygenators, were performed. 
An estimated 1,271,000 angioplasty procedures were performed (Rosamond et al. 2008). 
The number of implantable defibrillators, pacemakers and heart valves included 91,000; 
180,000; and 106,000 respectively (Rosamond et al. 2008). These statistics represent 
only the cardiac applications of biomaterials. The numbers will be a lot higher if all 
applications using blood-contacting devices were considered. 
This research focuses on modifying the surface of a polymeric biomaterial to 
improve the haemocompatibility. Polymeric biomaterials were chosen to be explored 
because of the wide range of blood-contact applications. Synthetic polymers have been 
used in catheters, blood bags, dressings, implants and extracorporeal devices (Lee et al. 
2003). The main advantage of polymeric biomaterials is the ease of producing different 
shapes with desired mechanical and physical properties. Polymeric biomaterials are also 
cost effective. These advantages make polymers a viable option. 
Polyethylene terephthalate (PET) was chosen as the model polymer. PET is a 
linear, aromatic polyester shown to have the desirable mechanical strength and durability 
for biomedical applications (Bide et al. 2006; Nissen et al. 2008). PET also has a wide 
range of medical applications which include vascular prostheses (Vinard et al. 1988; 
Kottke-Marchant et al. 1989; Haulon et al. 2003; Blanchemain et al. 2007a; Blanchemain 
et al. 2007b), heart valve sewing cuffs (Tweden et al. 1997; Illingworth et al. 1998; Jin et 
al. 2007), implantable sutures (Homsy et al. 1968; 21CFR878.5000 2008), and surgical 
mesh (Zieren et al. 2004; Bracco et al. 2005). 
 8
With several of the PET applications involving contact with blood, PET was a 
suitable model polymer to be explored for this research. However, PET is an inert 
polymer and lacks active functional groups on the surface to attach biologically active 
molecules. Hence, surface functionalization of polyethylene terephthalate is necessary for 
immobilizing biomolecules which will improve haemocompatibility.  
The goal of this work is to improve the haemocompatibility of PET surfaces by 
identifying and utilizing a naturally occurring platelet inhibition mechanism. In nature, 
there are multiple anti-coagulant pathways to regulate blood clotting. One such 
mechanism is adenosine diphosphate (ADP) scavenging. Platelets exposed to foreign 
surfaces get activated and secrete ADP. ADP leads to further irreversible platelet 
aggregation. Scavenging the ADP secreted will inhibit irreversible platelet aggregation. 
In nature, ADP induced platelet aggregation is counteracted by an enzyme called 
nucleoside triphosphate diphosphohydrolase (NTPDase). NTPDase rapidly metabolizes 
ADP to release adenosine monophosphate (AMP) and inorganic phosphate (Pi), resulting 
in the platelets to return to the resting state (Marcus et al. 1997). Bakker et al. had used 
NTPDase as the biologically active compound for inhibiting platelet deposition (Bakker 
et al. 1991; van der Lei et al. 1992). Their results show that NTPDase coating on 
polyurethane vascular prostheses improves haemocompatibility.  However, for the case 
of NTPDase coated polyurethane, rapid release of the non-specifically bound NTPDase 
could result in undesired effects. Also, once the coated NTPDase is washed off, the 
polymer would lose the haemocompatibility. Biomaterials with covalently attached 
NTPDase have shown enhanced platelet inhibition when in vivo studies were performed 
by insertion into a dog’s femoral vein (Marconi et al. 1983). Marconi et al. immobilized 
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NTPDase to hydrolyzed PET, despite hydrolyzed PET showing loss of mechanical 
strength due to hydrolysis of PET (Ellison et al. 1982; Sanders and Zeronian 1982; Kao 
et al. 1998; Liu et al. 2005). Based on these studies, effective NTPDase immobilization 
to mechanically stable PET would potentially enhance haemocompatibility. 
Another thromboregulatory mechanism that inhibits platelet adhesion involves the 
release of endothelium derived relaxing factor (EDRF) or nitric oxide (NO). Studies have 
shown that NO inhibits platelet adhesion by a cGMP dependent mechanism (Mellion et 
al. 1981; Konishi et al. 1996). Some studies had been performed to improve 
haemocompatibility by attaching NO-releasing compounds to polymer surfaces 
(Saavedra et al. 1996; Smith et al. 1996). However, attaching NO-releasing compounds 
has a number of limitations including superoxide formation, interactions with iron and 
exhaustion of NO. It has been established that cysteine molecules attached to biopolymer 
surfaces utilize endogenous NO and inhibit platelet adhesion by up to 67% (Duan and 
Lewis 2002). This eliminates the limitations involved in attaching NO-releasing 
compounds. Furthermore, a study has shown that NTPDase enhanced the platelet 
inhibition effect of NO in an additive dose-dependent manner (Ramamurthi et al. 2001). 
Hence, attaching both NTPDase and cysteine to PET surface will exhibit enhanced 
platelet inhibition. 
The objectives for this project include modifying PET surfaces to introduce 
reactive functional groups, successfully immobilizing NTPDase, characterizing the 
modified polymer to understand surface and bulk properties, studying the enzyme 
kinetics of immobilized NTPDase, demonstrating improved haemocompatibility and 
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immobilizing NTPDase and cysteine together on PET surface. These objectives are 
outlined in more detail below. 
 
1.1 Objective #1: Analysis of functionalized PET 
 
As mentioned earlier, PET is an inert polymer and lacks active functional groups 
on the surface. Hence, surface functionalization of polyethylene terephthalate is 
necessary for immobilizing biomolecules. Currently, many techniques such as hydrolysis 
(Ellison et al. 1982; Kao et al. 1998; Bide et al. 2006), reduction (Bùi et al. 1993), 
glycolysis (Fadeev and McCarthy 1998), aminolysis (Ellison et al. 1982; Avny and 
Rebenfeld 1986; Duan and Lewis 2002; Gappa-Fahlenkamp and Lewis 2005; Bide et al. 
2006; Liu et al. 2008), amination (Nissen et al. 2008) and carboxylation (Yang et al. 
2000) have been utilized. In this work, aminolysis, hydrolysis and carboxylation were 
performed to introduce functional groups on a PET surface. Surface characteristics of the 
modified PET were studied using a scanning electron microscope (SEM) and an atomic 
force microscope (AFM). To understand the bulk properties of the modified polymer, 
tensile strength was studied. NTPDase was covalently attached to the modified polymers. 
The attachment was verified by studying the activity of NTPDase. 
 
1.2 Objective #2: Kinetic analysis of immobilized NTPDase 
 
Immobilized NTPDase kinetics were studied and compared with free NTPDase 
kinetics. Immobilized NTPDase kinetics were modeled. The stability and the 
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effectiveness of the attachment were also analyzed. The effects of storage on NTPDase-
modified PET was also analyzed. 
 
1.3 Objective #3: In vitro studies of NTPDase-modified PET 
 
For analyzing the haemocompatibility of NTPDase-modified polymer, protein 
adsorption in vitro studies were performed. For this purpose, adsorption of bovine serum 
albumin on the modified polymer was measured and compared with unmodified polymer. 
Platelet-rich plasma studies were performed to analyze platelet deposition on the 
modified surfaces. Whole blood analysis was also performed to verify 
haemocompatibility. These results were compared to that of unmodified polymer. 
 
1.4 Objective #4: Immobilization of both NTPDase and cysteine 
 
NTPDase and cysteine were immobilized on the surface of carboxylated PET. 
The attachment was verified by studying the activity of NTPDase and measuring the 
concentration of cysteine on the polymer surface. Stability of the attachment was studied. 
 While developing a material for biomedical applications, it is important to 
understand the biocompatibility of the material. It is also critical to evaluate the surface 
and the bulk properties of the material, as these properties play a vital role in determining 
the applications in which the material can be used. However most of the research 
performed in developing haemocompatible biomaterials does not analyze the surface and 
the bulk properties. Without this information, it is very difficult to evaluate the 
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applications of biomaterials. Although there are many studies involving improving 
haemocompatibility of biomaterials, this work is unique because it discusses both aspects 
involved in developing a useful biomedical material, namely, physical properties of the 
modified polymer and ability to immobilize biologically active molecules to the modified 
surface. In this research, a haemocompatible polymer with desired surface and bulk 
properties was developed. This study also provides further insight into the potential of 
utilizing ADP scavenging as a technique to improve haemocompatibility. This study also 
explores the potential of utilizing both NTPDase and cysteine simultaneously to possibly 
provide enhanced haemocompatibility. As NTPDase and cysteine inhibit platelet 
adhesion via separate mechanisms, immobilizing NTPDase cysteine would utilize two 
different endogenous platelet inhibition pathways simultaneously. Such a method would 
be a significant improvement over the current technologies. 
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CHAPTER 2 
 
 
LITERATURE REVIEW 
 
 For developing a biomaterial that utilizes naturally occurring anti-coagulant 
pathways to improve haemocompatibility, understanding the blood coagulation 
mechanism and the anti-coagulant pathways is critical. Furthermore, in-depth knowledge 
of desirable properties of biomaterials is also vital for developing a viable biopolymer. 
This chapter reviews the mechanisms and the components involved in the blood 
interaction with biopolymer surfaces. The current techniques that are used for improving 
haemocompatibility and their limitations are also discussed. Functionality of NTPDase in 
regulating blood coagulation and its potential in improving haemocompatibility of 
biomaterials are examined thoroughly. 
 
2.1 Constituents of Blood 
 
 Blood is a specialized bodily fluid that acts as a vehicle of transportation 
mediating the cellular interactions and physiological mechanisms. Blood constitutes 
about 7% of human body weight with an average volume of around 5 liters (Alberts 
2005). Blood contains various types of cells suspended in plasma (Beutler and Williams 
1995). The formed elements of blood are erythrocytes or red blood cells (RBC), 
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leukocytes or white blood cells (WBC) and platelets. These cells constitute 45% of the 
whole blood volume and the plasma constitutes the remaining 55%. 
 
2.1.1 Plasma 
  
A normal adult has an average of 25 to 45 ml of plasma per kg of body weight 
(Berne and Levy 1993). Plasma is a complex aqueous medium in which innumerable 
substances are dissolved (Ratnoff 1983). Some of the substances dissolved in plasma 
include oxygen, carbon dioxide, nitrogen, electrolytes, proteins, lipids, carbohydrates, 
amino acids, vitamins, hormones and nitrogenous breakdown products of metabolism. 
The concentration of these substances varies with diet, metabolism and the levels of 
hormones and vitamins. Usually, many homeostatic mechanisms help in maintaining the 
composition of blood in a biologically safe and useful range. 
The charged components present in the plasma help in maintaining the osmolarity 
and pH of blood within physiological limits (Ratnoff 1983). The primary inorganic cation 
in plasma is sodium. Plasma also contains lesser quantities of ionic potassium, calcium 
and magnesium (Ratnoff 1983). The primary anion in plasma is chloride. Plasma also 
contains bicarbonate, plasma protein, phosphate, sulfate and organic acids (Ratnoff 
1983). Highly structured metabolic and physiological processes regulate the 
concentration of ions present in the plasma to maintain the normal composition. 
Plasma also contains hundreds of dissolved proteins. Total protein concentration 
in plasma is approximately 7 g/dl (Berne and Levy 1993). Most the proteins are of two 
types, namely, albumin and immunoglobulins. Albumin, which is synthesized in the liver 
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by hepatic parenchymal cells, is present at a concentration of 4 g/dl (Fournier 1999). 
Albumin plays a key role in providing colloid osmotic or oncotic pressure as it doesn’t 
diffuse easily through intact vascular endothelium. This helps in regulating the passage of 
water and diffusible solutes through the capillary (Ratnoff 1983). Albumin is also a 
carrier for substances that are adsorbed to it. 
Immunoglobulins or antibodies constitute the second highest concentration in 
blood plasma. These are synthesized by the plasma cells in the lymphoid organs (Ratnoff 
1983). Antibodies play a vital role in defense against infections. On exposure to antigens, 
which are usually stimulants foreign to the normal body, lymphocytes get stimulated. 
This results in formation of specific antibodies. Immunoglobulins are classified into five 
groups based on the amino acid composition, structure and functions. They are IgG, IgM, 
IgA, IgD and IgE. IgG antibodies are found in all body fluids. They are the smallest but 
most common antibody (75% to 80%) of all the antibodies in the body (Pier et al. 2004). 
IgG antibodies are very important in fighting bacterial and viral infections. IgG 
antibodies are the only type of antibody that can cross the placenta in a pregnant woman 
to help protect her baby (Pier et al. 2004).  
Plasma also contains clotting factors required for blood coagulation, such as 
fibrinogen, the most abundant; complement, a group of proteins involved in immune 
responses; enzymes, enzyme precursors and enzyme inhibitors; specific carriers of 
constituents like iron and copper; and scavengers of agents inadvertently released in to 
the plasma (Ratnoff 1983). Plasma lipids such as triglycerides, phospholipids, cholesterol 
and fatty acids are transported as complexes with plasma proteins (Ratnoff 1983). 
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2.1.2 Red Blood Cells 
 
Red blood cells or erythrocytes contribute to the majority of the cellular 
composition of blood. RBCs occupy 48% of the total volume of blood in men and 42% in 
women (Ratnoff 1983). The percent of RBC in blood is called as hematocrit. The red 
blood cell count ranges between 4-6 million/µl (Ratnoff 1983). Red blood cells are 
continuously produced in our bone marrow from stem cells. Red blood cells are devoid of 
a nucleus, as they lose their nuclei before entering into the blood stream. As seen in 
Figure 2.1a, red blood cells are shaped like a biconcave lens. Vitamin B12, folic acid and 
iron are required for effective maturation of red blood cells. Iron is required for formation 
of hemoglobin, the primary constituent of the cytoplasm of red blood cells (Ratnoff 
1983). Hemoglobin is produced in the red blood cell precursors inside the bone marrow. 
Hemoglobin is a complex protein containing four polypeptide “globin” subunits attached 
to a prosthetic group consisting of tetrapyrrole heme. Each heme unit surrounds an atom 
or iron. Atmospheric oxygen, diffusing into the red blood cells, attach to this iron atom. 
Oxygen is then released to the tissues in the peripheral capillaries. Hemoglobin is also 
involved in transport of some carbon dioxide attached to the globin portion (Ratnoff 
1983). Reduced levels of red blood cells in the blood stream is called anemia. This occurs 
due to reduced synthesis of red blood cells or premature destruction or loss due to 
hemorrhage. Reduced synthesis could occur due to deficiencies in vitamin B12 or iron, 
which are required for formation of hemoglobin. Life span of red blood cells is normally 
about 120 days (Ratnoff 1983). This may be shortened due to damage caused by 
antibodies resulting in a process called hemolysis. 
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Figure 2.1. Cellular Components of Blood. (a) Erythrocytes or Red Blood Cells; (b) 
Neutrophils; (c) Eosinophils; (d) Basophils; (e) Monocytes; (f) Lymphocytes; (g) 
Platelets. Images were obtained from The Merck Manuals: Online Medical Library 
(Frenkel 2006).
 18
2.1.3 White Blood Cells 
 
White blood cells or leukocytes are a small portion of blood cellular constituents. 
Normal WBC count in human blood is between 4000-10,000 cells/µl. White blood cells 
are responsible primarily for defending the body against infection. White blood cells can 
be categorized into five classes, namely, neutrophils, eosinophils, basophils, monocytes 
and lymphocytes. Neutrophils (Figure 2.1b) are the most common type of leukocytes. 
Neutrophils protect the body against infections by killing and ingesting bacteria and fungi 
and ingesting foreign materials (Berne and Levy 1993; Beutler and Williams 1995; 
Frenkel 2006). Eosinophils (Figure 2.1c) are involved in allergic responses. They are also 
responsible for killing parasites and destroying cancer cells (Ratnoff 1983; Frenkel 2006). 
Basophils (Figure 2.1d) are also involved in allergic responses (Ratnoff 1983; Frenkel 
2006). Neutrophils, eosinophils and basophils are collectively known as the granulocytes. 
Monocytes (Figure 2.1b) are the largest form of leukocytes with an average diameter of 
15 to 20 µm (Ratnoff 1983). Monocytes ingest dead or damaged cells and help defend 
against many infectious organisms. Lymphocytes are a heterogeneous group of cells with 
large nuclei. Three types of lymphocytes have been identified based on differences in 
function. They are B-cells, T-cells and null cells. On stimulation by antigens, B-cells 
transform to produce specific immunoglobulin antibodies (Ratnoff 1983). T-cells help 
protect against viral infections and can detect and destroy some cancer cells. Null cells 
are also called as killer cells. They are capable of destroying tissue cells that are coated 
with antibody. 
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Some white blood cells flow smoothly through the bloodstream, but many adhere 
to blood vessel walls or even penetrate the vessel walls to enter other tissues. When white 
blood cells reach the site of an infection or other problem, they release substances that 
attract more white blood cells. The white blood cells function like an army, dispersed 
throughout the body but ready at a moment's notice to gather and fight off an invading 
organism. White blood cells accomplish this by engulfing and digesting organisms and 
by producing antibodies that attach to organisms so that they can be more easily 
destroyed. 
 
2.1.4 Platelets 
 
Platelets are anuclear disk-shaped cells found in the blood plasma (Figure 2.1g). 
They have an average diameter of 3-4 µm, a thickness ~1 µm and an average volume of 
around 10 µm3 (Frojmovic and Panjwani 1976). Platelets are produced by megakaryotes 
in the bone marrow and have a life span of 8 to 12 days in humans (Ratnoff 1983). 
Platelets circulate at a average count of 250,000 cells per microliter of whole blood 
(Hanson 2004). The primary function of platelets is control of bleeding by causing blood 
coagulation. The mechanism of blood coagulation is discussed in detail in the next 
section. The organelles and components present in platelets (Figure 2.2) that are involved 
in blood coagulation are explained here. 
Two glycoproteins on the platelet membrane, namely, glycoprotein (GP) IIb/IIIa 
and GP Ib-IX, act as principal receptors. GP IIb/IIIa receptor binds strongly to fibrinogen 
(Sims et al. 1991) and von Willebrand factor (vWF) (Savage et al. 1996) after platelet 
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activation leading to platelet aggregation. Platelet membrane phospholipids also play a 
role in platelet activation and clot formation. Actin microfilament present in the platelet 
cytoskeleton is responsible for developing filopodia, a long spike protruding from the 
growing tip on a cell, via polymerization and phosphorylation during activation (Fox and 
Phillips 1982). Microtubules in the cytoskeleton reassemble during platelet activation and 
cause the platelet shape change from discoid to round (Fox et al. 1993). The granular 
compartment and the membrane of α-granules store several important proteins involved 
in blood coagulation, including platelet factor 4 (Harrison et al. 1990), vWF, fibronectin, 
fibrinogen (Wencel-Drake et al. 1985), coagulation factor V (Hayward et al. 1995) and 
GP IIb/IIIa (Cramer et al. 1990). Dense granules contain adenosine diphosphate (ADP), 
adenosine triphosphate (ATP), Ca2+ and serotonin (5-HT). ADP acts as a trigger for 
platelet aggregation and calcium ions are critical for platelet functions as most enzymatic 
functions are calcium-dependent. Lysosomal granules are released slowly and 
incompletely, suggesting they play a greater role in anticoagulation (White 1993). 
 
2.2 Blood Coagulation 
 
Blood coagulation is an important defense mechanism to prevent excessive 
bleeding. It is also known as hemostasis. Hemostasis proceeds in two phases: primary 
and secondary hemostasis. Primary hemostasis is characterized by platelet adhesion to the 
damaged blood vessel, platelet activation due to agonists, and platelet aggregation via 
fibrinogen. Primary hemostasis is short lived. If flow is allowed to increase, the platelet 
aggregate could be sheared from the injured surface. 
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Figure 2.2. Structure of human platelet (Hanson 2004). 
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Secondary hemostasis is responsible for stabilizing the platelet aggregate by 
granular secretion and complex interaction between platelet membrane, enzymes, and 
coagulation factors. During secondary hemostasis, coagulation cascade activates the 
coagulation factors and leads to the conversion of fibrinogen to fibrin, which stabilizes 
the clot. Figure 2.3 is a schematic representation of platelet reactions when exposed to a 
stimulus. 
 
2.2.1 Platelet Adhesion and Activation 
 
The first step in blood coagulation is platelet adhesion. When blood is exposed to 
an injured vessel, platelets adhere to the surface by an interaction between the 
glycoprotein Ib (GP Ib) on the platelet surface and the connective tissue elements 
(especially collagen) that are exposed mediated by von Willebrand factor (vWF) as a 
required cofactor (Colman et al. 2005). When blood is exposed to a foreign surface, 
platelets adhesion may be mediated through glycoprotein IIb/IIIa as well as GP Ib-vWF 
interaction (Hanson 2004). GP IIb/IIIa is the platelet receptor for adhesive plasma 
proteins such as fibrinogen, vWF, fibronectin and vitronectin (Gresele et al. 2002). These 
plasma proteins aid in cell attachment. This binding usually occurs when GP IIb/IIIa has 
undergone a conformational change due to platelet activation. Platelets in the resting state 
do not bind these proteins. Platelets are activated when they come in contact with an 
injured blood vessel or a foreign surface or a platelet agonist such as ADP, 5-HT and 
thromboxane A2 (TXA2). Unactivated GP IIb/IIIa may also bind to surface proteins that 
have undergone conformational changes (Hanson 2004). 
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Figure 2.3. Platelet reactions to a stimulus (injured blood vessel or contact to foreign 
surface). Figure modified from (Adams 1985)
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2.2.2 Platelet Aggregation 
 
Platelet aggregation occurs within one minute of activation (Savi and Herbert 
1996). After platelet adhesion, the following reactions occur: (1) the release of dense 
granule ADP, (2) formation of small quantities of thrombin and (3) activation of platelet 
biochemical processes leading to the generation of TXA2. ADP, thrombin and 
thromboxanes, released into the blood plasma, act as agonists that activate more platelets. 
Due to this more, platelets are recruited to form a platelet aggregate. Platelet activation 
caused by these agonists results in the binding of activated GP IIb/IIIa on the platelet 
surface to the plasma proteins (primarily fibrinogen) that promote platelet aggregation. 
Platelet-platelet interactions develop when the GPIIb/IIIa complex is activated to bind 
fibrinogen. Each molecule of fibrinogen recognizes two GPIIb/IIIa complexes, which 
allows Ca2+-dependant molecular bridges to form between two adjacent platelets 
(Perutelli and Mori 1992). Thrombin also binds to the platelet thrombin receptors. This 
results in (1) activating platelets, which then catalyze the formation of more thrombin, (2) 
stimulating ADP release and TXA2 formation and (3) stimulating the formation of fibrin, 
which stabilizes the thrombus. 
 
2.2.3 Granular Secretion 
 
The release of substances stored in the platelet granules to the blood plasma is 
called granular secretion. Some of the physiologically important granules include ADP, 
collagen, epinephrine and thrombin. These granules act as release-inducing agents by 
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interacting with the platelets through specific receptors on the surface. α-granules such as 
platelet factor 4 (PF4), β-TG, vWF, fibronectin and fibrinogen are released by relatively 
weak agonists like ADP. Dense granules such as adenosine diphosphate (ADP), Ca2+ and 
serotonin (5-HT) are released by stronger agonists like thrombin. Agonist binding to 
platelets also initiates the formation of TXA2, activation of contractile-secretory 
apparatus and mobilization of calcium from intracellular storage sites. This granule 
secretion and release of ADP promotes further aggregation through autocrine and 
paracrine stimulation and leads to blood coagulation (Holmsen 1994). 
 
2.2.4 Platelet Coagulant Activity 
 
Platelet aggregation also results in expression of negatively charged membrane 
phospholipids. This accelerates factor X activation and the conversion of prothrombin to 
thrombin. Hence, the platelet aggregate surface acts as a site for rapid synthesis of 
thrombin in excess of the neutralizing capacity of blood anticoagulant mechanisms. 
Thrombin is also required for polymerizing fibrinogen to form fibrin. Fibrin polymer then 
forms a stable clot. 
 
2.2.5 Coagulation Cascade 
 
Blood coagulation proceeds through a cascade of reactions that occur following a 
stimulus (injured vessel or contact to foreign surface). The coagulation factors (serine 
proteases) present in the inactive form in blood get activated due to the stimulus or 
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proteolytic cleavage by other coagulation factors. These active coagulation factors 
continue the series of reactions resulting in a cascade. Figure 2.4 shows a schematic of 
the blood coagulation cascade.  
The coagulation cascade can either be intrinsic (when exposed to foreign surface) 
or extrinsic (injured vessel). The cascade mechanisms are well established (Ratnoff 1983; 
Hanson 2004). During intrinsic cascade, adhesion of contact factors to a negatively 
charged surface results in activation of factor XII (Hageman factor). The activated factor 
XII (XIIa) converts prekallikrein to kallikrein. More factor XIIa and kallikrein are 
produced by reciprocal activation. Factor XIIa also activates factor XI (Rosenthal’s 
factor) to form XIa. Both prekallikrein and factor XI bind to a cofactor, high-molecular 
weight kininogen (HMWK). Factor IX (Christmas factor) is activated by factor XIa in a 
calcium-dependent step. Factor IXa activates factor X (Stuart-Prower factor) using factor 
VIIIa as a cofactor. Factor VIIIa is formed from factor VIII (antihaemophilic globulin) by 
the activity of an enzyme such as thrombin (Factor IIa). In the extrinsic cascade, factor 
VII (proconvertin, serum prothrombin conversion accelerator) is activated by tissue 
factor, a cell membrane protein that becomes available when underlying vascular 
structures are exposed to flowing blood due to injury. Factor VIIa acts as the extrinsic 
pathway activator of factor X. The common pathway begins when factor X is activated to 
form factor Xa. Factor Xa forms a complex with factor Va, a cofactor. Factor Va is 
formed from factor V (proaccelerin, ac-globulin, labile factor) by the activity of an 
enzyme such as thrombin. Factor Xa-Va complex converts prothrombin to thrombin, in 
the presence of calcium and platelet phospholipids. In addition to activating factors VIII 
and V, thrombin also activates factor XIII (fibrinase, fibrin stabilizing factor) and  
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Figure 2.4. Blood coagulation cascade.         represents conversion or activation of 
factors, –| represents inhibition,           represents reactions catalyzed and        represents 
the other functions of thrombin. Image adapted from Wikipedia. HMWK – high 
molecular weight kininogen, PK – prekallikrein, F – factor, TFPI – tissue factor pathway 
inhibitor. Figure from (Jfdwolff 2004) 
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catalyzes the polymerization of fibrinogen to fibrin. Factor XIIIa stabilizes the fibrin 
polymer via cross-linking to form a stable clot. 
 
2.3 Anti-thrombotic control mechanisms 
 
Multiple mechanisms exist in blood and vasculature to control the platelet 
adhesion and aggregation to healthy blood vessels. These mechanisms also control the 
size of the clot. These control mechanisms regulate blood coagulation in such a way that 
it is a highly localized and transient phenomenon. Once the injured blood vessels heal, 
the blood clot is removed by natural mechanisms. Understanding these control 
mechanisms would aid in developing materials that utilize these natural pathways to 
improve haemocompatibility.  
At least five different types of control mechanisms need to be considered. First, 
blood flow may reduce the concentration of precursors and activated materials (Hanson 
2004). This would reduce the likelihood of a blood clot growing in size. Second, many of 
the blood coagulation cascade reactions are catalyzed by surface contact (Hanson 2004). 
These reactions include the activation of factor X by factor VIIa and activation of 
prothrombin. Third, naturally occurring inhibitors for coagulation factors could stop the 
cascade and regulate blood coagulation (Hanson 2004). Antithrombin, for example, can 
inhibit thrombin and other coagulation enzymes. Another example would be tissue factor 
pathway inhibitor (TFPI), which inhibits factor VIIa. Fourth, during the coagulation 
cascade, enzymes are generated to degrade coagulation factors (Ratnoff 1983). 
Thrombomodulin, a transmembrane protein, forms a complex with thrombin and 
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activates protein C, which in turn inhibits cofactors V and VIII. Fibrinolytic enzyme 
plasmin activated during coagulation degrades fibrinogen, fibrin and also inactivates 
cofactors V and VIII. Fifth, platelet reactivity is controlled by the endothelium via 
biochemical systems (Marcus et al. 2005). The endothelium synthesizes fluid phase 
reactants intracellularly called autacoids, which are released when the cells come in 
contact with agonists. These autacoids lead to the formation of prostacyclin, nitric oxide 
(NO) and endothelial ecto-adenosine phosphatase (ADPase/CD39/NTPDase), which 
regulate blood coagulation (Marcus et al. 2003; Raggio and Morris 2004; Lwaleed and 
Bass 2005; Wise 2007).  
The control mechanisms can also be classified into two broad categories, namely, 
late thromboregulators and early thromboregulators (Marcus et al. 2003). Late 
thromboregulators apply the effects after thrombin formation and early 
thromboregulators inhibit the events preceding thrombin formation. Antithrombin, tissue 
factor pathway inhibitor, protein C pathway and fibrinolysis are all classified as late 
thromboregulators (Marcus et al. 2003). Prostacyclin, nitric oxide and ecto-
ADPase/CD39/NTPDase are classified as early thromboregulators (Marcus et al. 2003). 
For the purpose of developing a haemocompatible material, detailed understanding of 
naturally occurring inhibitors, enzymes that degrade coagulation factors and endothelium 
regulation is important. 
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2.3.1 Naturally occurring inhibitors 
 
Antithrombin III (ATIII) was the first plasma inhibitory agent that was delineated 
(Ratnoff 1983). ATIII is the primary inhibitor of thrombin and factor Xa (Figure 2.4). 
ATIII also inhibits other activated coagulation factors to a lesser degree. ATIII forms a 
stoichiometric complex with the activated enzymes (Ratnoff 1983). The critical role of 
ATIII in regulating blood coagulation is evident from the frequency of thrombosis in 
people with a deficiency of this inhibitor (Ratnoff 1983). Heparin and heparan sulfate can 
augment the rate of ATIII inhibition of these enzymes by several thousand-fold (Raggio 
and Morris 2004). Heparin, a negatively charged sulfated polysaccharide, forms a 
complex with ATIII and inhibits thrombin. Without ATIII, heparin isn’t a significant 
anticoagulant (Ratnoff 1983). Heparin is widely used for prevention and treatment of 
thrombotic states. 
α1-Antitrypsin is a glycoprotein synthesized in the liver. This protein acts as a 
protease inhibitor. In vitro studies show that α1-antitrypsin inhibits factor XIa, thrombin, 
kallikrein and plasmin. But the biological significance of this protein in blood 
coagulation is not well established because deficiency of α1-Antitrypsin doesn’t cause 
any disturbance in clotting or fibrinolysis (Ratnoff 1983). However, deficiency of α1-
Antitrypsin causes obstructive pulmonary disease or cirrhosis of the liver (Wise 2007).  
Tissue factor pathway inhibitor (TFPI) is a single-chain polypeptide which plays 
an important role in regulating tissue factor induced blood coagulation. TFPI is an 
endogenous anticoagulant protein, a serine protease inhibitor and is the only known 
regulator of the TF-dependent pathway of blood coagulation (Lwaleed and Bass 2005). 
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TFPI inhibits factor VIIa-TF complex in a factor Xa dependent manner (Figure 2.4) 
(Lwaleed and Bass 2005). Thus, TFPI prevents further activation of factor X in a 
feedback mechanism dependent on the concentration of factor Xa. In the presence of 
TFPI, additional factor Xa can be produced only via the intrinsic pathway. TFPI can 
inhibit activation of factor IX by factor VIIa-TF complex in the absence of factor Xa also. 
But this is achieved by a two-step process: TFPI binds to and inactivates factor Xa (Broze 
1995) and this complex inhibits the factor VIIa-TF complex (Moncada et al. 1990; 
Gurewich 2000). TFPI does not inhibit the intrinsic pathway that is triggered by exposure 
to foreign surfaces. Hence, TFPI may an effective molecule for improving 
haemocompatibility. 
 
2.3.2 Protein C Pathway 
 
Thrombomodulin (TM), a transmembrane protein prevalent on the surface of 
endothelial cells, acts as a cofactor for thrombin induced activation of protein C. TM 
functions as a high affinity receptor for thrombin, which binds with a 1:1 stoichiometry. 
This thrombin-thrombomodulin complex activates protein C. Activated protein C 
degrades factors Va and VIIIa (Figure 2.4). In vivo, the protein C pathway is a vital 
anticoagulant pathway (Esmon 2003; Colman et al. 2005). In addition to activating 
protein C, thrombin bound to TM shows decreased ability to convert fibrinogen to fibrin 
and stimulate platelets (Esmon 1989). The binding of thrombin to TM also accelerates 
inhibition of thrombin by ATIII (Preissner et al. 1987). 
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2.3.3 Fibrinolysis 
 
Fibrinolysis is carried out by the production of the enzyme plasmin from the 
inactive proenzyme plasminogen. Plasminogen is activated by two-chain tissue 
plasminogen activator (t-PA) or two-chain urokinase plasminogen activator (u-PA). 
These activators are secreted as single chain molecules that are converted to two-chain 
activators by plasmin (Cesarman-Maus and Hajjar 2005). The generated plasmin 
degrades the fibrin clot and extracellular matrix molecules (Gurewich 2000). Both t-PA 
and u-PA can be inhibited by plasminogen activator inhibitors (PAI) (Cesarman-Maus 
and Hajjar 2005), while plasmin is inhibited by its major inhibitor, α2-antiplasmin, and to 
a lesser extent by α2-macroglobulin (α2-MG) (Cesarman-Maus and Hajjar 2005). Plasmin 
is then rapidly inhibited unless it remains bound to fibrin or to its cell surface receptors. 
Figure 2.5 shows a simplified fibrinolytic pathway. 
 
2.3.4 Prostacyclin 
 
Prostacyclin (PGI2) is an early thromboregulator (Marcus et al. 2003) and the 
most potent endogenous inhibitor of platelet aggregation (Moncada et al. 1990). PGI2 is 
the main product formed in endothelial cells during arachidonic acid metabolism by the 
action of cyclooxygenase system with PGI2 synthase (Lim and Dey 2002). First, 
arachidonic acid is released from the phospholipid pools by phospholipase A2. This 
arachidonic acid is converted to prostaglandin H2 by the action of cyclooxygenase. 
Prostaglandin H2 is then converted to PGI2 by PGI2 synthase (Vane and Botting 1995). 
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Endothelial cells are the major source of PGI2 in the vasculature. PGI2 helps in regulating 
platelet aggregation and vasodilation (Jin et al. 2005). PGI2 release can be stimulated by 
mechanical and chemical stimuli. PGI2 has a half life of 60 minutes in plasma and it loses 
the inhibitory effects on platelet aggregation in about 30 minutes (Moncada 1982; Jin et 
al. 2005). PGI2 inhibits platelet aggregation via a cAMP-Protein Kinase A signal 
transduction mechanism. PGI2 interacts with a specific G protein receptor on the platelet 
surface, resulting in the activation of adenylate cyclase (Jin et al. 2005). Activation of 
adenylate cyclase increases the production of cyclic adenosine monophosphate (cAMP) 
in platelets (Gorma et al. 1977; Tateson et al. 1977). Increase in cAMP concentrations 
causes phosphorylation of vasodilator-stimulated phospho-protein (VASP) via protein 
kinase A and inhibition of Ca2+ mobilization and granule release (Aszódi et al. 1999). 
VASP regulates fibrinogen receptor inactivation resulting in inhibition of 
fibrinogen binding and fibrinogen-dependent platelet cross-linking (Horstrup et al. 1994). 
Inhibition of Ca2+ mobilization and granule release prevents further platelet activation 
and aggregation (Jin et al. 2005). In addition to inhibiting platelet aggregation, PGI2 also 
returns the activated platelets to a rested state (Jin et al. 2005). Usually PGI2 is used to 
inhibit platelet activation and aggregation during preparation of platelet suspensions 
(Shahbazi et al. 1994; Radomski et al. 1996). Modifying the blood-contacting surface of 
the biomaterial by attaching prostacyclin might not be efficient because of the low half-
life. Also, prostacyclin doesn’t play an important role in inhibiting platelet adhesion 
(Higgs et al. 1978). 
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Figure 2.5. A simplified schematic of fibrinolysis. –| represents inhibition and  
represents reactions. sc-u-PA – single chain urokinase plasminogen activator, sc-t-PA – 
single chain tissue plasminogen activator, tc-u-PA – two chain urokinase plasminogen 
activator, tc-t-PA – two chain tissue plasminogen activator, PAI – plasminogen activator 
inhibitor, α2-MG – α2-macroglobulin. Figure adapted from (Cesarman-Maus and Hajjar 
2005) 
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2.3.5 Nitric Oxide (NO) 
 
In 1980, Furchgott and Zawadzki discovered the presence of an endothelium-
derived relaxing factor (Furchgott and Zawadzki 1980), which was later identified to be 
nitric oxide (Palmer et al. 1987; Ignarro et al. 1999). Nitric oxide has been identified to 
play a vital role in regulating vasodilation, vascular permeability, neurotransmission and 
antithrombotic processes in the vasculature (Palmer et al. 1987). Nitric oxide is 
synthesized in different cells including endothelium, macrophages and platelets 
(Giustarini et al. 2009). Nitric oxide is synthesized enzymatically during the conversion 
of L-arginine to L-citrulline by the action of a class of enzymes called nitric oxide 
synthases (NOS). NOS requires flavin mononucleotide, flavin adenine dinucleotide and 
tetrahydrobiopterin as cofactors and nicotinamide adenine dinucleotide phosphate and 
molecular oxygen as co-substrates (Marletta 1994). NOS is classified into three types 
based on the location and pattern of expression and dependence of Ca2+: nNOS (NOS I) – 
neuronal NOS expressed primarily in the neurons, iNOS (NOS II) – inducible NOS 
expressed in macrophages, smooth muscle cells and neutrophils and eNOS (NOS III) – 
endothelial NOS expressed primarily in the endothelial cells. Activities of nNOS and 
eNOS depend on Ca2+. iNOS is less dependent to the Ca2+ concentrations. NO synthesis 
by iNOS is regulated at the transcription levels. 
Platelets also synthesize and release NO. The levels of NO release is increased 
multiple fold by platelet activation. It has been shown that platelets in the rested state 
release up to 20 nM NO and activated platelets release 5-15 µM NO (Freedman et al. 
1997). This NO released in activated platelets inhibit platelet recruitment for further 
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aggregation (Freedman et al. 1997). This platelet-derived NO could play a major role in 
regulating blood coagulation. 
NO acts in multiple ways to control blood coagulation. NO shows high affinity 
towards heme iron and binds to heme containing proteins including soluble guanylate 
cyclase (sGC). NO bound sGC catalyzes the conversion of guanosine triphosphate (GTP) 
to 3, 5-cyclic guanosine monophosphate (cGMP). cGMP activates cGMP dependent 
kinase that phosphorylates specific proteins leading to platelet inhibition (Mellion et al. 
1981). NO has also been associated with decreasing the intracellular levels of Ca2+ (Jin et 
al. 2005). Lower Ca2+ concentration results in inhibition of cytoskeletal rearrangement, 
α- and dense granule secretion and overall platelet activation (Jin et al. 2005). cGMP, 
produced by the action of NO, and cGMP-dependent protein kinase inhibit the TXA2 
mediated platelet activation by catalyzing the phosphorylation of TXA2 receptors (Wang 
et al. 1998). Studies have suggested that NO attenuates the expression of P-selectin, a 
protein required for platelet adherence to the endothelium, via cGMP-dependent protein 
kinase (Davenpek et al. 1994; Maurohara et al. 1995). NO can also slow down the cross-
linking of activated platelets by reducing the number of GPIIb/IIIa receptors on the 
platelet surface (Mendelsohn et al. 1990) and by increasing the dissociation constant of 
the receptor for fibrinogen (Jin et al. 2005). Due to these effects, platelet-platelet 
interaction is reduced as the activated platelets can’t bind with the fibrinogen, which is 
required for forming molecular bridges. NO also diffuses readily to act on the other 
surrounding platelets. Figure 2.6 is a schematic representation of the multiple roles of NO 
in platelet inhibition. 
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Figure 2.6.  Effects of nitric oxide on platelet inhibition. NO – nitric oxide, TXA2 
receptors – thromboxane A2 receptors, sGC – soluble guanylate cyclase, GTP – 
guanosine triphosphate, cGMP – cyclic guanosine monophosphate.  represents 
activation or formation, –| represents inhibition or suppression and        represents 
diffusion. Figure adapted from (Jin et al. 2005) 
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2.3.6 Endothelial ecto-adenosine phosphatase (ADPase/CD39/NTPDase) 
 
Platelets in the circulating blood are maintained at the rested state by the action of 
prostacyclin and NO released by endothelial cells. As discussed in blood coagulation, 
when the platelets are exposed to a stimulus, platelets adhere to the surface, get activated 
and release ADP and other agonists such as TXA2 and 5-HT. ADP acts as a paracrine 
signal for recruiting other platelets and forming a thrombus (Dai et al. 2004). This ADP-
induced platelet aggregation is regulated by the action of a nucleotidase, CD39 (Gayle III 
et al. 1998; Weksler 2000). 
Although the presence of a nucleotidase on the plasma membrane of cells has 
been known for over 50 years (Rothstein et al. 1953), the identification of these enzymes 
was done in the last decade (Plesner 1995; Handa and Guidotti 1996). 
ADPase/CD39/NTPDase is membrane glycoprotein initially found in the lymphoid cells 
(Jin et al. 2005). CD39 hydrolyzes nucleotide tri and/or diphosphates in the presence of 
bivalent cations such as Ca2+ and Mg2+ (Kaczmarek et al. 1996; Wang and Guidotti 
1996). CD39 is an integral membrane protein with two transmembrane domains – a small 
amino and carboxy terminal in the cytoplasm and a large extracellular domain that is 
responsible for the enzymatic activity (Treuheit et al. 1992; Stout and Kirley 1994). 
Micromolar concentrations of ADP, released during dense granule secretion by the 
platelets, cause the platelets to change shape from smooth discoids to spiculated spheres, 
leading to platelet aggregation (Savi and Herbert 1996; Dai et al. 2004). ADP binds to the 
P2 purine receptors on platelets, causing platelet aggregation (Savi and Herbert 1998).  
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CD39 rapidly metabolizes ADP released from activated platelets resulting in 
return of platelets to the resting state (Marcus et al. 1997). ADP metabolized by CD39 
forms adenosine monophosphate (AMP), which is further metabolized to form adenosine 
by the action of 5’-nucleotidase (Zimmerman 1992). Adenosine activates adenylate 
cyclase and triggers the cAMP-dependent inhibition of platelet aggregation (Marcus and 
Safier 1993). These actions of CD39 modulates intravascular platelet accumulation and 
helps localize thrombus formation to the setting of tissue injury (Marcus and Safier 
1993). Some studies have demonstrated that CD39 also blocks the binding of fibrinogen 
or von Willebrand factor to platelets by inhibiting the activation of platelet glycoprotein 
IIb/IIIa adhesion receptors (Makita et al. 1998). CD39 maintains vascular fluidity in the 
complete absence of PGI2 and NO, indicating that the latter are ancillary components of 
thrombosis (Marcus et al. 2005). Studies done on three different animal models have 
shown that CD39 is an effective thromboregulator purely by acting on the platelet 
releasates (Marcus et al. 2003; Marcus et al. 2005). Figure 2.7 shows the mechanism by 
which CD39 inhibits platelet aggregation. Metabolic removal of ADP secreted by the 
activated platelets has potential to be used as an effective anti-thrombotic mechanism for 
enhancing haemocompatibility. 
 40
 
Figure 2.7. Mechanism of platelet inhibition by CD39/NTPDase by regulating ADP-
induced platelet aggregation.  represents formation or release and –| represents 
inhibition.
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Enzymes that catalyze hydrolysis of ADP to form AMP have also been identified 
in the salivary glands of arthropods (Basanova et al. 2002), which inhibit ADP-induced 
blood coagulation to facilitate blood feeding, the endoplasmic reticulum of rats, which 
plays an intracellular role in glycosylation (Failer et al. 2002), skeletal muscle transverse 
tubules in rabbits (Treuheit et al. 1992), gizzard smooth muscles in chicken (Stout and 
Kirley 1994), vascular endothelium, smooth muscle, spleen and lungs of pigs (Lemmens 
et al. 2000), stems of garden pea (Pisum sativum) (Shibata et al. 1999) and potato tubers 
(Solanum tuberosum) (Handa and Guidotti 1996). Similar nucleotidases have also been 
identified and characterized in a number of other organisms including Caenorhabditis 
elegans (Ucceletti et al. 2008), baker’s yeast (Saccharomyces cerevisiae) (Gao et al. 
1999), fission yeast (Schizosaccharomyces pombe) (D'Alessio et al. 2003) and 
Toxoplasma gondii (Asai et al. 1995). Immobilizing one of these enzymes to the surface 
of a biomaterial would potentially improve the haemocompatibility by inhibiting ADP-
induced platelet aggregation. 
 
2.4 Current technologies used to improve haemocompatibility 
 
Currently many techniques are employed to improve haemocompatibility of 
biomaterials. These methods can be classified into three broad techniques, namely, (1) 
increasing surface hydrophilicity, (2) disguising material surfaces and (3) attaching 
biologically active molecules. Surface hydrophilicity can be enhanced by grafting long 
hydrophilic chains (Golander and Kiss 1988; Brinkman et al. 1989; Nojiri et al. 1990) or 
incorporating hydrogels to the surface. The main problem with this approach is that when 
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the surface interacts with the surroundings, these long chains create high steric hindrance 
that affects the biological properties of the biomaterials. The retention of large quantities 
of water by hydrogels makes the surface similar to biological tissues. However, low cell 
adhesion, because of hydrogels, does not translate to low thrombogenicity as a number of 
hydrogels used as dialysis membrane materials are recognized as thrombogenic (Sefton 
1990). Surfaces that come in contact with blood can also be disguised so that they are not 
recognized as a foreign material by blood. Some of the common procedures are 
endothelialization (Herring et al. 1984), albumin passivation (Kottke-Marchant et al. 
1989; Amiji et al. 1992), and phopholipid mimicking surfaces (Durrani et al. 1986; 
Ishihara et al. 1991; Iwasaki et al. 1996; Ishihara et al. 1999a; Ishihara et al. 1999b). But, 
preparing surface disguised biomaterials in bulk and storing them could be a challenge. 
Also, this technique doesn’t stop platelet activation when the material is used in 
extracorporeal systems (Borgdorff et al. 1999). 
Attaching biologically active molecules to improve haemocompatibility is a 
commonly used procedure. Some commonly used compounds are heparin (Heyman et al. 
1985; Han et al. 1989), hirudin (Seifert et al. 1997), nitric oxide (Tullett and Rees 1999) 
and NO-releasing compounds (Smith et al. 1996). Coating surfaces with heparin (Gott et 
al. 1963) is one of the most popular techniques in improving haemocompatibility. In 
addition to the effect on ATIII, heparin also helps in the formation of a blood-friendly 
secondary superficial membrane (Vroman 1988; Wendel and Ziemer 1999). Heparin has 
been attached to different surfaces physically, ionically and covalently. Ionic binding of 
heparin has been used in the commercial manufacture of polyurethane catheters 
(Angiocath, Toray Industries) and cardiopulmonary bypass circuits (Baxter Bentley 
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Healtcare Systems). However, if heparin is bound ionically to a surface, it can be slowly 
released over time (Magnani and Piras 2008). Covalent binding of heparin leads to loss of 
activity.  Surface coating with heparin shows improved haemocompatibility over a period 
of time. However, uncontrolled release, loss of heparin activity over time and 
consumption of plasma coagulation factors limit its use (Larsson et al. 1987). Direct 
inhibition of thrombin can be achieved by immobilizing molecules such as hirudin 
(Seifert et al. 1997). Although hirudin improves haemocompatibility and doesn’t bind 
with plasma coagulation factors, the long term use is very limited due to the short half 
life of 1 – 1.5 h (Nowak et al. 1992).  
Protein C pathway has been utilized to improve haemocompatibility by covalently 
immobilizing thrombomodulin (Sperling et al. 2004). By attaching thrombomodulin to 
the surface of poly(ethylene glycol), Sperling et al. proved improved haemocompatibility 
of the material. But this method could pose a serious limitation. Activated protein C, 
which has a half-life of 20 – 30 minutes (Sperling et al. 2004), may be transported by 
blood flow and it could inhibit clot formation on an injured vessel. This could cause 
hemorrhage. In short, this procedure might not have the desired site-specificity.  
Fibrinolytic pathway can be used to enhance haemocompatibility of materials. 
Attachment of plasmin to the material would not provide sustained haemocompatibility 
as plasmin has a very short half life (Wiman and Collen 1978). However, the fibrinolytic 
pathway may be used to enhance haemocompatibility by attaching plasminogen 
activation factors to the surface. Antithrombotic mechanisms of a polymer surface with 
immobilized urokinase have been studied (Sugitachi and Takagi 1978; Ohshiro and 
Kosaki 1980; Kitamoto et al. 1987; Kitamoto et al. 1991). The results showed enhanced 
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haemocompatibility of the polymers. However, urokinase is not an easily available 
protein and hence, using it for mass production of blood-contact materials might not be 
economically feasible. Also, action of urokinase takes effect only in the fibrinolysis 
process. Due to this, the formation of blood clots is not prevented, but the clots formed 
are degraded by the action of plasmin activated by the urokinase-modified material. 
An earlier study has applied the concept of NO inhibition of platelet adhesion to 
improve haemocompatibility by incorporating NO-releasing compounds in polymers 
which release NO following contact with blood (Saavedra et al. 1996). Another study 
demonstrated the covalent attachment of NO-releasing compounds to polymeric matrices 
in which the time-course of NO release was variable (Smith et al. 1996). The major 
drawback of these techniques is the exhaustion of NO molecule. This limitation can be 
overcome by utilizing endogenous NO. Although the free NO in blood stream is only 3 
nM, the concentration of S-nitrosothiols (RSNO) is 7 µM and is primarily composed of 
S-nitrosoalbumin (Stamler et al. 1992). These S-nitrosothiols are considered to be 
endogenous reservoirs of NO. It is established that in solution the NO associated with S-
nitroso albumin preferentially transferred to cysteine (Meyer et al. 1994). Earlier work 
done in this lab has shown that attaching cysteine to PET and polyurethane inhibits 
platelet deposition by 67% (Duan and Lewis 2002). These results show that the 
haemocompatibility is enhanced by modifying the surface of the biomaterial with 
cysteine. 
Bakker et al. used metabolic removal of ADP to improve haemocompatibility of 
polymer surfaces by coating polyurethane vascular prostheses with NTPDase from potato 
(Bakker et al. 1991; van der Lei et al. 1992). When these NTPDase coated prostheses 
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were implanted to the peritoneal cavity of rats (Bakker et al. 1991) and carotid arteries in 
rabbits (Bakker et al. 1991; van der Lei et al. 1992), results show that NTPDase coating 
on prostheses improves haemocompatibility of biomaterials. However, their results 
showed that one of the prostheses, coated with NTPDase, was completely occluded when 
the implant was taken out after 3 weeks (van der Lei et al. 1992). This shows that the 
NTPDase coated polymer lacked prolonged haemocompatibility due to the release of 
NTPDase into the blood stream. Another study has shown that covalent attachment of 
NTPDase to biopolymer surfaces enhance platelet inhibition (Marconi et al. 1983). When 
NTPDase immobilized rings were placed in a dog’s femoral vein for 15 days, the 
materials showed significant haemocompatibility (Marconi et al. 1983). The activity of 
NTPDase immobilized on the biopolymer was approximately 0.7 µM of inorganic 
phosphate released in an hour per cm2 (Marconi et al. 1983). However, the surface 
modification techniques used by Marconi et al. were shown by various studies to cause 
surface deterioration and weakening of mechanical properties (Ellison et al. 1982; 
Sanders and Zeronian 1982; Kao et al. 1998; Liu et al. 2005). These changes in surface 
and bulk properties could limit the applications of the haemocompatible material. Based 
on these studies, it is expected that covalently attaching NTPDase to biopolymer surfaces, 
using a surface modification technique that would not significantly alter the surface and 
bulk properties of the material, would be an effective solution for minimizing the current 
limitations and enhancing platelet inhibition by metabolizing ADP (Marcus et al. 1997). 
This technique would provide effective site-specific platelet inhibition and potentially 
enhance haemocompatibility.  
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The combined effects of NO and NTPDase on platelet deposition has been studied 
in solution (Ramamurthi et al. 2001). Ramamurthi et al. performed an in vitro study to 
compare the inhibition of platelet deposition to a biomaterial by NO in the absence and 
presence of soluble NTPDase. The results of these platelet inhibition studies with NO and 
NTPDase show that the inhibitory effects of NO and NTPDase are additive (Ramamurthi 
et al. 2001). The platelet inhibitory effect of NO was enhanced by the presence of 
NTPDase in a dose-dependent manner (Ramamurthi et al. 2001). Effective 
immobilization of NTPDase and cysteine to the surface of a biomaterial would block 
ADP-induced platelet aggregation and promote NO mediated platelet inhibition. This 
additive nature can be used to further enhance the haemocompatibility in biomaterials. 
 
2.5 Polyethylene terephthalate – a model polymer 
 
To study the effect of NTPDase attachment in improving haemocompatibility, 
NTPDase had to be attached successfully to a model polymer. Polyethylene terephthalate 
(PET) was chosen as the model polymer based on its wide range of biomedical 
applications in blood-contacting systems and desired mechanical strength and durability. 
PET is a linear, aromatic polyester first manufactured by Dupont in 1940s. PET is used in 
vascular prostheses (Vinard et al. 1988; Kottke-Marchant et al. 1989; Haulon et al. 2003; 
Blanchemain et al. 2007a), heart valve sewing cuffs (Tweden et al. 1997; Illingworth et 
al. 1998; Jin et al. 2007), implantable sutures (Homsy et al. 1968; 21CFR878.5000 
2008), surgical mesh (Zieren et al. 2004; Bracco et al. 2005) and components of 
percutaneous access devices (von Recum 1984). PET was first used in biomedical 
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applications as sutures in the 1950s (Taylor 1975). Clinical use of vascular prostheses 
made of woven and knitted PET has been prevalent since the 1960s (Lindenauer et al. 
1976). The biomaterial properties of PET that make the polymer suitable for biomedical 
applications are biostability (Greenwald et al. 1994), promotion of tissue ingrowth 
(Feldman et al. 1983), a well understood fibrotic response (Tilney and Boor 1975; Müller 
and Dasbach 1994) and a long history of human implantation (Brun et al. 1992). PET is 
one of very few materials that has a long history of biomedical applications and is still 
being used in a wide range of applications from sutures to vascular prostheses. 
For improving haemocompatibility of PET, NTPDase has to be covalently 
immobilized to the surface. However, PET is an inert polymer. Surface functional groups 
have to be introduced to attach NTPDase. Currently, many techniques such as hydrolysis 
(Ellison et al. 1982; Kao et al. 1998; Bide et al. 2006), reduction (Bùi et al. 1993), 
glycolysis (Fadeev and McCarthy 1998), aminolysis (Ellison et al. 1982; Avny and 
Rebenfeld 1986; Duan and Lewis 2002; Gappa-Fahlenkamp and Lewis 2005; Bide et al. 
2006; Liu et al. 2008) and amination (Nissen et al. 2008) are used to introduce reactive 
functional groups on PET surfaces. Although these techniques effectively introduce 
reactive groups, surface modifications accompany the limitation of modifying surface 
and bulk properties of PET. Loss of mechanical strength is a common problem associated 
with surface modification due to degradation of the polymer (Ellison et al. 1982; Sanders 
and Zeronian 1982; Fukatsu 1992; Kao et al. 1998). This results in reducing the 
durability of PET in implants and other long term biomedical applications. Even with 
these limitations, many studies have demonstrated immobilization of active biomolecules 
(Kottke-Marchant et al. 1989; Bùi et al. 1993; Duan and Lewis 2002; Aggarwal et al. 
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2005; Liu et al. 2005; Phaneuf et al. 2005; Blanchemain et al. 2007a; Blanchemain et al. 
2007b; Liu et al. 2008). These studies have also showed improved haemocompatibility 
(Heyman et al. 1985; Han et al. 1989; Kottke-Marchant et al. 1989; Duan and Lewis 
2002; Liu et al. 2008), infection resistance (Illingworth et al. 1998; Aggarwal et al. 2005; 
Phaneuf et al. 2005; Blanchemain et al. 2007a; Blanchemain et al. 2007b), and cell 
adhesion (Liu et al. 2005). In addition to techniques such as aminolysis and hydrolysis, 
carboxylation has been performed to introduce reactive carboxyl groups to PET surfaces 
(Yang et al. 2000). However, the surface and bulk properties of carboxylated PET 
haven’t been explored. Covalent immobilization of NTPDase to a functionalized PET 
surface with desired surface and bulk properties would fabricate a viable biomaterial with 
enhanced haemocompatibility. 
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CHAPTER 3 
 
 
ANALYSIS OF FUNCTIONALIZED POLYETHYLENE TEREPHTHALATE WITH 
IMMOBILIZED NTPDase 
 
 Biomaterials developed for specific functions need to possess particular surface 
and bulk properties. When designing a biomaterial for blood-contact systems, it is critical 
to understand the surface properties of the material. Surface properties of the material 
could determine many biological reactions and responses, such as protein adsorption and 
blood compatibility. Surface properties also influence cell adhesion and cell growth, 
which would be important for the material to integrate with the body. The importance of 
surface properties on biological responses has been appreciated for a long time. In 
addition to surface properties, desired bulk properties such as mechanical strength, 
permeability and durability also influence the applications of biomaterials. Classic 
techniques have been developed by engineers and material scientists for studying the 
surface and bulk properties of biomaterials. This chapter discusses three different 
techniques to introduce reactive functional groups to polyethylene terephthalate and the 
associated effects of functionalization on the surface and bulk properties. Studies 
performed on immobilizing NTPDase on functionalized PET and the effectiveness of the 
immobilization are also discussed. Based on these studies, a preferred method of surface 
modification is identified and used for further exploration. 
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3.1 Introduction 
 
For this research, it was important to choose a model polymer that had various 
clinical and biomedical applications. The polymer also had to be mechanically strong 
with desirable surface properties. Based on these requirements, polyethylene 
terephthalate (PET), a linear, aromatic polyester, was chosen. Many studies have shown 
that PET is a strong and durable polymer for biomedical applications (Bide et al. 2006; 
Nissen et al. 2008). PET also has a wide range of medical applications which include 
vascular prostheses (Vinard et al. 1988; Kottke-Marchant et al. 1989; Haulon et al. 2003; 
Blanchemain et al. 2007a), heart valve sewing cuffs (Tweden et al. 1997; Illingworth et 
al. 1998; Jin et al. 2007), implantable sutures (Homsy et al. 1968; 21CFR878.5000 2008) 
and surgical mesh (Zieren et al. 2004; Bracco et al. 2005). With several of the PET 
applications involving contact with blood, haemocompatibility is a major concern. An 
effective approach to improve haemocompatibility is to modify the surface with 
biologically active compounds that would inhibit platelet adhesion and aggregation. Such 
biologically active molecules can be immobilized on the polymer surfaces by physical 
adsorption or covalent binding. Physical adsorption would only provide a short-term 
effect as the material would lose its haemocompatibility once the biologically active 
molecule is lost into blood. Covalent binding provides the strongest immobilization. 
Hence, covalently binding a biologically active molecule would potentially improve and 
provide prolonged haemocompatibility. However, PET is an inert polymer and lacks 
active functional groups on the surface to covalently attach biologically active molecules. 
Hence, introducing reactive functional groups to the surface of PET is necessary for 
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immobilizing biomolecules that could potentially improve the haemocompatibility. 
Currently, many techniques such as amination (Nissen et al. 2008), reduction (Bùi et al. 
1993), glycolysis (Fadeev and McCarthy 1998), hydrolysis (Ellison et al. 1982; Kao et al. 
1998; Bide et al. 2006) and aminolysis (Ellison et al. 1982; Avny and Rebenfeld 1986; 
Duan and Lewis 2002; Gappa-Fahlenkamp and Lewis 2005; Bide et al. 2006; Liu et al. 
2008) are used to introduce reactive functional groups on PET surfaces.  
Although these surface functionalization techniques effectively introduce reactive 
groups, these processes alter the surface properties and the mechanical strength of PET. 
During surface functionalization, PET is degraded by the effect of chemical reactions and 
this causes significant loss of mechanical strength (Fukatsu 1992; Bùi et al. 1993; Kao et 
al. 1998; Liu et al. 2005; Nissen et al. 2008). These changes in the surface and bulk 
properties make the polymer less viable for biomedical applications, as the material no 
longer has the desirable mechanical strength required for long-term biomedical 
applications. However, many studies have shown that these surface functionalization 
techniques can be used to immobilize active biomolecules (Kottke-Marchant et al. 1989; 
Bùi et al. 1993; Duan and Lewis 2002; Aggarwal et al. 2005; Liu et al. 2005; Phaneuf et 
al. 2005; Blanchemain et al. 2007a; Blanchemain et al. 2007b; Liu et al. 2008). There are 
studies that have demonstrated improved haemocompatibility (Kottke-Marchant et al. 
1989; Duan and Lewis 2002; Liu et al. 2008), infection resistance (Aggarwal et al. 2005; 
Phaneuf et al. 2005; Blanchemain et al. 2007a; Blanchemain et al. 2007b) and cell 
adhesion (Liu et al. 2005). For this reason, functionalizing PET surfaces with minimal 
changes to the surface and bulk properties would provide a valuable tool to improve the 
biological property of PET in biomedical applications. In the recent past, carboxylation 
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has been used to introduce reactive carboxyl groups to PET surfaces (Yang et al. 2000). 
However, the effect of carboxylation on the surface and bulk properties hasn’t been 
studied. Understanding the effects of carboxylation on surface and bulk properties could 
potentially provide an effective PET surface modification. 
When biomaterials are developed for medical devices and artificial organs, the 
surface and bulk properties of the material has to be studied. In blood contact systems, it 
is obvious that the surface properties significantly impact the haemocompatibility of the 
material, as only the surface comes in contact with blood. Although all the parameters 
that influence the biological response of surfaces are not completely understood, many 
studies have shown the importance of roughness, wettability, surface charge, etc (Ratner 
2004). Many techniques have been developed for studying these surface properties. This 
study has analyzed carboxylated PET to understand the effects of the surface 
modification on surface and bulk properties, namely possible surface deterioration, 
surface roughness and mechanical strength. Also, two other commonly used techniques 
to introduce functional groups to PET surface, namely, aminolysis and hydrolysis were 
analyzed for comparison. During surface analysis, multiple pieces of information are 
required for constructing a picture of the surface. Hence, it is usually advised to use more 
than one technique to analyze surfaces. If the data obtained from these methods agree 
with one another, the results obtained would be reliable. Hence, in this work a scanning 
electron microscope (SEM) and atomic force microscope (AFM) have been used to study 
the surfaces, both qualitatively and quantitatively. High resolution images obtained from 
the SEM were used to understand the possible surface deterioration due to surface 
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functionalization. The surfaces were also analyzed using AFM to quantitatively estimate 
the surface roughness. 
Bulk properties such as mechanical strength, permeability and elasticity play an 
important role in understanding the durability of a biomedical device or an implant. 
Mechanical strength is a critical parameter in determining the functionality and efficacy 
of the material in biomedical applications. The fundamental test for understanding 
mechanical strength is tensile testing. Mechanical strengths of aminolyzed, hydrolyzed 
and carboxylated PET were studied using tensile testing. The results were compared to 
the mechanical strength of unmodified PET. 
As mentioned earlier, PET is used in many blood contacting systems. In such an 
environment, contact with a foreign material such as PET activates platelets and leads to 
platelet aggregation. Covalent or ionic binding of anticoagulant or other biologically 
active molecules to the reactive functional groups on modified PET can potentially 
improve the haemocompatibility. Studies have shown that nucleoside triphosphate 
diphosphohydrolase (NTPDase) improves haemocompatibility of polymers. NTPDase 
has been used to improve the haemocompatibility of polymers either by coating (Bakker 
et al. 1991; van der Lei et al. 1992) or by covalent binding (Marconi et al. 1983). When 
blood comes in contact with a foreign material, irreversible platelet aggregation is 
effected by the release of adenosine diphosphate (ADP) molecules in a concentration 
dependent manner (Meyers et al. 1979; Holmsen 1994; Riddell et al. 1997). NTPDase is 
an enzyme that has been shown to inhibit ADP-induced platelet aggregation by 
hydrolyzing ADP to AMP and inorganic phosphate (Pi) (Mans et al. 2000; Costa et al. 
2004; Glenn et al. 2008).  
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Although NTPDase coating and covalent binding improved the 
haemocompatibility of the materials, both protocols had their limitations. In the case of 
coating polyurethane with NTPDase, a rapid release of the non-specifically bound 
NTPDase could result in undesired effects. Also, once the coated NTPDase is washed off, 
the polymer would lose its haemocompatibility. Earlier studies immobilized NTPDase to 
hydrolyzed PET (Marconi et al. 1983) despite hydrolyzed PET showing a loss of 
mechanical strength due to hydrolysis (Ellison et al. 1982; Sanders and Zeronian 1982; 
Kao et al. 1998; Liu et al. 2005). However, in vivo testing by inserting the NTPDase-
modified hydrolyzed PET in a dog’s femoral vein for 15 days showed that the polymer 
was haemocompatible (Marconi et al. 1983). Based on these studies, it is evident that 
immobilization of NTPDase to mechanically stable PET would potentially enhance 
haemocompatibility, while retaining the desirable properties for biomedical applications.  
For understanding the potential of NTPDase attachment, NTPDase was 
immobilized on aminolyzed and carboxylated PET. Attachment of NTPDase was 
assessed by studying the activity of immobilized NTPDase. The effectiveness of 
NTPDase immobilization on aminolyzed and carboxylated PET was assessed by 
comparing the NTPDase activity of the above mentioned polymers with the activity 
observed on NTPDase immobilized on hydrolyzed PET (Marconi et al. 1983). Stability 
of NTPDase immobilization on these polymers was also studied. 
Besides exploring the effects of three PET surface modification techniques, 
namely aminolysis, hydrolysis and carboxylation, this chapter also analyzes the 
immobilization of NTPDase to aminolyzed and carboxylated PET. By performing these 
tasks, this chapter analyzes both aspects involved in developing a useful biomedical 
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material, namely, physical properties of the modified polymer and the ability to 
immobilize biologically active molecules to the modified surface. 
 
3.2 Materials and methods 
 
Polyethylene terephthalate (PET) (thickness = 0.2 mm) was supplied by DuPont 
(Hopewell, VA). Ethylenediamine, bromoacetic acid, 1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC), 2-(N-morpholino)ethanesulfonic acid (MES), 
tris[hydroxymethyl]aminomethane (Trizma base), malachite green hydrochloride, 
ammonium molybdate tetrahydrate, polyoxyethylenesorbitan monolaurate (Tween 20), 
adenosine diphosphate (ADP) and NTPDase (Apyrase from potato, Grade VII containing 
the isoenzyme Desirée with low ATPase/ADPase ratio) were purchased from Sigma (St. 
Louis, MO). Sodium hydroxide, sodium phosphate (monobasic and dibasic), sodium 
chloride, acetone, acetic acid, formaldehyde, calcium chloride, sulfuric acid and other 
reagents were purchased from Fisher Scientific (Fair Lawn, NJ). 
Before modifying the surfaces to introduce reactive functional groups, PET films, 
were cut in to 5 cm × 1 cm strips, soaked in acetone for 24 h and then dried in a nitrogen 
environment. These acetone-treated PET films were used in the following protocols. 
 
3.2.1 Aminolysis 
 
PET surfaces were aminolyzed by treatment with ethylenediamine using the 
protocol described earlier (Desai and Hubbell 1991). Briefly, 5 cm × 1 cm acetone-
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treated PET was reacted with 5 ml of either 20, 40 or 60% ethylenediamine solution for 
24 h at 40˚C (Gappa-Fahlenkamp and Lewis 2005). This formed aminolyzed PET by 
introducing primary amines to the ester linkage (Figure 3.1a).   In addition to introducing 
primary amines, ethylenediamine treatment also exposes carboxylic acid functional 
groups on the PET surface due to the breaking of ester linkages (Figure 3.1b) (Aggarwal 
et al. 2005). 
 
3.2.2 Hydrolysis 
 
PET surfaces were hydrolyzed by performing an alkaline hydrolysis described 
earlier (Dave et al. 1987). Acetone treated PET was reacted with 5 ml of 1 M sodium 
hydroxide solution at 50˚C for 5 h. This cleaved the ester bonds present in PET exposing 
reactive carboxyl groups, referred to as hydrolyzed PET in this work (Figure 3.1c). 
 
3.2.3 Carboxylation 
 
PET surfaces were carboxylated using the protocol described earlier (Yang et al. 
2000). Briefly, acetone treated PET was incubated with 18.5% formaldehyde solution in 
1 M acetic acid for 4 h. This hydroxylated the PET surface (Figure 3.1d) (Massia and 
Hubbell 1990). The hydroxylated PET was then treated with 1 M bromoacetic acid 
solution in 2 M sodium hydroxide for 18 h (Löfås and Johnsson 1990) . This introduced 
the carboxyl group to the PET surface, referred to as carboxylated PET (Figure 3.1e). 
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Figure 3.1. Schematic diagram showing surface modification of PET (a) primary amines 
introduced by ethylenediamine treatment, (b) carboxyl groups exposed due to aminolysis, 
(c) carboxyl groups introduced by hydrolysis, (d) hydroxylated intermediates formed 
during carboxylation and (e) carboxyl groups introduced by carboxylation. The active 
functional groups introduced to the PET surface are highlighted 
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All modified PET was thoroughly washed three times with DI water and soaked 
in DI water for 5 minutes. This was repeated three times. Then, modified PET was dried 
in a glove box under a nitrogen environment before being used. 
 
3.2.4 Analysis of surface properties 
 
Scanning electron microscope (SEM) studies were performed to verify possible 
PET surface deterioration due to the modifications. The SEM was used to obtain high 
resolution images that provided a visual perspective of the three dimensional quality of 
the surface being studied. SEM uses a high energy electron beam that focuses and scans 
the surface to be studied. As the high energy beam hits the surface, low energy secondary 
electron emissions are emitted from the spot. The intensity of the low energy secondary 
electrons is a function of the atomic composition and the geometry of the surface being 
studied. The intensity of the secondary electron emission is used to spatially reconstruct 
the surface image on a phosphor screen or a charged coupled device detector. Since the 
secondary electrons emitted have low penetration, only the electrons emitted from the 
surface escape and impact the intensity. Hence, SEM images are used for surface 
analysis. In the case of non-conductive materials, a thin metal coating is given to the 
surface to reduce accumulation of negative charges from the electron beam. For this 
research, modified and unmodified PET surfaces were coated with a thin layer of gold 
and SEM images were captured using a Jeol JSM 6360 scanning electron microscope 
(Jeol USA, Inc., Peabody, MA). 
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Atomic force microscopy (AFM) studies were performed to measure the 
roughness factors of modified and unmodified PET surfaces. AFM uses a piezo drive 
mechanism, which measures the deflection of a tip mounted on a flexible cantilever arm. 
The tip is deflected due to van der Waals and electrostatic repulsion and attraction 
between an atom at the tip and an atom on the surface. The movements of the cantilever 
arm are magnified by monitoring the position of a laser, which is reflected by a mirror on 
the cantilever arm, on a spatially resolved photosensitive detector. AFM is used to study 
surfaces using primarily one of the two modes, namely, contact mode and tapping mode. 
In contact mode, the tip is in contact with the surface. The contact mode is effective in 
studying the surface of rigid materials. However, in the case of softer specimens, like 
proteins and polymers, the surface could be damaged by the contact mode AFM studies. 
In the case of tapping mode or intermittent force mode, the tip barely touches the surface. 
The tip oscillates at a frequency close to the resonance of the cantilever. The force 
interaction of the tip and the surface can affect the amplitude of the oscillation and the 
oscillation frequency of the tip. This change is the amplitude is used to measure the 
surface properties. In this study, the roughness factors of modified and unmodified PET 
surfaces were measured using a Veeco Multimode Scanning Probe Microscope with 
conductive AFM module and Nanoscope V controller (Veeco Metrology Inc., Tucson, 
AZ) operated in a tapping mode. 
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3.2.5 Analysis of mechanical properties 
 
Tensile testing of modified and unmodified PET was performed by using an 
Instron 5542 single column testing system (Instron, Grove City, PA). PET films were cut 
into 5 cm × 1 cm strips. These strips were loaded onto the testing system and were tightly 
clamped to avoid any slippage. A tensile stress was then applied at 10 mm of elongation 
per minute. The strain on the PET strip was measured. Elongation was continued until the 
PET film ruptured. The maximum load applied, tensile stress and strain at break, and the 
Young’s modulus were computed using the data obtained. 
 
3.2.6 NTPDase immobilization 
 
Aminolyzed PET was incubated with 20 U/ml of NTPDase at 4˚C for 16 h. 
NTPDase is immobilized on aminolyzed PET using imine bonds (similar to studies in the 
literature (Brown et al. 1968; Patel et al. 1969)) between the primary amine group on the 
aminolyzed PET and possibly the aldehyde groups, which are introduced by 
glycosylation during posttranslational modification of the glycoprotein NTPDase 
(Ivanenkov et al. 2005). However, if mannose exists as a hemi-acetal in the ring structure 
causing the aldehyde groups to be inaccessible, NTPDase immobilization could have 
occurred due to adsorption. This modified polymer is denoted as PET-NH2-NTPDase in 
this work (Figure 3.2a). Since the reaction is carried out in the absence of any carboxyl 
group activating agent, NTPDase doesn’t form an amide bond with the exposed carboxyl 
groups on the aminolyzed PET (Figure 3.1b).  
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Figure 3.2. Schematic diagram showing NTPDase immobilization: (a) NTPDase 
immobilized on aminolyzed PET via imine bonds [PET-NH2-NTPDase], (b) NTPDase 
immobilized on carboxylated PET via amide bonds [PET-COOH-NTPDase] 
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Carboxylated PET was incubated with 0.1 M EDC and 20 U/ml of NTPDase in 
0.1 M phosphate buffer (pH = 6.8) at 4˚C for 16 h. This immobilized NTPDase on 
carboxylated PET using amide bonds between the carboxyl group on the carboxylated 
PET and ε-amine group of the lysine molecules on NTPDase (Marconi et al. 1983). This 
modified polymer is denoted as PET-COOH-NTPDase in this work (Figure 3.2b). 
NTPDase was also immobilized using 0.1 M MES buffer (pH = 6.8) instead of phosphate 
buffer.  
Control samples, to confirm the absence of NTPDase immobilization and/or 
absorption without PET modification, were prepared by incubating acetone treated PET 
with 20 U/ml of NTPDase at 4ºC for 16 h. All the modified polymers and control samples 
were first washed using 1 M NaCl and then thoroughly rinsed with DI water. 
 
3.2.7 Analysis of NTPDase attachment 
 
The attachment of NTPDase was verified by exposing 10 cm2 of NTPDase 
modified PET to 50 ml of 0.25 mM ADP in the presence of 0.1 M Tris buffer (pH = 7.4) 
and 5 mM CaCl2 (Figure 3.3a). ADP was converted to AMP and inorganic phosphate 
(Pi). The sample solution was assayed for Pi concentration using a malachite green 
solution assay (Baykov et al. 1988; Geladopoulos et al. 1991). Briefly, 2.5 ml of 7.5% 
ammonium molybdate, 10 ml of 0.122% malachite green in 6 N H2SO4 and 0.2 ml of 
0.11% Tween 20 were mixed to form the malachite green solution. 800 µl of sample was 
mixed with 200 µl of the malachite green solution. 
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Figure 3.3. Experimental designs for analyzing NTPDase attachment. (a) 50 ml of 0.25 
mM ADP in the presence of 0.1 M Tris buffer (pH = 7.4) and 5 mM CaCl2 with 10 cm2 
of NTPDase modified PET (b) 1.5 ml of 0.25 mM ADP in the presence of 0.1 M Tris 
buffer (pH = 7.4) and 5 mM CaCl2 with 2 cm2 of NTPDase modified PET. Inorganic 
phosphate (Pi) concentration is measured using a malachite green assay (MG).
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Ammonium molybdate reacts with the inorganic phosphate to form 
phosphomolybdate. This phosphomolybdate forms a highly colored complex with 
malachite green, which is stabilized by Tween 20. The absorbance was measured at 630 
nm using a Shimadzu UV-1601 UV-visible spectrophotometer (Shimadzu Scientific 
Instruments, Columbia, MD). Similar experiments were also performed using control 
samples to verify covalent attachment of NTPDase. 
Malachite green solution (MG) was prepared freshly on the day of the 
experiments. As multiple experiments were performed on the same day, it was important 
to verify if the assay predicted the Pi concentration consistently when the MG was stored 
for prolonged hours. To confirm this, MG reagent was prepared. The freshly prepared 
reagent was first calibrated using phosphate standards prepared with potassium phosphate 
(tribasic).  800 µl of standard and 200 µl of MG solution were mixed and allowed to 
stand for 10 minutes and the absorbance was measured at 630 nm. Similar calibrations 
were performed after storing the MG solution for 3, 6, 9 and 11 hours. The results, shown 
in Figure 3.4, clearly prove that the assay is stable over the period of time. Therefore, MG 
solution was prepared before running all the experiments. 
For some experiments involving PET-COOH-NTPDase, 2 cm2 of PET-COOH-
NTPDase was exposed to 1.5 ml of 0.25 mM ADP in the presence of 0.1 M Tris buffer 
(pH = 7.4) and 5 mM CaCl2 (Figure 3.3b). To study the stability of immobilizations, 
NTPDase modified PET was first stored in air or in solution containing equal volumes of 
5 mM CaCl2 and 0.1 M Tris buffer (pH = 7.4) for 100 or 200 min. Then, the stored 
polymers were washed thoroughly with DI water before performing the analysis. All 
analysis and storage was at 37˚C. 
 65
 
Figure 3.4. Malachite green assay sensitivity over time. The plot shows absorbance at 630 
nm (Abs630) vs. Pi concentrations for malachite green solution that was freshly prepared 
(♦), stored for 3 h (□), 6 h (▲), 9 h (∆) and 11 h (■).
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3.3 Results and Discussion 
 
3.3.1 Surface characterization of modified PET 
 
SEM studies were performed to analyze the possibility of surface deterioration 
due to chemical modifications. Figure 3.5a is an SEM image of unmodified PET. 
Unmodified PET shows a smooth surface with no deterioration. However, as seen in 
Figure 3.5b, aminolysis resulted in the formation of cracks on the surface. Aminolyzed 
PET showed significantly different surface properties compared to the unmodified PET. 
Figure 3.5c highlights pit formation on hydrolyzed PET surfaces. These pits, formed due 
to the ester bond breakage during alkaline hydrolysis, alter the surface properties of the 
hydrolyzed PET significantly. These images are consistent with previous studies that 
have described cracks due to aminolysis (Ellison et al. 1982; Holmes 1996; Nissen et al. 
2008) and pitting due to hydrolysis (Ellison et al. 1982; Rahman and East 2006). 
On the other hand, carboxylated PET (Figure 3.5d) does not show any cracks or 
pits that would modify the surface properties and potentially weaken the mechanical 
strength. The spots seen on the surface of carboxylated PET were not caused by surface 
modifications as similar spots were also observed on SEM images of several unmodified 
PET samples. Thus, surface properties were not significantly altered due to 
carboxylation, while they were drastically changed by aminolysis and hydrolysis. 
Although the qualitative analysis using SEM images shows that carboxylated PET would 
show surface properties similar to unmodified PET, it was also important to perform a 
quantitative analysis.
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Figure 3.5. Scanning Electron Microscope images of (a) unmodified PET, (b) aminolyzed 
PET, (c) hydrolyzed PET and (d) carboxylated PET. Cracks on aminolyzed PET are 
clearly visible and pits on hydrolyzed PET are highlighted.
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To further understand the change in surface properties quantitatively, AFM 
studies were performed. Roughness factors of unmodified, aminolyzed, hydrolyzed and 
carboxylated PET were measured using the protocol described earlier. The results are 
shown in Table 3.1. Unmodified PET was very smooth with a low roughness factor 
(Figure 3.6a). While preparing the aminolyzed PET using 60% ethylenediamine for 
aminolysis, the roughness factor increased drastically. The high roughness factor couldn’t 
be measured using an AFM. Hence, AFM studies were performed with aminolyzed PET 
using a 20% and 40% ethylenediamine solution (Figures 3.6b and 3.6c respectively). The 
results show that the roughness of aminolyzed PET increased with an increase in the 
concentration of ethylenediamine used during aminolysis. Based on this, it is clear that 
using 60% ethylenediamine for introducing amine groups on PET surfaces would 
severely alter the surface properties. The average roughness factor of hydrolyzed PET 
was almost twice that of unmodified PET. However, the regions on hydrolyzed PET that 
showed pitting (as highlighted in Figure 3.6d) had roughness factors as high as 37.9 nm. 
These AFM studies confirm the observations from SEM images about pitting due to 
hydrolysis of PET. 
On the other hand, carboxylated PET showed a similar roughness as unmodified 
PET (Figure 3.6e). These studies show that carboxylated PET shows no surface 
deterioration and minimal surface roughness, comparable to unmodified PET. Based on 
these results, it is evident that carboxylation of PET to introduce reactive functional 
groups to the surface is clearly more desirable compared to aminolysis and hydrolysis.
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Table 3.1. Roughness analysis of modified polymers 
Polymer Roughness factor (nm) 
Unmodified 4.94±2.41 
20% Aminolyzed 21.87±4.66 
40% Aminolyzed 109.00 
Hydrolyzed 11.32±3.22 
Carboxylated 4.17±1.40 
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Figure 3.6. Atomic Force Microscope images of (a) unmodified PET, (b) 20% 
aminolyzed PET, (b) 40% aminolyzed PET, (d) hydrolyzed PET and (e) carboxylated 
PET. Cracks on aminolyzed PET are clearly visible and pits on hydrolyzed PET are 
highlighted.
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3.3.2 Bulk characterization of modified PET 
 
Based on the surface characterization of unmodified, aminolyzed, hydrolyzed and 
carboxylated PET, it was expected that aminolyzed and hydrolyzed PET would show 
lesser mechanical strength due to the surface cracks and pits. To verify this, mechanical 
strengths of modified and unmodified PET were compared by tensile testing. As 
expected, the results, shown in Table 3.2, confirm significant loss of tensile strength in 
aminolyzed and hydrolyzed PET due to the cracks and pits formed. This is consistent 
with previous studies (Ellison et al. 1982; Kao et al. 1998). In contrast, the results show 
that carboxylated PET exhibits a tensile strength comparable to unmodified PET. It is 
clear that carboxylated PET shows more desirable surface and bulk properties compared 
to aminolyzed and hydrolyzed PET. 
 
3.3.3 NTPDase immobilization on aminolyzed PET 
 
As described earlier, NTPDase was immobilized on aminolyzed PET (PET-NH2-
NTPDase), possibly by imine bonds between the primary amines on aminolyzed PET and 
the aldehyde groups present on the glycoprotein NTPDase. The presence of active 
NTPDase on aminolyzed PET was tested by performing NTPDase kinetic experiments in 
50 ml of 0.25 mM ADP (12.5 µmoles) exposed to 10 cm2 of PET-NH2-NTPDase. Figure 
3.7 shows that freshly prepared PET-NH2-NTPDase had significant NTPDase activity 
and that all of the ADP released Pi within approximately 30 minutes. The initial release 
rate of Pi is approximately 3 µmoles Pi released h-1 cm-2.
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Table 3.2. Tensile testing of modified polymers 
Polymer Max Load (N) 
Tensile Stress at 
Break (MPa) 
Tensile Strain at 
Break (MPa) 
E-modulus 
(MPa) 
Unmodified 100 197 71 3700 ± 200 
60% Aminolyzed 65 49 36 3450 ± 600 
Hydrolyzed 72 48 31 3150 ± 300 
Carboxylated 103 205 77 3350 ± 150 
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Figure 3.7. Rate of inorganic phosphate (Pi) release due to ADP hydrolysis catalyzed by 
NTPDase immobilized on aminolyzed PET (PET-NH2-NTPDase). Pi released from 50 
ml of 0.25 mM ADP (initially 12.5 µmoles) by 10 cm2 freshly prepared (◊), stored in air 
for 100 min (□) stored in air for 200 min (∆), stored in solution for 100 min (■), and 
stored in solution for 200 min (♦) are shown. The solution in which PET-NH2-NTPDase 
was stored contains equal volumes of 0.1 M Tris buffer (pH = 7.4) and 5 mM CaCl2. All 
storage and kinetic analysis were done at 37˚C.
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PET-NH2-NTPDase was also stored at 37˚C in air and in a solution containing 
equal volumes of 0.1 M Tris buffer (pH = 7.4) and 5 mM CaCl2 solution prior to kinetic 
analysis. PET-NH2-NTPDase was removed after 100 and 200 minutes in storage 
conditions and tested for activity. Figure 3.7 shows that the rate and amount of Pi 
released due to prior storage in air for 100 min and 200 min was comparable to that of 
freshly prepared PET-NH2-NTPDase. This indicates no loss of NTPDase activity with 
time when stored in air. Figure 3.7 also shows that the rate and amount of Pi released due 
to prior storage in solution was significantly lower for 100 minutes of storage and even 
more significantly lower for 200 minutes than that of freshly prepared PET-NH2-
NTPDase. This was probably due to loss of NTPDase into the storage solution. The 
storage solution showed detectable NTPDase activity. However, the activity could not be 
quantified reliably. This problem can potentially be overcome by reducing the imine 
bonds into an alkylamine linkage (Hermanson 1996). Since the aminolyzed PET had 
mechanical strength limitations, stabilizing the immobilization was not explored. 
 
3.3.4 NTPDase immobilization on carboxylated PET 
 
NTPDase was also immobilized to carboxylated PET (PET-COOH-NTPDase) by 
an amide bond between the carboxyl group on the polymer and the ε-amine group of the 
lysine molecule on NTPDase. When 10 cm2 of freshly prepared PET-COOH-NTPDase 
was exposed to 50 ml of a 0.25 mM ADP solution (12.5 µmoles), ADP was not quickly 
consumed to form an equivalent amount of Pi– unlike PET-NH2-NTPDase which    
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Figure 3.8. Inorganic phosphate (Pi) release due to ADP hydrolysis catalyzed by 
NTPDase immobilized on carboxylated PET (PET-COOH-NTPDase) for prolonged 
reaction. Pi released from 50 ml of 0.25 mM ADP (initially 12.5 µmoles) by 10 cm2 of 
PET-COOH-NTPDase (a) during the first 450 minutes and (b) after 18 hours are shown.
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completely consumed the ADP within 60 minutes.  However, when the reaction 
continued for over 18 h, ADP was mostly consumed to form Pi in an amount similar to 
the initial ADP concentration (Figure 3.8b).  
The stability of PET-COOH-NTPDase was then studied by storing PET-COOH-
NTPDase at 37˚C in air and in a solution containing equal volumes of 0.1 M Tris buffer 
(pH = 7.4) and 5 mM CaCl2 solution for 200 min before analysis. 10 cm2 of these stored 
PET-COOH-NTPDase polymers were exposed to 50 ml of 0.25 mM ADP (12.5 µmoles), 
similar to the experimental conditions used for Figure 3.8. Figure 3.9 shows that the 
amount of Pi released with prior storage in air or solution was comparable to that of 
freshly prepared PET-COOH-NTPDase. In contrast to PET-NH2-NTPDase, these results 
clearly show that there was no detectable loss of NTPDase activity due to storage 
conditions. These experiments demonstrate a stable NTPDase immobilization on a 
mechanically strong PET surface.  
All these studies were performed using PET-COOH-NTPDase prepared with 0.1 
M phosphate buffer (pH = 6.8) during carbodiimide coupling.  However, phosphate 
buffer is known to interfere with carbodiimide coupling to form a  phosphoramidate 
linkage (Hermanson 1996). Hence, PET-COOH-NTPDase was also prepared in 0.1 M 
MES buffer (pH = 6.8) during carbodiimide coupling. 2 cm2 of PET-COOH-NTPDase 
polymers prepared in the two different buffers were separately exposed to 1.5 ml of 0.25 
mM ADP (0.375 µmoles). Figure 3.9 shows a very low rate of Pi release by PET-COOH-
NTPDase prepared in MES buffer compared to that of PET-COOH-NTPDase prepared in 
phosphate buffer. 
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Figure 3.9. Inorganic phosphate (Pi) release due to ADP hydrolysis catalyzed by 
NTPDase immobilized on carboxylated PET (PET-COOH-NTPDase). Pi released from 
50 ml of 0.25 mM ADP (initially 12.5 µmoles) by 10 cm2 freshly prepared (♦), stored in 
air for 200 min (▲), stored in solution for 200 min (■) are shown. All PET-COOH-
NTPDase were prepared in phosphate buffer.  The solution contains equal volumes of 0.1 
M Tris buffer (pH = 7.4) and 5 mM CaCl2. All storage was done at 37˚C. The figure also 
shows Pi released from 1.5 ml of 0.25 mM ADP (initially 0.375 µmoles) by 2 cm2 PET-
COOH-NTPDase freshly prepared in phosphate buffer (□) and freshly prepared in MES 
buffer (∆). All storage and kinetic analysis was performed at 37˚C.
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The initial release rate of Pi for PET-COOH-NTPDase prepared in phosphate 
buffer and exposed to 1.5 ml was approximately 0.13 µmoles Pi released h-1 cm-2, which 
is 4% of the release rate for PET-NH2-NTPDase. One possible reason for PET-NH2-
NTPDase showing a higher Pi release rate could be the presence of a higher NTPDase 
concentration on PET-NH2-NTPDase. Since the available surface area for aminolyzed 
PET is greater than the external surface area due to surface cracks, more NTPDase could 
be attached to aminolyzed PET as compared to carboxylated PET. It is important to note 
that release rates were calculated based on the external surface area and that inclusion of 
the surface area due to cracks would reduce the calculated release rate of Pi for PET-
NH2-NTPDase. 
In comparing Figures 3.8-3.9 for the 50 ml volume/10 cm2 studies, it is notable 
that the amount of Pi released at a given time was much lower in Figure 3.8 as compared 
to Figure 3.9.   Upon further examination, it should be noted that the data shown in 
Figure 3.8 was obtained using PET-COOH-NTPDase prepared with an old batch of 
NTPDase.  Therefore, it’s important to recognize the impact of the NTPDase source on 
making the polymers.   Another important note is that in Figure 3.9, the release of Pi per 
unit membrane area is approximately 2x higher in the 1.5-ml reactor as compared to the 
50-ml reactor. Furthermore, it was observed that almost the entire ADP was hydrolyzed 
to form Pi when PET-COOH-NTPDase (prepared with phosphate buffer) was exposed to 
a 1.5 ml solution as compared to a 50 ml solution. 
The following mathematical analysis was used to assess the reason for the 
different Pi accumulation rates (per unit polymer area) observed for different liquid 
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volumes. Using a mole balance in a well-mixed bulk solution, the rate of accumulation of 
<Pi> (moles of phosphate per unit polymer area) in the bulk solution is given as 
 ( )ibL
i ADPADPk
dt
Pd ][][ −=  (3.1) 
where kL is the mass transfer coefficient in length per unit time and [ADP]b and [ADP]i 
are the bulk and interfacial concentrations of ADP, respectively, in moles per unit 
volume. Using a mole balance at the polymer interface and assuming no accumulation in 
the adjacent boundary layer, the rate of accumulation of <Pi> is also given as 
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where vmax and KM are Michaelis-Menten constants in moles per unit volume per unit 
time and moles per unit volume, respectively. 
If mass transfer is the only limiting mechanism for ADP conversion to Pi in both 
1.5-ml and 50-ml reactors, then [ADP]b>>[ADP]i. From equation 3.1, the rate of 
accumulation of <Pi> would become 
bL
i ADPk
dt
Pd ][=  (3.3) 
Therefore, if both volume studies had the same initial ADP concentration and 
were mass transfer limiting with the same kL, the rates of <Pi> accumulation would be the 
same. This is contrary to the experimental results. If kL was higher for the lower volume 
study, this would result in a faster <Pi> accumulation rate, which is consistent with 
observations.  It should be noted that in the 50-ml reactor, the polymer was cut into five 1 
cm × 1 cm pieces and added to 50 ml of reaction mixture that was mixed using a 
magnetic stirrer. Under this experimental setup, the polymer pieces were continuously 
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moving in the reaction mixture. For the 1.5-ml reactor, a 1 cm × 1 cm polymer piece was 
introduced to a 2-ml vial containing 1.5 ml of reaction mixture that was mixed using an 
orbital mixer. The polymer piece was stationary inside the 2-ml vial as the liquid was 
moving. Under these conditions, the relative motion of the reaction mixture to the 
polymer would be higher in the 1.5-ml reactor as compared to the 50-ml reactor. 
Therefore, there is a strong possibility that kL was higher in the 1.5-ml reactor as 
compared to the 50-ml reactor. 
Another scenario is when both mass transfer and reaction kinetics play a role in 
regulating the rate for both 1.5-ml and 50-ml studies. This scenario can be examined by 
equating equations 3.1 and 3.2 such that:  
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Rearrangement of equation 3.4 would show that [ADP]i increases with increasing kLA/V. 
Therefore, when kLA/V increases, the driving force ([ADP]b – [ADP]i) is lowered. For 
the 1.5-ml reactor in comparison to the 50-ml reactor, A/V is larger and it’s likely that kL 
is higher (see preceding paragraph)—leading to a larger kLA/V. Also, vmax is a product of 
the enzyme rate constant and the enzyme concentration. Since the 50-ml reactor had 10 
cm2 polymer and the 1.5-ml reactor had 2 cm2 polymer, vmax would be five times higher 
for the 50-ml reactor.   Using this information in sensitivity analysis calculations, with 
assumed values of vmax, KM and kL, it can be shown that increasing kLA/V can result in an 
increase (2x or more) in the rate of <Pi> accumulation.  Again, this is consistent with the 
experimental observations. 
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Finally, a third scenario is when both 1.5-ml and 50-ml studies are not limited by 
mass transfer. In this scenario, the interfacial concentration of ADP is equal to the bulk 
concentration of ADP ([ADP]b=[ADP]i). Hence equation 3.2 becomes 
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Equation 3.5 shows that the rate of <Pi> accumulation is proportional to the ratio of 
reaction volume to the area of polymer used.  For the 50 ml studies, V/A= 5 and for the 
1.5 ml studies, V/A = 0.75. Also, as noted above, vmax is a five times higher for the 50 ml 
study. Hence, if mass transfer doesn’t play a role in both studies, the rate of <Pi> 
accumulation would be significantly higher for the larger volume study which is contrary 
to the experimental results. 
Based on the above analyses, if both studies have the same limiting conditions, 
the possible reason for the higher rate of <Pi> accumulation in the 1.5-ml reactor is a 
higher kL due to the differences in hydrodynamic mixing conditions. It is also possible 
that 1.5-ml and 50-ml reactions have different limiting conditions. Considering the 
reactor mixing conditions in which flow relative to the polymer was likely higher with 
the 1.5-ml reactor, it’s likely that the kL value was higher. In addition, A/V is also higher 
for the 1.5-ml reactor.  A higher kLA/V would lead to a higher [ADP]i (see Equation 3.4) 
such that reaction kinetics would play a more dominant role. Hence, it is possible that the 
1.5-ml reactor is kinetic-limited while the 50-ml reactor is mass transfer-limited. Such a 
condition would also result in an increased rate of <Pi> accumulation in the 1.5-ml 
reactor. Therefore, several possibilities discussed above would explain the higher rate of 
<Pi> accumulation in the 1.5-ml reactor. 
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3.3.5 Effect of EDC to NTPDase ratio on NTPDase immobilization 
 
During NTPDase immobilization on carboxylated PET, the ratio of EDC to 
NTPDase was a critical factor. NTPDase activity on PET-COOH-NTPDase was 
significantly altered when a different ratio of EDC to NTPDase was used during 
immobilization. For understanding the importance of the EDC concentration on 
immobilization, PET-COOH-NTPDase was prepared using different concentrations of 
EDC (0.05 M, 0.1 M, 0.2 M, 0.3 M). The activity of NTPDase was studied. Although 
using higher concentrations of EDC helped in activating the carboxyl groups on the 
polymer surface, results showed that higher ratios of EDC concentration to NTPDase 
concentration resulted in a lower NTPDase activity (Figure 3.10). This is possibly 
because carboxyl groups present in NTPDase molecules also get activated, thereby 
resulting in reactions amongst NTPDase molecules themselves. This could result in loss 
of NTPDase activity. 
 
3.3.6 Comparison of NTPDase immobilizations 
 
From the results shown in Figures 3.7 and 3.9, it is clear that both PET-NH2-
NTPDase and PET-COOH-NTPDase show detectable levels of NTPDase activity. 
Experiments performed with the control samples didn’t show any detectable NTPDase 
activity. This indicates that the NTPDase activity on the modified polymers is due to 
NTPDase immobilization. 
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Figure 3.10. Rate of inorganic phosphate (Pi) release due to ADP hydrolysis catalyzed by 
NTPDase immobilized on carboxylated PET (PET-COOH-NTPDase) using different 
concentrations of EDC. Pi released from 50 ml of 0.25 mM ADP (initially 12.5 µmoles) 
by 10 cm2 of PET-COOH-NTPDase prepared using 0.05 M EDC (◊), 0.1 M EDC (□), 0.2 
M EDC (∆) and 0.3 M EDC (■) are shown. 
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NTPDase activity on PET-NH2-NTPDase was approximately twice the NTPDase 
activity achieved by Marconi et al. by immobilizing NTPDase on hydrolyzed PET (1.5 
µmoles Pi released h-1 cm-2) (Marconi et al. 1983). As discussed earlier, similar to 
aminolyzed PET, hydrolyzed PET also shows surface deterioration and loss of 
mechanical strength and would not be a viable polymer for biomedical applications. 
Although NTPDase activity on PET-NH2-NTPDase was high, aminolyzed PET showed 
surface deterioration and a loss of mechanical strength. In addition, the immobilization 
was not stable in solution. However, the imine bonds present in PET-NH2-NTPDase 
could be stabilized by reduction. As aminolyzed PET would not be a desirable choice for 
biomedical applications, studies were not performed to stabilize imine bonds in PET- 
NH2-NTPDase.  
In contrast, NTPDase immobilization was stable with carboxylated PET in that no 
surface deterioration was shown and mechanical strength was maintained. Although the 
NTPDase activity observed was 9% of the release rate observed with NTPDase 
immobilized on hydrolyzed PET (Marconi et al. 1983), it is important to recognize that a 
higher activity can be observed as a result of cracks or pits increasing the surface area for 
NTPDase attachment. Studies done with immobilizing NTPDase on nylon and C 50 steel 
rings showed a NTPDase activity around 0.3 µmoles Pi released h-1 cm-2, which was 
sufficient to significantly improve platelet inhibition (Marconi et al. 1983). This activity 
is more consistent with the PET-COOH-NTPDase. Optimization of NTPDase 
immobilization on carboxylated PET could potentially improve the NTPDase surface 
concentration (and thus increase Pi release rate) of PET-COOH-NTPDase. Thus, 
carboxylated PET is a potentially viable polymer for stable NTPDase immobilization in 
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which significant NTPDase activity is present and the polymer maintains characteristics 
similar to unmodified PET. 
 
3.4 Conclusions 
 
In this study, both effects of PET surface modification and immobilization of 
NTPDase were analyzed. The effects of PET modifications, namely aminolysis, 
hydrolysis and carboxylation, on surface and bulk properties were studied by analyzing 
possible surface deterioration, roughness and mechanical strength of modified and 
unmodified PET. The results show that carboxylated PET has the minimum change in the 
surface and bulk properties as it maintained the roughness and mechanical strength of 
unmodified PET. Based on these results, carboxylated PET could potentially improve the 
biomedical applications of PET.  Immobilization of biologically active molecules was 
studied by attaching NTPDase to aminolyzed and carboxylated PET. NTPDase could 
potentially improve the haemocompatibility of PET. NTPDase was successfully 
immobilized to aminolyzed PET and carboxylated PET using imine and amide bonds, 
respectively. NTPDase activity was significantly higher in PET-NH2-NTPDase compared 
to PET-COOH-NTPDase. However, PET-NH2-NTPDase exhibited imine bond instability 
in solution while PET-COOH-NTPDase showed stability in solution.  The PET-COOH-
NTPDase polymer also exhibited NTPDase activity that could potentially enhance 
platelet inhibition.  Thus, a mechanically strong NTPDase-modified PET (PET-COOH-
NTPDase) that showed bond stability in solution was demonstrated. Hence, it is 
important that the stability of immobilization is analyzed in different storage 
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environments when a molecule is attached to the modified polymer before performing 
further studies. In conclusion, carboxylation of PET showed great potential for 
biomedical applications due to minimum changes in surface and bulk properties and the 
ability to immobilize bioactive agents such as NTPDase. 
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CHAPTER 4 
 
 
KINETIC STUDIES OF FREE AND IMMOBILIZED NTPDase 
 
Studying both free and immobilized NTPDase kinetics would help in better 
understanding the mechanism of NTPDase functionality following immobilization. Such 
an understanding could be a valuable tool in optimizing the activity of NTPDase for 
obtaining improved haemocompatibility. With successful immobilization of NTPDase to 
a mechanically stable polymer, understanding the kinetics would add another dimension 
to developing a haemocompatible biomaterial. For this purpose, the kinetics of 
immobilized NTPDase were studied for PET-NH2-NTPDase and PET-COOH-NTPDase. 
These results were compared with free NTPDase kinetics. As PET-COOH-NTPDase 
would potentially be used in blood-contact systems, it is important to study the effect of 
immobilization on NTPDase activity when the polymer is stored in a solution at 37ºC. 
For this purpose, the effect storing free NTPDase in a solution at 37ºC was studied and 
compared to the results discussed in Chapter 3 in which immobilized NTPDase was 
stored in a solution at 37ºC. 
 
4.1 Introduction 
 
NTPDase (EC 3.6.1.5) is an enzyme that catalyzes the hydrolysis of 
pyrophosphoric bonds in organic and inorganic compounds in the presence of a bivalent
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cation. NTPDase activity has been reported in both animals and plants (Treuheit et al. 
1992; Stout and Kirley 1994; Handa and Guidotti 1996; Basanova et al. 2002; Failer et 
al. 2002). In humans, NTPDase plays an important role in regulating blood coagulation 
(Gayle III et al. 1998; Weksler 2000). NTPDase hydrolyzes ADP released from platelets 
during blood coagulation, thereby attenuating platelet aggregation caused by ADP. 
Understanding the mechanism and kinetics involved in ADP hydrolysis by NTPDase 
would provide valuable information. As the goal of this research is to develop a 
haemocompatible polymer using NTPDase modification, studying NTPDase kinetics and 
the effect of immobilization on the kinetics was important. For this purpose, ADP 
hydrolysis by NTPDase-modified polymers (PET-NH2-NTPDase and PET-COOH-
NTPDase) was studied under physiological temperature and pH.  
 
4.2 Materials and methods 
 
Polyethylene terephthalate (PET) (thickness = 0.2 mm) was supplied by DuPont 
(Hopewell, VA). Ethylenediamine, bromoacetic acid, 1-ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC), tris[hydroxymethyl]aminomethane (Trizma base), 
malachite green hydrochloride, ammonium molybdate tetrahydrate, polyvinyl alcohol 
(PVA), polyoxyethylenesorbitan monolaurate (Tween 20), adenosine diphosphate (ADP) 
and NTPDase (Apyrase from potato, Grade VII containing the isoenzyme Desirée with 
low ATPase/ADPase ratio) were purchased from Sigma (St. Louis, MO). Sodium 
hydroxide, sodium phosphate (monobasic and dibasic), sodium chloride, acetone, acetic 
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acid, formaldehyde, calcium chloride, sulfuric acid, hydrochloric acid and other reagents 
were purchased from Fisher Scientific (Fair Lawn, NJ). 
 
4.2.1 Free NTPDase batch kinetics 
 
For studying free NTPDase batch kinetics, 1 U of free NTPDase was added to 50 
ml of reaction mixture containing ADP in the presence of 0.1 M Tris buffer (pH = 7.4) 
and 5 mM CaCl2 at 37ºC. ADP was converted to AMP and inorganic phosphate (Pi). The 
Pi concentration was measured using a malachite green assay previously described (Chan 
et al. 1986; Henz et al. 2007). Briefly, 2.86 g ammonium molybdate was dissolved in 50 
ml of 6 N HCl, 1.16 g PVA was dissolved in 50 ml boiling water and 0.0812 g of 
malachite green was dissolved in 100 ml DI water. The colorimetric reagent was prepared 
by mixing two parts of malachite green solution, one part each of ammonium molybdate 
and PVA solutions and two parts of DI water. This mixture was prepared on the day of 
use. 800 µl of sample solution was mixed with 200 µl of malachite green reagent and 
allowed to stand for 10 minutes. The absorbance was measured at 630 nm. Malachite 
green assay described by Baykov et al. was not used for free enzyme analysis, as free 
NTPDase interfered with the assay. The procedure was performed for different ADP 
concentrations (0.05, 0.1, 0.15, 0.2, 0.25 and 0.3 mM). 
To assess the effect of storing free NTPDase in solution at 37ºC, NTPDase was 
dissolved in a mixture containing 0.1 M Tris buffer (pH = 7.4) and 5 mM CaCl2. This 
NTPDase solution was stored at 37ºC for 60, 120 and 240 minutes. 0.25 mM ADP 
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solution was reacted with the stored NTPDase solution. The rate of Pi formation was 
compared for freshly prepared NTPDase solution and the stored NTPDase solutions. 
 
4.2.2 Immobilized NTPDase batch kinetics 
 
For studying immobilized NTPDase kinetics, PET-NH2-NTPDase and PET-
COOH-NTPDase polymers were used. PET-NH2-NTPDase was prepared using the 
protocol described in Chapter 3. Briefly, aminolyzed PET, which was prepared by 
treating the polymer with 60% ethylenediamine at 40ºC for 24 h (Desai and Hubbell 
1991), was incubated with 20 U/ml NTPDase solution at 4ºC for 16 h. PET-COOH-
NTPDase was also prepared using the protocol described in Chapter 3. Briefly, PET was 
first hydroxylated by reacting with 18.5% formaldehyde solution in 1 M acetic acid 
(Massia and Hubbell 1990). This hydroxylated PET was then carboxylated by reacting 
with 1 M bromoacetic acid in 2 M NaOH solution (Löfås and Johnsson 1990). 
Carboxylated PET was then treated with 0.1 M EDC and 20 U/ml NTPDase in 0.1 M 
phosphate buffer (pH = 6.8) to form PET-COOH-NTPDase. 
Batch kinetics studies for PET-NH2-NTPDase were performed exposing 10 cm2 
of PET-NH2-NTPDase to 50 ml of ADP in the presence of 0.1 M Tris buffer (pH = 7.4) 
and 5 mM CaCl2 at 37ºC. The rate of Pi release was measured using the malachite green 
assay described earlier (Baykov et al. 1988). Briefly, 2.5 ml of 7.5% ammonium 
molybdate, 10 ml of 0.122% malachite green in 6 N H2SO4 and 0.2 ml of 0.11% Tween 
20 were mixed to form the malachite green solution. 800 µl of sample was mixed with 
200 µl of the malachite green solution. The experiment was repeated for different ADP 
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concentrations (0.1, 0.15, 0.2, 0.25 and 0.3 mM). Batch kinetics studies of PET-COOH-
NTPDase were performed by exposing 2 cm2 of PET-COOH-NTPDase to 1.5 ml of ADP 
in the presence of 0.1 M Tris buffer (pH = 7.4) and 5 mM CaCl2 at 37ºC. The rate of Pi 
release was measured using the malachite green assay (Baykov et al. 1988). The 
experiment was repeated for different ADP concentrations (0.1, 0.15, 0.2, and 0.25 mM). 
 
4.3 Results and Discussion 
 
4.3.1 Free NTPDase kinetics 
 
Free NTPDase kinetics were studied to understand the mechanism of enzyme 
reaction and to compare with immobilized NTPDase. Figure 4.1 shows the dimensionless 
formation of Pi (Pi formed/Initial [ADP]) in the free NTPDase studies.  
As observed, the amount of Pi formed was very rapid at the beginning and 
reached a plateau after a short time. Furthermore, the results show that ADP didn’t 
convert to AMP and Pi completely. The conversion of ADP ranged from about 60% to 
80%. One of the possible reasons for such an observation could be the loss of NTPDase 
activity when it is in solution, leading to complete loss in activity after a given time.  To 
test this hypothesis, NTPDase was stored for a given time in a solution composed of 0.1 
M Tris buffer (pH = 7.4) and 5 mM CaCl2.  Afterwards, the activity of NTPDase was 
assessed by adding ADP to the solution. The results are shown in Figure 4.2. 
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Figure 4.1. Dimensionless formation (Pi formed/Initial [ADP]) from free NTPDase with 
(a) Initial [ADP] = 0.05 mM, (b) Initial [ADP] = 0.1 mM, (c) Initial [ADP] = 0.15 mM, 
(d) Initial [ADP] = 0.2 mM, (e) Initial [ADP] = 0.25 mM and (f) Initial [ADP] = 0.3 mM.
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Figure 4.2. Effect of storing free NTPDase in 0.1 M Tris buffer at 37ºC for 0 minutes (♦), 
60 minutes (□), 120 minutes (▲) and 240 minutes (◊).
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As seen in these results, it is evident that NTPDase loses activity when stored in 
solution for long hours. However, the stability of PET-COOH-NTPDase (discussed in 
Chapter 3) showed that the polymer didn’t lose any NTPDase activity even when it was 
stored in solution at 37ºC for 200 minutes (Figure 3.9). These results indicate that 
immobilization of NTPDase on carboxylated PET improves the temperature stability of 
NTPDase when stored in a solution. This increased stability of NTPDase activity due to 
immobilization would potentially enhance the haemocompatibility for long-term 
biomedical applications.  
Due to the loss of NTPDase stability during free NTPDase kinetics, it was 
difficult to fit the Pi versus time curve for each experimental condition to the Michaelis-
Menten equation. Therefore, the initial rates of Pi formation for different initial ADP 
concentrations were calculated. Using these initial rates and ADP concentrations, a 
Lineweaver-Burke plot was made (Figure 4.3). Using the slope and the intercept from the 
Lineweaver-Burke plot, the Michaelis-Menten constants vmax = 0.0118 mM/min (95% 
confidence range is 0.0105 to 0.0133) and KM = 0.0643 mM (95% confidence range is 
0.060 to 0.068) were calculated.  As shown, the linear fit (R2
 
= 0.984) agrees very well 
with the linear expectation of a Lineweaver-Burke plot.  It is important to note that vmax 
includes not only the catalytic rate constant associated with NTPDase, but also the 
amount of enzyme in solution. 
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Figure 4.3. Lineweaver-Burke plot using initial rates from free NTPDase kinetics with 
different initial [ADP]. Using the slope and intercept the Michaelis-Menten constants 
were calculated as vmax = 0.0118 mM/min and KM = 0.0643 mM.
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4.3.2 Immobilized NTPDase kinetics (PET-NH2-NTPDase) 
 
For understanding the effect of immobilization on NTPDase kinetics, PET-NH2-
NTPDase polymers were analyzed. These kinetic studies and the analysis discussed in 
Chapter 3 regarding aminolyzed PET and PET-NH2-NTPase were performed 
concurrently. The results obtained for the rate of Pi formation for different initial ADP 
concentrations are shown in Figures 4.4a, 4.5a, 4.6a, 4.7a and 4.8a. The first observation 
from the results was that the error bars for the concentrations were relatively big. The 
possible reasons could include the instability of imine bonds on PET-NH2-NTPDase, loss 
of the activity of NTPDase that was detached from PET-NH2-NTPDase, and the 
inconsistent development of cracks in the polymer (leading to varying amounts of 
NTPDase that could attach). Also, in the 50-ml reactor, where 5 cm × 1 cm polymer was 
cut into five pieces, it was observed that these pieces stuck to each other or to the wall of 
the reactor in some trials. This could make the experimental conditions different for the 
different trials, which could have also resulted in the big error bars. 
Once the Pi concentrations over time were measured, ADP concentrations were 
calculated based on stoichiometry. These ADP concentrations were fit to a polynomial in 
terms of time. This equation for ADP concentration as a function of time was used to 
estimate the rate of change of ADP concentration. ADP concentrations and the 
corresponding rates of ADP consumption were fit to a Michaelis-Menten model using 
SigmaPlot (Figures 4.4b, 4.5b, 4.6b, 4.7b and 4.8b). 
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Figure 4.4. (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.1 
mM. Pi (□) and ADP (♦) concentrations are shown. The ADP concentration was fitted to 
a polynomial for estimating the derivative, (b) Rate of ADP conversion using PET-NH2-
NTPDase for initial [ADP] = 0.1 mM. Solid line is the Michaelis-Menten model with 
vmax = 0.01131 mM/min and KM = 0.1247 mM
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Figure 4.5. (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.15 
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was fitted to a 
polynomial for estimating the derivative, (b) Rate of ADP conversion using PET-NH2-
NTPDase for initial [ADP] = 0.15 mM. Solid line is the Michaelis-Menten model with 
vmax = 0.006949 mM/min and KM = 0.05151 mM
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Figure 4.6. (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.2 
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was fitted to a 
polynomial for estimating the derivative, (b) Rate of ADP conversion using PET-NH2-
NTPDase for initial [ADP] = 0.2 mM. Solid line is the Michaelis-Menten model with 
vmax = 0.06934 mM/min and KM = 0.01509 mM
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Figure 4.7. (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.25 
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was fitted to a 
polynomial for estimating the derivative, (b) Rate of ADP conversion using PET-NH2-
NTPDase for initial [ADP] = 0.25 mM. Solid line is the Michaelis-Menten model with 
vmax = 0.01242 mM/min and KM = 0.02425 mM
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Figure 4.8. (a) NTPDase reaction kinetics for PET-NH2-NTPDase using [ADP] = 0.3 
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was fitted to a 
polynomial for estimating the derivative, (b) Rate of ADP conversion using PET-NH2-
NTPDase for initial [ADP] = 0.3 mM. Solid line is the Michaelis-Menten model with 
vmax = 0.009873 mM/min and KM = 0.09461 mM
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From these plots, it was observed that the rates approached saturated kinetics as 
ADP concentrations increased—this is consistent with Michaelis-Menten kinetics. For 
example, at initial [ADP] = 0.1 mM, the rate of reaction never approached a saturation 
limit. Although most of the data obtained seemed to fit Michaelis-Menten kinetics, it was 
observed that the Michaelis-Menten constants were inconsistent for different initial ADP 
concentrations. It should be noted that some of the data was extrapolated to obtain the 
constants, which is problematic.   
As PET-NH2-NTPDase was stored at -20ºC (recommended storage condition for 
free NTPDase) for up to 7 days for some of the trials, it was important to verify if PET-
NH2-NTPDase lost any activity during storage. For this reason, PET-NH2-NTPDase was 
stored at -20ºC for 4 weeks and then tested for activity using 0.2 mM ADP. The results 
obtained, shown in Figure 4.9, indicate that there was no measureable loss of NTPDase 
activity due to storage at -20ºC. As storing the polymer didn’t affect the activity, the 
reasons for different Michaelis-Menten constants for different initial ADP concentrations 
could include instability of PET-NH2-NTPDase immobilization, loss of NTPDase activity 
after NTPDase was detached from the polymer and the uncertainties associated with the 
50-ml experimental system. 
With multiple factors regulating the kinetics in these experiments, rigorous 
analysis would be required to understand the reason behind different Michaelis-Menten 
constants. As aminolyzed PET didn’t have desired surface and bulk properties and PET-
NH2-NTPDase was not a stable immobilization, further analysis was not performed.
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Figure 4.9. Effect of storing PET-NH2-NTPDase at -20ºC for 4 weeks. Pi formation for 
freshly prepared PET-NH2-NTPDase (♦) and PET-NH2-NTPDase stored at -20ºC for 4 
weeks (□), with 0.2 mM ADP, are shown.
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4.3.3 Immobilized NTPDase kinetics (PET-COOH-NTPDase) 
 
To overcome the limitations seen in PET-NH2-NTPDase, immobilized NTPDase 
kinetics was studied using PET-COOH-NTPDase. As results discussed in Chapter 3 
showed that 50-ml experimental could cause mass transfer limitations, PET-COOH-
NTPDase kinetics were performed using small volume reactors. Pi concentrations at 
different times were measured using the malachite green assay. With the Pi 
concentrations at different times, the corresponding ADP concentrations were calculated 
using stoichiometry. This ADP concentration was plotted and fitted to a polynomial. The 
derivative of this polynomial was used to estimate the rate of ADP conversion for any 
given ADP concentration. Figures 4.10a, 4.11a, 4.12a and 4.13a show the Pi 
concentration, ADP concentration and the polynomial used to fit ADP concentration in 
terms of time. The results show that the error bars are very small, although the error could 
produce significant problems with estimating kinetic constants (see below). 
Using the polynomial for ADP concentration, the rates of ADP conversion were 
calculated and plotted against the corresponding ADP concentration. This plot was fit to a 
Michaelis-Menten model using SigmaPlot as shown in Figures 4.10b, 4.11b, 4.12b and 
4.13b. The results showed that most of the data obtained from the experiments were 
around the saturation condition, which makes it difficult to obtain good Michaelis-
Menten kinetic values. Even for low concentrations of ADP, such as [ADP] = 0.1 mM, 
the data suggests saturation.
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Figure 4.10. (a) NTPDase reaction kinetics for PET-COOH-NTPDase using [ADP] = 0.1 
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was fitted to a 
polynomial for estimating the derivative, (b) Rate of ADP conversion using PET-COOH-
NTPDase for initial [ADP] = 0.1 mM. Solid line is the Michaelis-Menten model with 
vmax = 0.000702 mM/min and KM = 0.003225 mM 
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Figure 4.11. (a) NTPDase reaction kinetics for PET-COOH-NTPDase using [ADP] = 
0.15 mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was fitted to 
a polynomial for estimating the derivative, (b) Rate of ADP conversion using PET-
COOH-NTPDase for initial [ADP] = 0.15 mM. Solid line is the Michaelis-Menten model 
with vmax = 0.000863 mM/min and KM = 0.01494 mM
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Figure 4.12. (a) NTPDase reaction kinetics for PET-COOH-NTPDase using [ADP] = 0.2 
mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was fitted to a 
polynomial for estimating the derivative, (b) Rate of ADP conversion using PET-COOH-
NTPDase for initial [ADP] = 0.2 mM. Solid line is the Michaelis-Menten model with 
vmax = 0.00181 mM/min and KM = 0.02246 mM
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Figure 4.13. (a) NTPDase reaction kinetics for PET-COOH-NTPDase using [ADP] = 
0.25 mM. Pi (□) and ADP (♦) concentrations are shown. ADP concentration was fitted to 
a polynomial for estimating the derivative, (b) Rate of ADP conversion using PET-
COOH-NTPDase for initial [ADP] = 0.25 mM. Solid line is the Michaelis-Menten model 
with vmax = 0.00278 mM/min and KM = 0.03848 mM
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As noted, different initial ADP concentration experiments resulted in different 
vmax and KM values. It was also observed that both vmax and KM calculated using 
SigmaPlot increased with an increase in the initial ADP concentrations (Table 4.1 and 
Figure 4.14). It’s possible for vmax to vary among experiments since vmax is proportional 
to the amount of NTPDase on a polymer but KM should be consistent. However, the 
calculation of KM value is very sensitive to the rate of Pi formation at low substrate 
concentrations. Thus, accurate measurement of these rates is required for precise 
calculation of KM values. 
Data in Figures 4.10a, 4.11a and 4.12a show that the error bars are bigger for Pi 
concentrations measured during the later stages of the experiment. For instance, ADP 
concentrations calculated from the measured Pi concentrations at 75, 90, and 120 minutes 
for the 0.1 mM study are 0.0478 ± 0.0042 mM, 0.0332 ± 0.0067 and 0.0172 ± 0.0050 
mM, respectively. As one can see, the measurement of Pi concentration, and therefore the 
corresponding ADP concentration, is not sensitive enough to measure smaller changes. 
This limitation has resulted in relatively larger error bars for Pi concentrations measured 
towards the final stages of the experiment. However, for calculating the rate of Pi 
formation at lower ADP concentrations, accurate measurement of Pi concentration is 
required. Since the data obtained shows variability at lower ADP concentrations, it is 
difficult to identify the actual rates at these concentrations. If the rate of Pi formation is 
lower, which is a distinct possibility, at lower ADP concentrations, KM values would be 
higher from the Michaelis-Menten curves. Therefore, further studies using protocols that 
are sensitive towards small changes in Pi concentrations are required for accurately 
measuring the rates for lower ADP concentrations and, thereby, accurate KM values.
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Table 4.1. vmax and KM calculated using Michaelis-Menten model for different initial 
ADP concentrations 
Initial [ADP], mM vmax, mM/min KM, mM 
0.1 
0.15 
0.2 
0.25 
0.000702 
0.000863 
0.001811 
0.002783 
0.003225 
0.01494 
0.02246 
0.03848 
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Figure 4.14. (a) vmax vs. initial ADP concentrations, (b) KM vs. initial ADP 
concentrations.
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Although error bars observed for Pi concentrations at very low ADP 
concentrations are bigger for the initial ADP studies less than 0.2 mM, it is important to 
note that the error bars were the smallest for the study with an initial ADP of 0.25 mM. 
These smaller error bars will give more accurate analysis of the constants. The data for 
the 0.25 mM study would have far less error in determining the Michaelis-Menten 
constants since the error bars are extremely small—perhaps a result of assessing Pi 
changes over larger concentration ranges. It’s interesting that the KM for the 0.25 mM 
immobilized study (0.038 mM) is the closest to the KM for the free NTPDase studies 
(0.064 mM).  The amount of error, although initially appearing small, may be a large 
reason as to the inconsistent kinetic analysis. 
By definition, vmax is the product of the enzyme rate constant and the 
concentration of the enzyme. Therefore, comparing the vmax values obtained for free 
NTPDase studies and the PET-COOH-NTPDase study performed with 0.25 mM initial 
ADP could provide information regarding NTPDase coverage on the PET-COOH-
NTPDase. Assuming one NTPDase molecule (MW 47,000) is spherical (with a radius of 
2.7 nm-see (Fournier 1999) for estimating radius), the maximum theoretical coverage of 
NTPDase by forming a tightly packed monolayer was calculated to be 0.0073 
nmoles/cm2.  Thus, in the 1.5 ml experiment, the concentration of NTPDase would be 9.7 
nM.   For the free enzyme study, the concentration was approximately 1.3 nM.  
Assuming the enzyme rate constant doesn’t change due to immobilization, the ratio of 
vmax for free NTPDase to vmax of PET-COOH-NTPDase with a maximum theoretical 
coverage would be equivalent to the ratio of the free NTPDase concentration to the 
NTPDase concentration in the PET-COOH-NTPDase study.  From the above reported 
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values, this NTPDase concentration ratio is 0.13 if NTPDase had complete coverage on 
the surface.  Thus, the vmax ratio would be 0.13.  From the experimental data, the ratio of 
vmax for free NTPDase to vmax calculated for PET-COOH-NTPDase studies using 0.25 
mM initial ADP is 4.2. Using this vmax ratio, the equivalent NTPDase ratio of 0.13 would 
suggest that the NTPDase concentration in the PET-COOH-NTPDase study is 0.13 nM.  
This concentration would equate to 1.3% of the maximum theoretical coverage.  
Although this seems reasonable, further work would need to be performed to assess the 
coverage. 
As noted above, it was difficult to accurately obtain the Michaelis-Menten 
constants for PET-COOH-NTPDase, although the 0.25 mM ADP study gave values 
closest to the free NTPDase studies. As seen for initial [ADP] = 0.25 mM, the Michaelis-
Menten equation provides a very good fit. Based on these results, it is evident that the 
reactions that were carried out in 1.5-ml reactors do not appear to be mass transfer limited 
since the data fits a reaction limited equation (i.e. Michaelis-Menton). One of the possible 
scenarios describing differences in the rate of Pi formation in the 50-ml and 1.5-ml 
reactors, as discussed in Chapter 3, was different limiting conditions for the two reactors. 
As seen in these results, it is reasonable to expect that reactions occurring in 1.5-ml 
reactors are reaction kinetic limited. 
Another interesting observation was that experiments using [ADP]0 = 0.25 mM 
were performed first, followed by [ADP]0 = 0.2 mM, [ADP]0 = 0.15 mM and [ADP]0 = 
0.1 mM. Therefore, experiments with [ADP]0 = 0.25 mM used fresh PET-COOH-
NTPDase and [ADP]0 = 0.1 mM used PET-COOH-NTPDase that had been stored the 
longest (approximately 12 hours). Again, as previously mentioned, the first study gave 
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the KM value closest to the free NTPDase KM value.  Free NTPDase is recommended to 
be stored at -20ºC. Also, NTPDase activity was not affected when PET-NH2-NTPDase 
was stored at -20ºC for 4 weeks. Hence, PET-COOH-NTPDase was stored at -20ºC, 
when not used. However, PET-COOH-NTPDase showed improved temperature stability 
in solution at 37ºC compared to free NTPDase. Therefore, it is possible that the effect of 
temperature is different for PET-COOH-NTPDase compared to free NTPDase and PET-
NH2-NTPDase. Further studies to verify if storing PET-COOH-NTPDase at -20ºC has an 
effect on NTPDase activity could provide additional insight into explaining the results. 
 
4.4 Conclusions 
 
Free NTPDase kinetics were studied and modeled using the Michaelis-Menten 
equation. The results obtained show that free NTPDase lost activity, when it was stored 
in a solution at 37ºC. However, from the results discussed in Chapter 3, PET-COOH-
NTPDase didn’t lose any activity when it was stored in solution at 37ºC. These results 
suggest that immobilizing NTPDase provides improved temperature stability at 37ºC. 
This could probably improve the potential of the polymer in long-term biomedical 
applications. Immobilized NTPDase kinetics were studied using PET-NH2-NTPDase and 
PET-COOH-NTPDase. PET-NH2-NTPDase kinetics were inconclusive as NTPDase 
immobilization was not stable. PET-COOH-NTPDase kinetics were also analyzed. 
Results obtained indicate that PET-COOH-NTPDase kinetic studies performed in the 1.5-
ml reactors appear to be kinetic limited and follow Michaelis-Menten kinetics. However, 
Michaelis-Menten constants for these reactions couldn’t be calculated with confidence 
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due to the limitations in the sensitivity of Pi measurements. Also, more studies are 
required to understand the effect of storing PET-COOH-NTPDase at -20ºC. Although the 
immobilized NTPDase kinetics couldn’t be modeled effectively, it is important to 
recognize that all PET-COOH-NTPDase polymers showed significant NTPDase activity. 
In addition to that, the results also indicate an increased stability of NTPDase activity in 
solution at 37ºC, due to immobilization. 
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CHAPTER 5 
 
 
IN VITRO STUDIES OF NTPDase-MODIFIED POLYETHYLENE 
TEREPHTHALATE TO VERIFY IMPROVED HAEMOCOMPATIBILITY 
 
 Haemocompatibility is the compatibility of a biomaterial when it comes in contact 
with blood. It is an important criterion in developing a biomaterial used in blood-
contacting systems.  The lack of haemocompatibility is a serious problem that limits the 
functionality of many biomaterials. Based on the Manufacturer and User Facility Device 
Experience (MAUDE) Database, at least 1510 cases of thrombosis in implants and other 
biomedical devices, of which 299 resulted in deaths, have been reported to the FDA in 
2008. These numbers have increased drastically from 2003, when 593 cases of 
thrombosis, of which 113 resulted in death, were reported. Such thrombosis events are 
occurring even with aggressive use of antithrombotic drugs, which can cause bleeding 
complications (van Oeveren 2005). The new types of catheters and stents that are being 
used today have actually caused an increase in the thrombotic events that are reported 
(van Oeveren 2005). Improving the haemocompatibility of a biomaterial will 
significantly improve the current situation. This will save lives and improve the quality of 
life for people living with implants. While developing a material for blood-contacting 
devices, testing the haemocompatibility is crucial. Understanding the blood-material 
interactions gives valuable information required in designing a biomaterial. 
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With surface and bulk characterization proving that PET-COOH-NTPDase has 
desirable properties, PET-COOH-NTPDase has the potential to be a valuable biomaterial. 
The polymer can have vast applications in blood-contacting systems, if the 
haemocompatibility is improved due to ADP scavenging by NTPDase. For testing this 
hypothesis, the haemocompatibility of PET-COOH-NTPDase was analyzed using in vitro 
studies. In this chapter, protein adsorption on unmodified, carboxylated and NTPDase-
modified PET was analyzed. Platelet adhesion on unmodified, carboxylated and 
NTPDase-modified PET when exposed to platelet rich plasma was also studied. This 
chapter also discusses thrombus formation when unmodified, carboxylated and 
NTPDase-modified PET were exposed to whole blood. Results obtained from these batch 
studies should provide greater understanding on the haemocompatibility of PET-COOH-
NTPDase. 
 
5.1 Introduction 
 
The significance of haemocompatibility in developing a blood-contacting material 
can’t be overstated. The lack of haemocompatibility causes serious complications in 
patients that could even lead to death. The use of biomedical devices, such as 
hemodialyzers, vascular grafts, heart valve prostheses, artificial heart etc., which come in 
contact with blood, is growing rapidly. Hence, it is vital to understand the 
haemocompatibility of materials that are used in blood-contacting systems. Extensive 
testing of materials is required to understand blood compatibility. Many experimental 
procedures have been developed to evaluate the effect of a material on blood coagulation 
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and thrombus formation. For a material to be used in a commercial biomedical device, it 
has to go through a series of biocompatibility and haemocompatibility testing. The 
regulations for testing these biomaterials are provided by many organizations, including 
the American Society of Testing and Materials International (ASTM), International 
Standards Organization (ISO), the American Dental Association (ADA), the National 
Institutes of Health (NIH) and the Food and Drug Administration (FDA). The first phase 
of testing the haemocompatibility is in vitro studies. In vitro studies are performed to 
screen materials that could potentially be used in biomedical applications. The next step 
is using an ex vivo system to evaluate the haemocompatibility under a more in vivo-like 
setup. In the final stage involving lab-scale testing, in vivo experiments using animal 
models are performed. Ultimately, clinical trials are designed to evaluate the safety of the 
biomaterial when used in humans. Such clinical trials are performed only after extensive 
in vitro and in vivo animal model testing has been done. However, clinical trials are 
usually intended towards testing the biomedical device as a complete unit, instead of 
testing the biomaterials used in building the device. 
 
5.1.1 In vitro systems 
 
In vitro testing is the most common and fundamental approach used to evaluate 
the material’s haemocompatibility. In vitro experiments are easier, faster, less expensive 
and safer compared to the in vivo studies. The experiments are performed in a more 
controlled environment. Hence, they provide a basic understanding of the material 
properties. There are many types of in vitro systems used for evaluating blood 
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compatibility. Protein adsorption studies and static studies, performed using platelet-rich 
plasma and human blood, are common in vitro experiments used for studying the 
potential of a biomaterial (Iwasaki et al. 1996; Li and Ruckenstein 2004; Joseph et al. 
2008; Liu et al. 2008; Lin et al. 2009). Protein adsorption is important to analyze as it is 
the first event when the material comes in contact with blood. Further interactions of the 
blood with the material are mediated by a layer of protein (Wilson and Cooper 1986). 
Therefore, protein adsorption is known to have a great influence on the thrombogenic 
nature of the material. Currently many different techniques are employed in studying 
protein adsorption on a polymer surface. Protein adsorption on a polymer surface can be 
quantified using simple colorimetric assays (Ishihara et al. 1999b; Lin et al. 2004; Pan et 
al. 2007; Liu et al. 2008). Conformational changes in the adsorbed proteins have also 
been explored using an ATR-FTIR flow cell method (Ito et al. 1986; Sanada et al. 1986), 
circular dichroism (Mcmillin and Walton 1974; Norde and Favier 1992) and calorimetric 
analysis (Chiu et al. 1976). 
Interactions between platelets and the material being investigated are studied by 
simple static systems. Platelet-rich plasma studies have been used extensively for this 
reason (Kang et al. 1997; Lee et al. 1998; Li and Ruckenstein 2004; Wu et al. 2007; Liu 
et al. 2008). In these experiments, the material comes in direct contact with platelet-rich 
plasma (PRP). Platelets that are activated by exposure to foreign surfaces trigger the 
intrinsic pathway of the blood coagulation cascade. This will result in platelet adhesion 
and aggregation on the material. Studying the PRP-material interaction can provide some 
valuable information about the haemocompatibility of the material. Platelet adhesion and 
aggregation on the surface can be analyzed using scanning electron microscope (Iwasaki 
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et al. 1996; Li and Ruckenstein 2004; Liu et al. 2008) or by measuring the platelet 
concentration using a lactate dehydrogenase assay (Tamada et al. 1995). Although PRP 
studies are useful for understanding the haemocompatibility of a material, thrombus 
formation has to be analyzed. For this purpose, whole blood studies are used (Kang et al. 
1997; Lin et al. 2004; Liu et al. 2008; Lin et al. 2009). In the whole blood studies, blood 
is contacted with a test surface for a fixed period of time. After this, both the blood and 
the surface may be examined. The most common tests performed on the blood are a 
partial thromboplastin time test, a platelet factor-3 assay, a prothrombin time test and 
counting of the platelet. The test surface exposed to blood can also be examined after 
blood contact. The degree of thrombus formation is usually measured using light, phase-
contrast or scanning electron microscopy (Wilson and Cooper 1986). 
 
5.1.2 Ex vivo systems 
 
In an ex vivo system, blood flows from the test animal via a shunt and through the 
test surface. The blood-material interactions in the test area are monitored. Ex vivo 
studies are usually performed to evaluate short-term interactions. Both arteriovenous and 
arterioarterial shunts may be used for performing ex vivo studies. Many configurations of 
ex vivo experiments are available. One basic experiment is the Dudley clotting time test 
(Dudley et al. 1976; Wilson and Cooper 1986). In the Dudley clotting time test, a tube is 
inserted into the vein of a test animal. The time taken for the blood to stop dripping from 
the end of the tubing is called the Dudley clotting time. The clotting times can be 
compared for different materials by changing the tubing properties. 
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5.1.3 In vivo systems 
 
Systemic and physiological processes are complex and are difficult to be 
simulated in vitro. Therefore, in vivo animal testing is necessary prior to human clinical 
testing. In vivo haemocompatibility tests are usually designed to simulate the geometry, 
flow dynamics and contact conditions of the material when used in its application. 
Although using in vivo animal testing is convenient, it is important to recognize that 
different species have different blood reactivity. This has to be considered while 
analyzing the data from in vivo animal models. In vivo haemocompatibility testing using 
animals is also complicated by the lack of adequate test materials such as antibodies for 
immunoassays. Also, the regulations of the governing bodies might restrict the use of 
some species in animal testing. For example, an arteriovenous shunt model in baboons 
shows results that are usually consistent with humans. However, non-human primates, 
which have blood reactivity very close to humans, can’t be used as test animals in 
Europe. 
 
5.1.4 Clinical trials 
 
Clinical trials are performed after extensive research. Although clinical trials give 
information regarding the biomaterial, they are usually designed to test the effectiveness 
of the biomedical device that is built from the material. Usually in the clinical trials for 
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implants, the condition of the patient is compared before and after the implant and the 
implant is also compared with similar implants using other materials. 
The first step in evaluating the haemocompatibility of a biomaterial is performing 
in vitro studies. For this reason, this research concentrates on understanding blood-
material interactions in vitro. As discussed earlier, protein adsorption can play a vital role 
in the haemocompatibility of the biomaterial. In addition, the most common measures of 
thrombogenicity are platelet adhesion and thrombus formation. Hence this chapter 
explores protein adsorption, platelet adhesion and thrombus formation. Protein adsorption 
onto PET-COOH and PET-COOH-NTPDase were compared to the protein adsorption on 
unmodified PET. Platelet adhesion and thrombus formation on the modified PET surfaces 
were also analyzed using PRP and whole blood studies performed under static conditions. 
 
5.2 Materials and methods 
 
Polyethylene terephthalate (PET) (thickness = 0.2 mm) was supplied by DuPont 
(Hopewell, VA). Bromoacetic acid, 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
glucose, bovine serum albumin (BSA), n-sodium dodecyl sulfate (SDS), NTPDase 
(Apyrase from potato, Grade VII containing the isoenzyme Desirée with low 
ATPase/ADPase ratio) were purchased from Sigma (St. Louis, MO). BCA protein assay 
kit was purchased from Thermo Scientific (Rockford, IL). Sodium hydroxide, sodium 
chloride, potassium chloride, sodium phosphate (monobasic and dibasic), potassium 
phosphate (monobasic), potassium chloride, sodium bicarbonate, magnesium chloride, 
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acetone, acetic acid, formaldehyde, ethanol and other reagents were purchased from 
Fisher Scientific (Fair Lawn, NJ). Platelet rich plasma (PRP) was donated by Dr. Wei 
Yin, School of Mechanical and Aerospace Engineering, Oklahoma State University. For 
performing whole blood studies, fresh samples of human blood were drawn from willing 
donors using buffered sodium citrate as the anti-coagulant. 
PET-COOH-NTPDase was prepared using the protocol described in Chapter 3. 
Briefly, PET was incubated in acetone for 24 h, then reacted with 18.5% formaldehyde 
solution in 1 M acetic acid for 4 h (Massia and Hubbell 1990) and finally reacted with 1 
M bromoacetic acid solution in 2 M sodium hydroxide for 18 h (Löfås and Johnsson 
1990) . This formed carboxylated PET (PET-COOH) (Yang et al. 2000). PET-COOH 
was incubated with 0.1 M EDC and 20 U/ml of NTPDase in 0.1 M phosphate buffer (pH 
= 6.8) at 4˚C for 16 h to form PET-COOH-NTPDase. The following in vitro studies were 
performed on unmodified PET, PET-COOH and PET-COOH-NTPDase to verify 
haemocompatibility. 
 
5.2.1 Protein adsorption studies 
 
Protein adsorption to the surface of unmodified, carboxylated and NTPDase-
modified PET was analyzed using the protocol described in previous studies (Ishihara et 
al. 1999b; Lin et al. 2004; Liu et al. 2008). Unmodified and modified PET films were 
equilibrated in phosphate buffered saline (PBS) (pH = 7.4) for 1 h at 37ºC. 1 mg/ml of 
BSA solution was prepared in PBS. The equilibrated films were then incubated in freshly 
prepared BSA solution at 37ºC for 3 hours with gentle shaking. The films were washed 
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gently with PBS to remove weakly adsorbed proteins. The films were then sonicated with 
1 wt% n-sodium dodecyl sulfate (SDS) for 1 hour to remove the adsorbed proteins. The 
protein concentration in the SDS solution was estimated using bicinchoninic acid (BCA) 
protein assay (Smith et al. 1985; Wiechelman et al. 1988; Brown et al. 1989). First, the 
BCA working reagent was prepared by mixing 50 ml of reagent A containing 
bicinchoninic acid, sodium bicarbonate, sodium tartarate and sodium carbonate in 0.1 M 
sodium hydroxide and 1 ml of reagent B containing 4% cupric sulfate in DI water. 50 µl 
of sample solution was then mixed with 200 µl of the working reagent. This mixture was 
incubated at 60ºC for 30 minutes. The absorbance was measured at 560 nm. The assay 
was calibrated using BSA standards. 
 
5.2.2 Platelet rich plasma (PRP) studies 
 
Platelet adhesion on the surface of unmodified and modified PET was analyzed 
using a protocol described in literature (Tamada et al. 1995; Kang et al. 1997; Lee et al. 
1998; Li and Ruckenstein 2004; Lin et al. 2004; Mao et al. 2005; Wu et al. 2007; Liu et 
al. 2008). Unmodified PET, PET-COOH and PET-COOH-NTPDase films were cut to 1 
cm × 1 cm pieces. These films were washed with DI water and placed in 24-well culture 
plates. PRP from human blood was donated by Dr. Wei Yin. Platelet counts in the 
platelet rich plasma were 1 × 106 platelets per µl. This PRP was diluted using HEPES-
Tyrode’s buffer (pH = 7.4) to reduce the platelet count to 350,000 platelets per µl. 
HEPES-Tyrode’s buffer was prepared using the recipe from literature (Lian et al. 2005). 
The buffer contained 134 mM NaCl, 3 mm KCl, 0.3 mM NaH2PO4, 12 mM NaHCO3, 2 
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mM MgCl2, 5 mM HEPES, 5 mM glucose and 0.35% bovine albumin. The diluted PRP 
was added to each of the wells in the 24-well culture plate containing polymer films. This 
was incubated at 37ºC for 2 hours without shaking. The films were then washed gently 
with PBS to remove loosely adhered platelets. The platelets adhered to the polymer 
surfaces were then fixed with 4% formaldehyde solution in PBS (pH = 7.4) for 1 h at 
room temperature. The polymer films with adhered platelets were then dehydrated using 
an ethanol graded series (50, 60, 70, 80, 90 and 100 volume %) for 30 minutes each. The 
polymers were then dried in a vacuum dessicator at room temperature for 12 hours. 
Platelet adhesion on unmodified PET, PET-COOH and PET-COOH-NTPDase surfaces 
was analyzed using SEM images. 
 
5.2.3 Whole blood studies 
 
Thrombus formation on unmodified PET, PET-COOH and PET-COOH-NTPDase 
surfaces was studied by exposing the polymers to freshly drawn human blood (Kang et 
al. 1997; Lin et al. 2004; Liu et al. 2008). Human blood was drawn from willing donors 
using buffered 0.109 M sodium citrate anticoagulant. Although many anticoagulants were 
available to choose from, sodium citrate was used as it didn’t affect normal platelet 
function. Polymer films were cut to 1 cm × 1 cm pieces and washed with DI water. These 
pieces were then placed into the wells of a 24-well culture plate. Citrated human blood 
(0.8 ml) was added to the wells and incubated at 37ºC for 2 hours. The films were then 
washed gently using PBS to remove any loosely adhered platelets and other cells. The 
thrombi formed on the surfaces were fixed using 4% formaldehyde solution in PBS (pH 
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= 7.4) for 1 hour at room temperature. The polymers were then dehydrated using an 
ethanol graded series (50, 60, 70, 80, 90 and 100 volume %) for 30 minutes each. The 
polymers were then dried in a vacuum dessicator at room temperature for 12 hours. 
Thrombi formation on unmodified PET, PET-COOH and PET-COOH-NTPDase surfaces 
was analyzed using SEM images. 
 
5.3 Results and Discussion 
 
5.3.1 Protein adsorption studies 
 
Protein adsorption is the very first event that occurs at the blood-material 
interface. Understanding protein-surface interactions has been one of the most important 
topics in biomaterials and has been explored for several decades. Protein adsorption is 
known to take place within the first few seconds of exposure to blood (Vroman 1967; 
Vroman and Adams 1969). It has also been shown that there is layer of protein between 
the surface and adhered platelets and thrombi (Dutton et al. 1969). Therefore, the 
interaction between blood and the material is mediated by a layer of protein on the 
surface. A number of studies have shown that protein adsorption on the material surface 
has a direct effect on platelet adhesion and activation (Kim et al. 1974; Lyman et al. 
1975; Brash and Uniyal 1979; Brash 1991; Tanaka et al. 2000; Higuchi et al. 2002; 
Zhang et al. 2008). Many researchers have studied the adsorption of one or more of the 
most abundant plasma proteins, namely, albumin, immunoglobulin G and fibrinogen in 
buffered solution (Brash and Uniyal 1979; Brash 1991; Lee et al. 1997; Zhang et al. 
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2008). These studies also show that adsorption of plasma proteins on the material surface 
plays a significant role in thrombus formation (Pankowsky et al. 1990; Ishihara et al. 
1991; Fedel et al. 2008; Mao et al. 2008; Lin et al. 2009). Based on these studies, it is 
clear that minimizing protein adsorption will play a key role in the haemocompatibility of 
the polymer. 
Protein adsorption on the surface depends on a variety of surface properties, such 
as hydrophilicity, roughness, charge and chemistry. It was important to analyze the 
influence of carboxylation and NTPDase modification of PET on protein adsorption as 
increased protein adsorption will increase platelet adhesion and aggregation and result in 
thrombus formation. For this reason, unmodified PET, PET-COOH and PET-COOH-
NTPDase were all incubated with bovine serum albumin, using the protocol described. 
The concentration of adsorbed albumin was measured using the BCA assay. The results 
obtained are shown in Figure 5.1. 
The results show that unmodified PET and PET-COOH-NTPDase adsorb similar 
concentrations of albumin. Therefore, attaching NTPDase to PET will not increase 
platelet activation and the blood coagulation cascade due to protein adsorption. On the 
other hand, it is seen that PET-COOH adsorbs a higher concentration of albumin. This is 
probably because of the difference in the surface chemistry. Similar results were 
observed with arginine modified PET, where aminolyzed PET showed an increase in 
protein adsorption compared to unmodified PET and arginine attached aminolyzed PET 
(Liu et al. 2008). As NTPDase modification reduced the protein adsorption, further 
studies were not performed to study the increased protein adsorption on PET-COOH. 
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Figure 5.1. Protein adsorption studies on unmodified and modified PET surfaces. 
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5.3.2 Platelet rich plasma studies 
 
From protein adsorption studies, it is evident that platelet activation caused by 
adsorbed proteins will be comparable for unmodified PET and PET-COOH-NTPDase. 
However, PET-COOH-NTPDase showed significant NTPDase activity. Hence, NTPDase 
will scavenge ADP released during platelet activation, thereby preventing further platelet 
activation. Therefore, it was expected that minimal platelet activation would be observed 
on PET-COOH-NTPDase. Based on this hypothesis, it was expected that NTPDase-
modified PET will show improved platelet inhibition. For verifying this hypothesis, PRP 
studies were performed on unmodified and modified PET. In vitro studies using PRP is a 
very common technique used in evaluating haemocompatibility. PET-COOH-NTPDase 
was exposed to PRP (350,000 platelets per µl) in static conditions at 37ºC for 2 hours. 
Platelet adhesion on PET-COOH-NTPDase surfaces was then compared with that on 
unmodified PET and PET-COOH surfaces. This comparison was performed qualitatively 
using scanning electron microscope (SEM) images. The results obtained are shown in 
Figures 5.2, 5.3 and 5.4. 
Figure 5.2 shows the platelet adhesion on unmodified PET when exposed to PRP. 
As seen in the SEM images, platelet adhesion on the unmodified PET is evident. The 
presence of pseudopods on the adhered platelets indicates that the platelets are activated. 
Based on the SEM images, platelet adhesion on unmodified PET surfaces is probably 
secondary adhesion. This is an irreversible attachment of platelets to the surface. On 
close observation, SEM images also indicate platelet aggregation during exposure to 
platelet rich plasma.
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Figure 5.2. SEM images of unmodified PET exposed to platelet rich plasma to understand platelet adhesion. All images are at 
3000x magnification. Platelet aggregates are highlighted. 
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Figure 5.3. SEM images of PET-COOH exposed to platelet rich plasma to understand platelet adhesion. All images are at 
3000x magnification. Platelet aggregates are highlighted. 
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Figure 5.4. SEM images of PET-COOH-NTPDase exposed to platelet rich plasma to understand platelet adhesion. All images 
are at 3000x magnification.
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Figure 5.3 shows the SEM images of carboxylated PET incubated with PRP. The 
images clearly show significant platelet adhesion on the surface of PET-COOH. 
Furthermore, from the pseudopods on the platelets adhered, it is evident that platelet 
activation has occurred. Based on these observations, it is reasonable to conclude that 
platelet adhesion on the carboxylated PET surface was secondary adhesion. Platelets 
aggregation is also observed. 
Figure 5.4 shows the SEM images of PET-COOH-NTPDase incubated with PRP. 
NTPDase-modified polymers show inhibition of platelet deposition. In two of the three 
polymers almost complete platelet inhibition is observed. Very few platelet cells are 
attached to the surface. Even the platelets attached don’t show any visible shape change. 
However, one of the PET-COOH-NTPDase polymers did show platelet adhesion. But, 
the platelets are relatively round in shape and didn’t exhibit any significant shape change. 
These observations indicate that platelet activation was reduced by the action of 
NTPDase. Also, even the platelets adhered to the PET-COOH-NTPDase surface were not 
aggregated. ADP, a dense granule that induces platelet aggregation, is consumed by the 
activity of NTPDase. Hence, platelet aggregation is very minimal. These findings 
indicate that even the reduced platelet adhesion observed on PET-COOH-NTPDase 
surface is primary adhesion, which is easily reversible.  
 
5.3.3 Whole blood studies 
 
In vitro studies using human blood provides useful information regarding 
haemocompatibility of a biomaterial. Performing whole blood studies provides 
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information that is not obtained from PRP studies. When a material is exposed to human 
blood, first plasma proteins attach to the surface. After this, platelet adhesion and 
activation occur. Then, the blood coagulation cascade is triggered. This results in 
thrombus formation. From the protein adsorption and PRP studies, it is expected that 
thrombus formation would be inhibited on PET-COOH-NTPDase surfaces. For testing 
this theory, PET-COOH-NTPDase was exposed to freshly drawn citrated human blood at 
37ºC for 2 h. Thrombus formation on the PET-COOH-NTPDase surface was analyzed 
qualitatively using SEM images. These results were compared with the thrombus 
formation on unmodified and carboxylated PET. The results are shown in Figures 5.5, 5.6 
and 5.7. 
Figure 5.5 shows the thrombus formation on unmodified PET exposed to human 
blood. As the SEM images suggest, unmodified PET is highly thrombogenic. This 
resulted in significant thrombus formation. Also, at higher magnifications, SEM images 
clearly showed that thrombus formed is strongly adhered to the surfaces. All the 
unmodified PET surfaces that were exposed to human blood showed significant thrombi 
formation. 
Figure 5.6 shows the thrombus formation on carboxylated PET exposed to human 
blood. As seen in the SEM images, carboxylated PET also showed significant 
thrombogenicity. Higher magnification images showed that thrombi on PET-COOH 
surfaces are also strongly attached. Although significant thrombi formation was observed 
on carboxylated PET surfaces, thrombi formation was lower than unmodified PET 
surfaces.
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Figure 5.5. SEM images of unmodified PET exposed to whole blood to understand 
thrombus formation. (a) 1400x, (b) 2000x, (c) 3000x and (d) 10000x magnifications 
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Figure 5.6. SEM images of PET-COOH exposed to whole blood to understand thrombus 
formation. (a) 2000x and (b) 8000x magnifications 
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Figure 5.7. SEM images of PET-COOH-NTPDase exposed to whole blood to understand 
thrombus formation (a) 1400x, (b) 2000x, (c) 2977x and (d) 10000x magnifications 
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Figure 5.7 shows the thrombus formation on PET-COOH-NTPDase surface 
exposed to human blood. The SEM images clearly show reduced thrombogenicity. PET-
COOH-NTPDase shows very little thrombi formation. Even the few platelets that 
adhered to the surface did not show any pseudopods, indicating minimal platelet 
activation. Even under higher magnifications, it is clear that thrombi formation was 
significantly reduced on PET-COOH-NTPDase. The presence of active NTPDase on 
PET-COOH-NTPDase clearly enhances anti-thrombogenicity. 
 
5.4 Conclusions 
 
In vitro studies were performed to analyze the haemocompatibility of NTPDase-
modified PET. The effect of NTPDase immobilization on protein adsorption, platelet 
adhesion and thrombus formation were analyzed under static conditions. The results 
showed that protein adsorption on PET-COOH-NTPDase was comparable to unmodified 
PET. Also, inhibition of platelet deposition due to NTPDase activity was obvious from 
the SEM images of unmodified PET, PET-COOH and PET-COOH-NTPDase following 
exposure to PRP. Whole blood studies showed that thrombus formation is also alleviated 
by NTPDase activity. On close examination of the SEM images from PRP and whole 
blood studies, it is apparent that even the platelets adhering to the surface of PET-COOH-
NTPDase were not activated. Hence, the platelet adhesion observed on the surface of 
PET-COOH-NTPDase was probably primary adhesion, which is reversible. Based on 
these in vitro haemocompatibility studies, it is clear that PET-COOH-NTPDase shows 
enhanced platelet inhibition. As enhanced haemocompatibility is observed only on PET-
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COOH-NTPDase and not on unmodified PET and PET-COOH, it is clear that NTPDase 
activity resulted in ADP scavenging, which in turn inhibits platelet deposition and 
thrombus formation. With desirable surface and bulk properties of carboxylated PET, 
improved haemocompatibility due to NTPDase immobilization makes the polymer a 
viable option in blood-contacting systems. 
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CHAPTER 6 
 
 
DUAL FUNCTIONAL POLYMER TO EXPLOIT THE ADDITIVE EFFECT OF 
NTPDase AND NITRIC OXIDE (NO) 
 
 In vitro studies demonstrated that modifying PET surfaces with NTPDase 
improved the haemocompatibility. In addition to using NTPDase, utilizing another 
naturally occurring platelet inhibition mechanism that provides an additive effect would 
potentially cause complete platelet inhibition. One of the molecules known to have an 
additive effect on platelet inhibition with NTPDase is nitric oxide (NO) (Ramamurthi et 
al. 2001). As nitric oxide is preferentially transferred from S-nitroso albumin to cysteine 
(Meyer et al. 1994), the platelet inhibition effect of nitric oxide has been utilized to 
improve the haemocompatibility by attaching L-cysteine to polymer surfaces (Duan and 
Lewis 2002). Attaching L-cysteine, along with NTPDase, to PET would take advantage 
of the additive effect of NTPDase and NO. This chapter discusses covalent 
immobilization of L-cysteine and NTPDase to carboxylated PET. The effectiveness of 
NTPDase attachment was studied by performing NTPDase activity studies. The 
concentration of L-cysteine immobilized on the dual functional polymer was also 
measured. Studies were done to verify the possibility of varying the L-cysteine and 
NTPDase surface concentrations by varying the ratio of L-cysteine to NTPDase during 
the immobilization process. 
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6.1 Introduction 
 
For developing a dual functional polymer that makes the most of two naturally 
occurring platelet inhibition mechanisms, choosing two pathways that have an additive 
effect on platelet inhibition is critical. In Chapter 5, in vitro studies demonstrated that 
NTPDase-modified PET showed enhanced haemocompatibility. Hence, choosing a 
mechanism, which works in an additive manner to the platelet inhibition caused by 
NTPDase, would potentially develop a biomaterial that exhibits total platelet inhibition. 
NO is a potent platelet inhibitor that attenuates platelet adhesion in multiple ways 
(Mellion et al. 1981; Mendelsohn et al. 1990; Davenpek et al. 1994; Maurohara et al. 
1995; Wang et al. 1998). NO is known to have an additive effect with NTPDase in 
platelet inhibition (Ramamurthi et al. 2001). Ramamurthi et al. showed that NTPDase 
enhanced the platelet inhibitory effect of NO in a dose-dependent manner in vitro, when 
NTPDase and NO were in solution. Results from this study showed that, for 0.05 ppm 
NO at 250 s-1, inhibition of platelet deposition increased from 43 ± 5% (no NTPDase) to 
62 ± 6% (0.025 U/ml NTPDase) and 89 ± 6% (0.05 U/ml NTPDase) (Ramamurthi et al. 
2001). Similar results were also observed for other concentrations of NO (Ramamurthi et 
al. 2001). These results clearly showed that NTPDase enhanced the platelet inhibition 
potency of NO in a dose-dependent manner. The summing of individual platelet 
inhibition percentages by NTPDase and NO, separately, was equal to the total inhibition 
produced by NTPDase and NO, proving the additive effect of NTPDase and NO on 
platelet inhibition (Ramamurthi et al. 2001). Based on this, it is expected that NTPDase 
and NO would function together to improve the haemocompatibility of a biomaterial. 
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NO-mediated platelet inhibition has been used to improve the haemocompatibility 
by attaching NO-releasing compounds to a polymer (Saavedra et al. 1996; Smith et al. 
1996). The major limitation of attaching NO-releasing compounds to a polymer is the 
exhaustion of NO molecules. This limitation can be overcome by utilizing endogenous 
NO. L-Cysteine can exploit endogenous NO. NO is a highly reactive molecule that is 
present in the blood stream as S-nitrosothiols, primarily S-nitroso albumin (Stamler et al. 
1992). However, since S-nitroso albumin can’t be transported easily in to the cells, NO 
must be transferred from S-nitroso albumin to perform physiological activities. 
Scharfstein et al. reported that NO is transferred from S-nitroso albumin and low 
molecular weight thiols, such as L-cysteine, in both in vitro and in vivo conditions 
(Scharfstein et al. 1994). NO transfer, under in vivo conditions, occurs transiently from 
high molecular weight thiols to low molecular weight thiols (Scharfstein et al. 1994). 
This reversible transfer of NO from an S-nitrosothiol to a thiol in exchange for a 
hydrogen atom is defined as transnitrosation (Feelisch et al. 1994). The reaction scheme 
of transnitrosation between S-nitrosoalbumin and L-cysteine can be given as follows. 
 
AlbSHCySNOCySHAlbSNO +→+  (6.1) 
 
Sulfhydryl amino acid residues (RSH), such as L-cysteine, have an affinity to NO 
up to three orders of magnitude greater than biological compounds (Wink et al. 1994). 
Kinetic studies on transnitrosation between S-nitrosothiols and free thiols, using 
glutathione, cysteine and serum albumin, showed that NO from S-nitroso albumin 
transferred rapidly to cysteine (Meyer et al. 1994). From a platelet inhibition standpoint, 
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NO is rapidly released from unstable CySNO, inhibiting platelet adhesion by multiple 
mechanisms. NO inhibits platelet adhesion by binding to soluble guanylate cyclase and 
catalyzing the conversion of guanosine triphosphate (GTP) to 3, 5-cyclic guanosine 
monophosphate (cGMP) (Reynolds and Burstyn 2000), decreasing intracellular levels of 
Ca2+ (Jin et al. 2005), inhibiting thromboxane A2 via the cGMP-dependent protein kinase 
(Wang et al. 1998), attenuating the expression of P-selectin via cGMP-dependent protein 
kinase (Davenpek et al. 1994; Maurohara et al. 1995), reducing the number of GPIIb/IIIa 
receptors on the platelet surface (Mendelsohn et al. 1990), and increasing the dissociation 
constant of the receptor for the fibrinogen (Jin et al. 2005). As illustrated in Figure 6.1a, 
attaching L-cysteine utilizes endogenous NO to activate the platelet inhibition caused by 
NO and improves the haemocompatibility of PET and polyurethane by up to 67% (Duan 
and Lewis 2002). 
Based on the results from Ramamurthi et al. (2001) and Duan and Lewis (2002), 
it was expected that successful immobilization of L-cysteine and NTPDase to a 
biomaterial would significantly improve the haemocompatibility of the material. For this 
reason, developing a dual functional polymer that exploits ADP scavenging by NTPDase 
and NO-mediated platelet inhibition by L-cysteine (Figure 6.1b) will have a significant 
impact in the biomedical applications of the polymer.
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Figure 6.1. Schematic diagram showing the mechanism of exploiting endogenous NO 
and ADP scavenging using an NTPDase/cysteine-modified dual functional polymer to 
improve haemocompatibility. (a) L-cysteine utilizing endogenous NO (1) 
Transnitrosation – NO transfer from S-nitrosoalbumin to L-cysteine immobilized on the 
surface, (2) Decomposition – Spontaneous release of NO from unstable S-
nitrosocysteine. (b) NTPDase scavenging ADP and forming adenosine 
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6.2 Materials and methods 
 
Polyethylene terephthalate (PET) (thickness = 0.2 mm) was supplied by DuPont 
(Hopewell, VA). Bromoacetic acid, 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide 
hydrochloride (EDC), L-cysteine, sodium nitrite, ethylenediaminetetraacetic acid, 
Ellman’s reagent, malachite green hydrochloride, ammonium molybdate tetrahydrate, 
polyoxyethylenesorbitan monolaurate (Tween 20), tris[hydroxymethyl]aminomethane 
(Trizma base), adenosine diphosphate (ADP) and NTPDase (Apyrase from potato, Grade 
VII containing the isoenzyme Desirée with low ATPase/ADPase ratio) were purchased 
from Sigma (St. Louis, MO). Sodium hydroxide, sodium phosphate (monobasic and 
dibasic), sodium chloride, acetone, acetic acid, formaldehyde, calcium chloride, sulfuric 
acid and other reagents were purchased from Fisher Scientific (Fair Lawn, NJ). 
A dual functional polymer was developed using the carboxylated PET, which is 
mechanically strong and exhibits desirable biomedical properties. Before attaching 
cysteine and NTPDase, PET surfaces were carboxylated using the protocol described in 
Chapter 3 (Yang et al. 2000). Briefly, acetone treated PET was hydroxylated by reacting 
with 18.5% formaldehyde solution in 1 M acetic acid for 4 h (Massia and Hubbell 1990). 
The hydroxylated PET was then carboxylated by reacting with 1 M bromoacetic acid 
solution in 2 M sodium hydroxide for 18 h (Löfås and Johnsson 1990) . Carboxylated 
PET was washed thoroughly with DI water and dried in a glove box under a nitrogen 
environment before use. 
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6.2.1 Dual functional polymer 
 
Two batches of NTPDase/cysteine-modified dual functional PET were prepared. 
For the first batch, carboxylated PET was reacted with 3 ml of 0.1 M EDC, 1.5 ml of 20 
U/ml NTPDase and 1.5 ml of 0.1 M cysteine in 0.1 M phosphate buffer (pH = 6.8) at 4˚C 
for 16 h. This immobilized NTPDase and cysteine on carboxylated PET using the amide 
bonds.  The ε-amine group of the lysine molecules on NTPDase (Marconi et al. 1983) 
and the primary amine group on cysteine react with the carboxyl groups present on the 
carboxylated PET (Figure 6.2). This polymer is referred to as high NTPDase/low cysteine 
PET. Another batch was prepared by reacting carboxylated PET with 3 ml of 0.1 M EDC, 
1.5 ml of 20 U/ml NTPDase and 1.5 ml of 0.2 M cysteine in 0.1 M phosphate buffer (pH 
= 6.8) at 4ºC for 16 h. This polymer is referred to as low NTPDase/high cysteine PET. 
This polymer should have a higher cysteine surface concentration compared to the high 
NTPDase/low cysteine PET. 
 
6.2.2 Cysteine immobilization 
 
Cysteine was also attached separately to carboxylated PET to study the stability of 
cysteine immobilization. For immobilizing cysteine to carboxylated PET, the modified 
polymer was incubated with 0.25 M EDC and 0.25 M cysteine in 0.1 M phosphate buffer 
(pH = 6.8) at 4˚C for 16 h. This formed an amide between the carboxyl group on the 
carboxylated PET and the amine group on cysteine. This modified polymer is referred as 
PET-COOH-Cys. 
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Figure 6.2. Schematic diagram of NTPDase and cysteine immobilization on carboxylated 
PET to form a dual functional polymer. The amide bonds formed during immobilization 
are highlighted.
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6.2.3 Analysis of NTPDase attachment 
 
The attachment of NTPDase was verified by testing for NTPDase activity on the 
dual functional polymer. The experimental protocol was similar to the methods described 
in Chapter 3. Briefly, dual functional polymers were exposed to 50 ml of 0.25 mM ADP 
in the presence of 0.1 M Tris buffer (pH = 7.4) and 5 mM CaCl2. ADP was converted to 
AMP and inorganic phosphate (Pi). The sample solution was assayed for Pi concentration 
using a malachite green solution assay (Baykov et al. 1988; Geladopoulos et al. 1991). 
 
6.2.4 Analysis of cysteine attachment 
 
Immobilization of cysteine on the dual functional polymer was verified by 
measuring the cysteine surface concentration. The cysteine surface concentration was 
quantified using an indirect method. The dual functional PET was incubated with 20 µM 
NaNO2 and 0.5 N HCl for 30 min. This decreased the nitrite concentration in the solution 
since the thiols on the surface are nitrosated. Meanwhile, a similar acidic nitrite solution 
was prepared, without exposure to a polymer, to use as a blank. Samples (20 µl) were 
taken from both the polymer-exposed solution and the blank solution and the nitrite 
concentration was measured by a Sievers NO chemiluminescence analyzer NOA 270B 
(Sievers Medical Instruments, Inc., Boulder, CO) using a potassium iodide/iodine (KI/I2) 
reducing solution in which nitrite was decomposed to form NO. The surface cysteine 
concentration was estimated by the following equation: 
[CySH]surface = ([NO2-]blank – [NO2-]sample) • V / A 
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where [NO2-]blank is the nitrite concentration of the blank solution, [NO2-]sample is the 
nitrite concentration of the solution containing the modified PET, V is the volume of the 
solution and A is the area of the polymer film. 
In addition to measuring the surface cysteine concentration, the cysteine 
concentration in solution was measured during some studies using Ellman’s method 
(Ellman 1959; Rootwelt 1967). Briefly, a 100 µL sample solution was mixed with an 
equal volume of Ellman’s reagent (5mM DTNB in 100mM pH 7.2 phosphate buffer and 
0.1mM EDTA) in a 96-well microplate (Falcon 353228). After 10 min, the absorbance of 
the solution was measured at 410 nm using a Packard® SpectraCountTM Microplate 
Photometer BS10000 (Packard Instrument Co., IL). 
 
6.3 Results and Discussion 
 
6.3.1 NTPDase activity on the dual functional polymer 
 
The presence of NTPDase on the high NTPDase/low cysteine PET and low 
NTPDase/high cysteine PET was verified by studying the NTPDase activity of modified 
polymers. Figure 6.3a shows the NTPDase activity of the dual functional polymers. As 
seen in these results, it is clear that NTPDase activity is significantly higher in high 
NTPDase/low cysteine PET compared to low NTPDase/high cysteine PET. This possibly 
indicates that the surface concentration of NTPDase is higher when the ratio of NTPDase 
to cysteine is higher during immobilization.  
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Figure 6.3. Analysis of NTPDase and cysteine attachment on dual functional polymers 
(a) NTPDase activity on high NTPDase/low cysteine PET (▲), low NTPDase/high 
cysteine PET (∆) and PET-COOH-NTPDase (■) (b) Cysteine surface concentrations on 
PET-COOH-Cys and the dual functional polymers, HNLC – high NTPDase/low cysteine 
PET, LNHC – low NTPDase/high cysteine PET
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Comparing these results with PET-COOH-NTPDase, it is clear that high 
NTPDase/low cysteine PET had almost similar NTPDase activity. This probably 
indicates that with low cysteine concentrations, NTPDase immobilization was not altered. 
Cysteine, a low molecular weight amino acid, probably attached only to the reactive 
carboxyl groups that were not accessible to NTPDase, a high molecular weight enzyme. 
 
6.3.2 Surface concentration of cysteine on the dual functional polymer 
 
The cysteine surface concentration was measured using chemiluminescence. The 
results obtained are shown in Figure 6.3b. As seen from the results, it is evident that 
cysteine is attached to the carboxylated PET. Also, the concentration of cysteine on PET-
COOH-Cys and the dual functional polymers were quantifiable. Furthermore, it is clear 
that the cysteine concentration was higher when the ratio of NTPDase to cysteine used 
was lower. Therefore, adjusting the ratio of NTPDase to cysteine during carbodiimide 
coupling will provide different surface concentrations of NTPDase and cysteine. This can 
be used to optimize the NTPDase and cysteine surface concentrations. 
 
6.3.3 Stability of cysteine immobilization 
 
The stability of the amide bond in PET-COOH-Cys was tested by exposure to 
water at room temperature for prolonged hours. As seen on Figure 6.4, the cysteine on the 
surface decreased with time (data obtained from Jun Gu).  
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Figure 6.4. Stability of cysteine immobilization on PET-COOH-Cys Cysteine 
concentrations were measured with time, when stored in DI water. Loss of cysteine from 
the polymer is probably due to thioester formation during carbodiimide coupling. Data 
from work done by Jun Gu.
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There was detectable (but not reliably quantifiable) amounts of cysteine in 
solution, indicating cysteine instability as a result of bond breakage. This instability of 
the amide bond is in contrast to the stable amide bond observed with PET-COOH-
NTPDase. The apparent bond breakage may be due to the formation of thioesters instead 
of amide bonds (Figure 6.5). During carbodiimide coupling, EDC forms a complex with 
cysteine to activate the carboxyl group. This cysteine with an activated carboxyl group 
could react with an amine group on another cysteine molecule to form long polymeric 
chains of cysteine. This would reduce the availability of amine groups on cysteine to 
react with the carboxyl groups present on the polymer. Therefore, thiol groups on 
cysteine (rather than amine groups) could react with the activated carboxyl groups on the 
polymer and form thioester linkages (Hermanson 1996). Formation of such thioester 
linkages is commonly observed during peptide synthesis when cysteine is used (Hiskey 
1980; Bodanszky and Martinez 1983; Atherton et al. 1985). These thioester linkages are 
not as stable as amide bonds in solution (Hermanson 1996). During peptide synthesis, 
thiol groups are protected to prevent side reactions (Hiskey 1980; Atherton et al. 1985; 
Albericio et al. 1989). Using thiol protected cysteine would avoid the formation of 
thioester linkage during carbodiimide coupling. Thiol groups can later be unprotected by 
simple hydrolysis. In addition to bond breakage, there is also a possibility of cysteine 
oxidation.
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Figure 6.5. Thioester formation in a dual functional polymer. The thioester bond, which 
might be the reason behind the instability of cysteine immobilization to carboxylated 
PET, is highlighted.
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6.4 Conclusions 
 
A dual functional polymer utilizing NTPDase and NO-mediated platelet 
inhibition mechanisms would likely show an additive effect on improving 
haemocompatibility. For this purpose, developing a polymer with stable NTPDase and 
cysteine immobilization is required. From the studies performed, it is clear that NTPDase 
and cysteine can be immobilized on carboxylated PET. However, only NTPDase 
immobilization is stable, while cysteine immobilization is not. This problem is possibly 
due to the formation of weaker thioester linkages, instead of amide bonds. Based on the 
peptide synthesis studies, it is expected that this problem can be overcome by using thiol-
protected cysteine during immobilization and then unprotecting the thiol group. Although 
cysteine immobilization was not stable, results for NTPDase activity and initial cysteine 
surface concentrations indicated that surface distribution of cysteine and NTPDase 
depends on the ratio of concentrations of NTPDase to cysteine during immobilization. 
This is valuable information for developing a dual functional polymer with optimal 
cysteine and NTPDase surface concentration for maximum haemocompatibility. 
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CHAPTER 7 
 
 
CONCLUSIONS AND FUTURE WORK 
 
The goal of this research was to develop a haemocompatible polymer, with 
desirable mechanical and surface properties, by successfully immobilizing NTPDase. The 
motivation of the project was based on the wide range of biomedical applications in 
which materials that lack haemocompatibility come in contact with blood. Improving the 
haemocompatibility of these materials will significantly improve the clinical applications 
and the quality of life of patients. Successful development of a haemocompatible material 
with desired biomedical properties will also have a significant economic impact. 
Previous studies have shown that NTPDase, when coated or covalently 
immobilized, can enhance the haemocompatibility of the material (Marconi et al. 1983; 
Bakker et al. 1991; van der Lei et al. 1992). However, these studies suffered from some 
serious limitations. NTPDase coating resulted in loss of NTPDase in the blood stream, 
causing the polymer to lose its haemocompatibility. On the other hand, surface 
modifications performed to covalently bind NTPDase caused significant changes to the 
surface and bulk properties of the material. The aim of this research was to overcome 
these limitations by covalently immobilizing NTPDase on a modified polymer that 
showed desirable mechanical and surface properties. This mechanically stable NTPDase-
modified polymer will scavenge ADP released from activated platelets and inhibit 
platelet deposition.
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7.1 Successfully accomplished objectives 
 
For accomplishing the defined goal, polyethylene terephthalate (PET), a model 
polymer, was chosen to be modified by attaching NTPDase. PET is used in a wide range 
of biomedical applications, where it comes in contact with blood. Attaching NTPDase to 
PET will significantly improve its applications. However, for covalently immobilizing 
NTPDase to PET, reactive functional groups had to be added to the PET surface. After 
extensive literature survey, multiple surface functionalization techniques were identified. 
Out of the different methods, three were specifically chosen for this research. They were 
aminolysis, hydrolysis and carboxylation. 
Aminolysis was an intriguing technique for introducing reactive functional groups 
to the PET surface because it had been used earlier in this lab for immobilizing cysteine 
(Duan and Lewis 2002; Gappa-Fahlenkamp and Lewis 2005). Hydrolyzed PET had also 
been used to immobilize NTPDase by an earlier study (Marconi et al. 1983). However, 
these two techniques have been known to damage to the surface properties and the 
mechanical strength of PET (Fukatsu 1992; Bùi et al. 1993; Kao et al. 1998; Liu et al. 
2005; Nissen et al. 2008). Carboxylation of PET was a relatively new method for 
introducing reactive functional groups to the PET surface (Yang et al. 2000; Hyun et al. 
2001). However, the effect of carboxylation on the surface and bulk properties of PET 
were not studied. In this research, surface and bulk properties of carboxylated PET were 
analyzed. The results obtained were compared with aminolyzed PET, hydrolyzed PET 
and unmodified PET. SEM, AFM and tensile analysis clearly showed that carboxylated 
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PET showed similar surface and bulk properties as the unmodified PET. These findings 
clearly show that carboxylation is preferred over aminolysis and hydrolysis of PET. 
In this research, NTPDase was successfully immobilized on carboxylated PET 
(PET-COOH-NTPDase). NTPDase was also immobilized on aminolyzed PET (PET-
NH2-NTPDase). However, the results showed that NTPDase immobilization on 
aminolyzed PET is not stable. This is potentially due to imine bond breakage. Although 
imine bonds can be stabilized by reducing them, further investigation was not warranted 
as the polymer showed significant surface deterioration and loss of mechanical strength. 
NTPDase immobilized on both carboxylated PET and aminolyzed PET was active. The 
presence of NTPDase was verified by testing the modified polymers for NTPDase 
activity. Although PET-NH2-NTPDase showed much higher NTPDase activity, the 
polymer can’t be used in biomedical applications because (1) NTPDase attachment was 
not stable, (2) the polymer lost its mechanical strength and (3) significant surface 
deterioration occurred. NTPDase activity on PET-COOH-NTPDase was lower than the 
activity on PET-NH2-NTPDase. However, NTPDase activity on PET-COOH-NTPDase 
was comparable to the activities observed with NTPDase-modified nylon and C 50 steel 
rings that showed improved haemocompatibility (Marconi et al. 1983). PET-COOH-
NTPDase, with quantifiable NTPDase activity and advantageous surface and bulk 
properties, will be a good biomedical polymer showing improved haemocompatibility. 
For understanding the effectiveness of NTPDase immobilization, kinetic studies 
were performed using PET-NH2-NTPDase and PET-COOH-NTPDase. Free NTPDase 
kinetics were also performed for comparison. The results obtained showed that free 
NTPDase lost activity in solution at 37ºC. However, PET-COOH-NTPDase didn’t lose 
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activity in solution at 37ºC. These results show that immobilizing NTPDase on 
carboxylated PET improved the stability of NTPDase activity in solution at 37ºC. This 
could potentially have significant implications for long-term biomedical applications. 
Furthermore, results obtained from 1.5-ml and 50-ml reaction systems showed that mass 
transfer limitations play a role in larger volume reactions, while small volume reactions 
were likely kinetic limited. Immobilized NTPDase kinetics was analyzed using PET-
COOH-NTPDase polymers. Although Michaelis-Menten model fit the data, there were 
inconsistencies with the values of vmax and KM. This was probably due to the limitations 
with the sensitivity of measuring small changes in Pi concentrations. Also, storing PET-
COOH-NTPDase at -20°C could have resulted in some of these inconsistencies. 
Therefore, with the information currently available, estimation of Michaelis-Menten 
constants for immobilized NTPDase kinetics is ambiguous. However, all the experiments 
performed do show that PET-COOH-NTPDase was consistently showing significant 
NTPDase activity. 
For the polymer to be useful in blood-contacting systems, the material should be 
haemocompatible. To verify this, in vitro studies were performed using PET-COOH-
NTPDase. As protein-adsorbed surfaces activate platelets and associated thrombus 
formation (Hanson 2004), the amount of protein adsorbed to the surface of unmodified, 
carboxylated and NTPDase-modified PET was measured. These protein adsorption 
studies showed that carboxylation of PET increased the quantity of protein adsorbed to 
the surface. However, when NTPDase was attached to the carboxylated PET, protein 
adsorption was comparable to the unmodified PET. Hence, PET-COOH-NTPDase should 
not cause any platelet activation due to excessive protein adsorption. Platelet rich plasma 
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and whole blood studies were also performed to verify the extent of clot formation on the 
polymer surface. SEM images of unmodified, carboxylated and NTPDase-modified PET 
showed that platelet adhesion was drastically lowered by the presence of NTPDase. 
Results also show that even the platelets adhered to the surface of PET-COOH-NTPDase 
were not activated, indicating primary adhesion. 
Another objective of this research was to utilize more than one naturally occurring 
platelet inhibition pathway to improve haemocompatibility. In this work, NO-mediated 
platelet inhibition, which is known to have an additive effect to NTPDase (Ramamurthi et 
al. 2001), was chosen as the additional pathway. To take advantage of NO-mediated 
platelet inhibition, cysteine was attached to carboxylated PET along with NTPDase. 
Results showed that cysteine and NTPDase can both be attached to carboxylated PET. 
However, only NTPDase attachment was stable. Stability studies performed using PET-
COOH-Cys showed that cysteine attachment was not stable in solution. This is possibly 
due to the formation of weaker thioester bonds, instead of the stable amide bonds. This 
limitation can be overcome by using thiol-protected cysteine during carbodiimide 
coupling. The thiol group would later have to be unprotected. Although cysteine 
attachment wasn’t stable, results show that the surface concentration of cysteine and 
NTPDase depended on the ratio of NTPDase to cysteine used during carbodiimide 
coupling. Therefore, combined cysteine and NTPDase immobilization can be used to 
optimize a dual functional polymer to attain increased haemocompatibility. 
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7.2 Future direction 
 
The findings of this research have contributed significantly to previous results. 
Further studies can be performed to pursue the ultimate goal of total platelet inhibition. 
• Haemocompatibility studies can be performed on PET-COOH-NTPDase 
under flow conditions. The shear stress caused during blood flow results in the 
release of ADP, which can cause blood coagulation. Testing PET-COOH-
NTPDase with flowing blood will provide further insights for applications of 
the polymer. 
• Ex vivo and in vivo testing of PET-COOH-NTPDase will provide valuable 
information that wasn’t considered during in vitro studies. 
• Durability and the half-life of NTPDase activity on PET-COOH-NTPDase 
will have to be studied for understanding the potential of this polymer in long-
term applications, like implants. 
• Optimization of NTPDase concentration and activity on PET-COOH-
NTPDase will help in further enhancing the haemocompatibility of the 
polymer. 
Developing an effective dual functional polymer that takes advantage of ADP 
scavenging by NTPDase and NO-mediated platelet inhibition by cysteine will be another 
useful future direction. For accomplishing this, the following objectives have to be 
fulfilled. 
• Cysteine attachment to carboxylated PET has to be stabilized. For this to 
occur, thiol-protected cysteine can be used. The thiol group has to be 
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unprotected later on by simple hydrolysis.  However, the technique used must 
be evaluated with regards to NTPDase activity. 
• Once cysteine is successfully immobilized to carboxylated PET, a stable dual 
functional polymer can be developed. 
• Haemocompatibility studies using the dual functional polymer should be done 
to understand the additive effect of NTPDase and cysteine. 
• The surface concentrations of NTPDase and cysteine on the dual functional 
polymer have to be optimized by using different NTPDase to cysteine ratios 
during carbodiimide coupling. 
• The long-term properties of the dual functional polymer have to be studied. 
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